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Abstract 
 
This thesis is divided into two parts, assessing marine and synthetic compounds active firstly against 
Plasmodium falciparum (Chapter 3 and 4) and secondly active against methicillin resistant 
Staphylococcus aureus (MRSA, Chapter 5).   In Chapter 3 the synthesis of nine new tricyclic 
podocarpanes (3.203-3.207 and 3.209-3.212) from the diterpene (+)-manool is described.  Initial SAR 
study of synthetic podocarpanes concluded that the most active compound was a C-13 phenyl 
substituted podocarpane (3.204, IC50 6.6 μM).  By preparing analogues with varying halogenated 
substituents on the phenyl ring (3.209-3.212) the antiplasmodial activity was improved (IC50 1.4 μM), 
while simultaneously decreasing the haemolysis previously reported for this class of compounds.  
Inspired by the antiplasmodial activity of Wright and Wattanapiromsakul’s tricycle marine isonitriles 
(2.16-2.21 and 2.24-2.27) an unsuccessfully attempt was made to convert tertiary alcohol moieties 
to isonitrile functionalities in compounds 3.188, 3.204-3.207 and 3.209-3.212. 
Over a decade ago Wright et al. proposed a putative antiplasmodial mechanism of action for marine 
isonitriles (2.4, 2.9, 2.15, 2.19 and 2.35) and isothiocyanate (2.34) which involved interference in 
haem detoxification by P. falciparum thus inhibiting the growth of the parasite.  In Chapter 4 we 
describe how we successfully managed to scale down Egan’s β-haematin inhibition assay for the 
analyses of small quantities of marine natural products as potential β-haematin inhibitors.  Our 
modified assay revealed that the most active antiplasmodial marine isonitrile 2.9 (IC50 13 nM) 
showed total β-haematin inhibition while 2.15 (IC50 81 nM) and 2.19 (IC50 31 nM) showed partial 
inhibition at three equivalents relative to haem.  Using contempary molecular modelling techniques 
the charge on the isonitrile functionality was more accurately describe and the modified charge data 
sets was used to explore docking of marine isonitriles to haem using AutoDock. 
In Chapter 5 we describe how a lead South African marine bisindole MRSA pyruvate kinase inhibitor 
(5.8) was discovered in collaboration with colleagues at the University of British Columbia (UBC) and 
how this discovery inspired us to design a synthetic route to the dibrominated bisindole, 
isobromotopsentin (5.20) in an attempt to increase the bioactivity displayed by 5.8.  We devised a 
fast and high yielding synthetic route using microwave assited organic synthesis.  We first tested this 
synthesis using simple aryl glyoxals (5.27-5.32) as precursors to synthesize biphenylimidazoles (5.21-
5.26), which later allowed us to synthesize the ascidian natural product 5.111.   This method was 
sucessfully extended to the synthesis of deoxytopsentin (5.33) from an N-Boc protected indole 
methyl ketone (5.89).  We subsequently were able to effectively remove the carbamate protection 
 
ii 
via thermal decomposition by heating the protected bisindole imidazole (5.90) in a microwave 
reactor for 5 min under argon.  The synthesis of 5.20 resulted in an inseparable mixture of 
monoprotected and totally deprotected topsentin products, and due to time constraints we were 
not able to optimise this synthesis.  Nonetheless our synthesis of the marine natural product 5.33 
which was faster and higher yielding than previously reported routes could be extended to the 
synthesis of other topsentin bisindoles (5.138-5.140).  Work towards this goal continues in our 
laboratory. 
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1.1. What are natural products? 
 
Natural products or secondary metabolites are chemicals produced by an organism (plant, 
invertebrate or microbe) for functions seemingly superfluous to the primary metabolism of that 
organism.  These functions may include inter alia toxins to reduce predation or growth inhibitors of 
other organisms competing for the same pool of nutrients or space.  The world’s oceans cover more 
than 70% of the world’s total surface area and therefore provides vast habitats where organisms 
may live and diversify.  The diverse marine biota inhabiting environments from the deep abyssal 
plain to the shallow coastal tidal pools provide a unique reservoir of marine natural products. 
Paradoxically, many marine natural products have been shown to possess potential medicinal 
properties especially in the treatment of cancer.1,2    The marine environment hosts approximately 
100 000 species of marine invertebrates, a number which is estimated to be far higher due to 
numerous species undiscovered or undescribed.3  Many of these invertebrates belong to the 
Coelenterata, Porifera, Bryozoa, Mollusca and Echinodermata phyla, which include organisms which 
may be sessile, slow moving or slow growing and lack physical defences such as spines or shells.  
These soft bodied organisms may therefore contain chemical defences to combat predation by 
fishes, crustacea etc.3 In a recent model described by Erwin et al.4 an estimated 250,000-600,000 
new chemical structures from marine organisms was projected, of which 90-93% have yet to be 
discovered.  Erwin et al.4 further calculated that the successful discovery and testing of these marine 
compounds would add a US $563 billion-5.69 trillion value to the pharmaceutical industry as anti-
cancer drugs.  With the ever growing burden of infection and disease there exists an overwhelming 
need for the discovery of new drugs and the ocean offers a diverse source of new pharmaceuticals 
for the treatment of many diseases.  Currently there are four marine natural products registered by 
the FDA and one by the EMEA and approximately eleven marine natural products in clinical trials for 
the treatment of a plethora of afflictions ranging from cancer to schizophrenia.5    
1.2. Approved and current drugs of marine origin in the drug 
discovery pipeline 
 
In order for a drug to successfully make it to the consumer market it has to be approved by the 
Federal Drug Administration (FDA) or the European Agency for the Evaluation of Medical Products 
(EMEA) for the USA and Europe respectively.  These drugs are only approved after successfully 
passing Phase I, II and III clinical trials.  Phase I clinical trials involve the testing of the drug on 20-100 
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healthy individuals in order to assess the pharmacovigilance, tolerability, pharmacokinetics and 
pharmacodynamics of a drug.  Once the drug has been successfully assessed in Phase I, the drug will 
be tested in Phase II trials where 100-300 patients are administered the drug/placebo to gauge the 
effectiveness of the drug on a particular disease or condition and to determine the short-term side 
effects and risk.  Phase III clinical trials are multicentred and require testing on 300-3000 patients as 
the definitive assessment of safety and effectiveness of the drug in question.  Should Phase III be 
successful the “regulatory submission”  containing all the relevant information concerning human 
and animal testing, manufacturing procedure, formulation details and shelf life is submitted to the 
relevant regulatory body for final drug approval.6               
 
1.2.1. FDA and EMEA approved drugs 
 
Currently there are four marine natural products or marine natural product derived compounds 
approved by the FDA for the safe use as drugs, namely cytarabine (Cytosar-U®, Depocyt®), 
vindarabin (Vira-A®), ziconotide (Prialt®) and eribulin mesylate (Halaven®), while the EMEA has 
recently approved trabectedin (Yondelis®) for use in the treatment of cancer (Figure 1.1).  
 Cytarabine and vindarabin were the first marine natural products to be approved by the FDA in 
1969.  Both cytarabine and vindarabin are synthetic compounds inspired by spongothymidine and 
spongouridine respectively, which were orginally isolated from the Caribbean sponge Tethya crypta.7  
Cytarabine acts as an inhibitor of DNA polymerase and hence DNA synthesis and is therefore used in 
the treatment of acute lymphocytic leukemia, acute mylocytic leukemia and meningeal leukemia.8,9  
Vira-A® inhibits viral DNA polymerase and DNA synthesis in Herpes, Vaccinia and Varicella zoster 
viruses.10  Over thirty years later ziconotide was approved by the FDA in 2004 for the treatment of 
severe pain.  Ziconotide binds to N-type calcium channels of nociceptive afferent nerves thus 
reducing the release of neurotransmitter from the afferent nerve terminal relieving pain.11,12  
Ziconotide is the synthetic equivalent of a naturally occurring 25 amino acid containing peptide ω-
conotoxin MVIIA  originally isolated from the marine snail Conus magnus.13  Yondelis® received 
EMEA approval for the treatment of soft tissue sarcoma in 2007 and in 2009 received EMEA 
approval for the treatment of ovarian carcinoma.5  Trabectedin was isolated from a tunicate 
Ecteinascidia turbinata, which is found in the Caribbean and Mediterranean sea.14,15  The problems 
associated with obtaining sufficient supplies of tabectedin are discussed briefly in Section 1.3.3.2. 
Tabectedin covalently binds to the minor groove in DNA16 and interacts with different proteins 
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involved in the nucleotide excision repair system17 thus reducing the growth of the cancer.  In 2010 
the FDA approved eribulin mesylate, a simplified synthetic analogue of the marine natural product 
halichondrin B, which was originally isolated from a marine sponge Halichondria okadai,18 for the 
treatment of metastatic breast cancer.19  Eribulin mesylate has an unique mechanism of action 
against cancer cells, by inducing an irreversible antimitotic effect leading to apoptosis of the cancer 
cells.20                    
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Figure 1.1: Current FDA or EMEA approved drugs of marine origin.  The 3D structure of ω-conotoxin MVIIA 
obtained from the PDB (1TTK) visualized in DSVisualizer
21
, peptide backbone tubes coloured by 
secondary structure and disulfide bonds indicated by large yellow tubes.  Amino acid sequence 
above 3D structure, where # denotes the C terminus.  
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1.2.2. Phase III clinical trials of marine drug candidate  
 
Currently Yondelis® is completing Phase III trial in the US for soft tissue sarcomas and ovarian cancer 
and awaiting FDA approval for sale in America.    Solidotin is a synthetic derivative inspired by 
dolastatin 10 which was originally isolated from the sea hare, Dolabella auricularia22,23 and 
subsequently from a marine cyanobacteria Symploca sp.  Solidotin is a vascular disrupting agent 
which results in vasculature failure within tumors, thus resulting in the death of the tumor cells.24     
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Figure 1.2: Solidotin a marine inspired drugs currently in Phase III clinical trials. 
 
1.2.3. Phase II clinical trials of marine drug candidates 
 
Bryostatin 1, isolated from the bryozoan Bulgula neritina, has shown an ability to bind protein kinase 
C5 and is currently being tested as an anticancer agent.25  Bryostatin 1 has also recently been 
approved to begin Phase I clinical trials as an anti-Alzheimer’s drug.25       The full synthetic analogue 
of the marine Aspergillus metabolite halimide,26 plinabulin inhibits tublin polymerization, leading to 
vascular disruption within the tumour resulting in the death of the cancer cells.27  DXMBA is a 
synthethic analogue of an alkaloid, anabaseine, present in many marine worms (e.g. Amphiporus 
lactifloreus)28 which selectively stimulates α7 nicotinic acetylcholine receptor.29 This bioactivity has 
resulted in DXMBA being tested for the treatment of schizophrenia.30  The new DNA-binding alkaloid 
Zalypsis® isolated from the Pacific nudibranch Joruna funebris,31 binds to guanines in DNA resulting 
in double strand breaks, S-phase arrest and apoptosis in cancer cells.5  Aplidin® was originally 
isolated from the Mediterranean tunicate Aplidium albicans, however, this compound is now 
obtained via total synthesis.  Aplidin® is a potent inducer of apoptosis in cancer cells and is currently 
being tested for the treatment of relapsing and refractory multiple myeloma and T cell lymphoma.32  
Tasidotin is a synthetic compound inspired by the marine natural product dolastatin-15.  The 
mechanism of action is thought to be inhibition of tubulin assembly resulting in cancer cell death.5  
Pseudopterosin A is an example of the pseudopterosin class of diterpenes isolated from the marine 
solidotin 
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octocoral Pseudopterogorgia elisabethae.33-35  Pseudopterosin A has displayed anti-inflammatory 
and wound healing properties for which it is currently being tested in Phase II clinical trials.36              
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Figure 1.3: Marine inspired drugs currently in Phase II clinical trials. 
 
1.2.4. Phase I clinical trials of marine drug cadidates 
 
The nudibranch, Elysia rufescens, metabolite, Irvalec®, has shown potent antitumor activity against a 
variety of human tumour cell lines.  While the exact mechanism of action is unknown, it has been 
reported that Irvalec® induces cell death via oncolysis as opposed to apoptosis.5,25   The compound 
marizomib, isolated from the marine Actinomycete Salinispora tropica,37,38 exhibits potent inhibition 
DMXBA plinabulin 
tasidotin 
plitidepsin (Aplidin®) 
pseudoterosin A 
PM00104 (Zalypsis®) 
bryostatin 1 
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of the proteasome37 and is currently being tested in the treatment of various cancers.5  Hemiasterlin 
which has been isolated from numerous marine sponges (e.g. the South African sponge 
Hemiasterella minor)39 has shown antimiotic activity resulting in cancer cell death via apoptosis.40  
This lead to the development of synthetic analogues e.g. E7974 which is currently in Phase I clinical 
trials for solid malignant tumours.25,40  
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Figure 1.4: Marine inspired drugs currently in Phase I clinical trials. 
 
1.3. Problems associated with marine natural products 
1.3.1. The problem of intellectual property rights 
 
A major concern to pharmaceutical companies is ownership of the intellectual property rights for the 
medical use of natural products.  The Rio Convention on Biodiversity41 highlighted the sovereign 
rights of countries, from where the natural products originates, ensuring equitable distribution to 
the host country of the resulting benefits arising from development of the bioactive natural product.  
With the pharmaceutical industry investing all the financial capital ($ 350 million total average cost 
marizomib 
E7974 
elisidepsin (Irvalec®) 
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for the development of a drug),42 the payment of intellectual property rights to a third party 
unaffected by the enormous financial risk inherent in the drug development process is unappealing.          
 
1.3.2. The problem of dereplication 
 
The general lack of expertise in the field of marine invertebrate taxonomy (with the exception of 
sponges) often results in the recollection of already studied invertebrates or poses a challenge in the 
re-isolation of invertebrates of interest.43  The purification and structural characterization of 
complex crude mixtures of marine extracts is often difficult and time consuming, which may result in 
discovery of already known compounds, which cannot be patented.44  The re-isolation of already 
known compounds may result in little or no return on investment to the pharmaceutical company 
and effective dereplication strategies (e.g. LCMS) are crucial to minimize wasted effort of time and 
economic resources.             
1.3.3. The problem of supply 
 
The demand for large quantities of test compound (several kilograms are required for the successful 
completion of preclinical and clinical trials) is often problematic for drug candidates isolated from 
marine organisms.  For example in order to obtain 1 g of Yondelis® from a biological source, one 
metric tonne (wet weight)45 of Ecteinascidia turbinata is required.  The recommended dosage of 
Yondelis® is 1.5mg/m2 body surface area every three weeks for the treatment of soft tissue sarcoma.  
An average male patient would therefore require 2.9 kg of E. turbinata every three weeks to provide 
the required amount of trabectedin.  It is estimated that in 2011, 10 980 Americans will be 
diagnosed with soft-tissue sarcomas resulting in an estimated tri-weekly demand of 31.8 metric 
tonnes of E. turbinata to treat American patients alone.46 The use of SCUBA in collection of source 
organism for marine natural products is often expensive and lengthy, while the use of dredging is 
non-specific and may lead to large patches of the ocean floor becoming uninhabited.42  The three 
main methods for the production of marine natural products to solve the supply issue for use as 
drugs are; aquaculture, fermentation and organic synthesis.          
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1.3.3.1. Aquaculture 
 
Due to the large quantities of biomass required in order to sustain the supply of the bioactive 
compound an easily accessible source must be available, i.e. the development of aquaculture.  The 
aquaculture of the sponge Lissodendoryx sp. (producer of halichondrin B) will be discussed as a case 
study to illustrate a few of the problems associated with this method of providing a sustainable 
supply of a marine natural product drug.   Lissodendoryx sp. is a deep water sponge growing 
exclusively on the Kaikoura Peninsula, New Zealand.  In 1998 a ~5 km2 ‘sponge field’ was discovered 
by a remotely operated underwater vehicle (ROV) with a calculated biodensity of 69 ± 21 g.m-2 
resulting in an estimated biomass of 289 ± 90 tons of Lissodendoryx.47  Should the entire ‘field’ be 
harvested, the total yield of halichondrin B would be 62-118 g, enough to sustain 1.2-2.3% of the 
estimated annual requirement of halichondrin B.45  Therefore, the New Zealand National Institute of 
Water and Atmospheric Research (NIWA), in collaboration with University of Canterbury and the 
National Cancer Institute (NCI) conducted a Lissodendoryx aquaculture feasibility study.47  It was 
soon discovered that seasonal factors played a huge role in the success of sponge aquaculture with a 
summertime mortality rate of 95% dropping to 15% in the wintertime.47  With the increased winter 
survival rate Munro et al.  turned their attention to determining whether halichondrin B was being 
produced under these artificial conditions.  They found that the cultured sponges were indeed 
biosynthesizing halichondrin B, however at only 30-60% of the yield of halichondrin B produced by 
the wildtype Lissodendoryx sponge.  This reduced production would of course lead to a greater 
requirement of cultured biomass resulting in a need for a larger area for aquaculture.47        
1.3.3.2. Fermentation 
 
A comparison of natural products isolated from sponges, tunicates and other marine invertebrates 
to those isolated from a microbial origin often have a significant structural similarity, suggesting that 
the biosynthesis of many marine metabolite may in fact be microbial rather than originating from 
the marine invertebrate.  Filter feeders may incorporate large microbial colonies (endosymbionts) 
accounting for up to 40% of the sponge’s biomass.45  The discovery of these endosymbiots lead to 
research being developed in order to isolate and cultivate these putative producers of bioactive 
metabolites.  However, many bacteria and cyanobacteria are highly selective with regards to growth 
media and conditions, resulting in less than 1% of the microbes present in the marine invertebrate 
tissue being culturable.45  The development of novel growth media for sponge-associated bacteria 
may result in the fermentation of previously un-culturable marine bacteria, affording access to large 
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quantities of bioactive materials.  While bacteria may not produce the complete natural product of 
interest, microbes may produce a structurally similar compound which could be used a precursor in 
the semi-synthesis of desired bioactive compound.  For example in the case of trabectidin, two 
thirds of the complex chemical structure is biosynthesised by the culturable bacteria Pseudomonas 
fluorescens in the form of cyanosafricin B.48  Cuevas et al.49 have described a semi-synthetic pathway 
to trabectidin using cyanosafricin B as a precursor which has enabled PharmaMar to meet global 
demands for trabectidin (ca. 5 kg p.a.).   
 
 
 
Figure 1.5: Structural similarities between cyanosafriacin B and trabectedin.  
 
1.3.3.3. Synthesis 
 
The design of a synthetic route from commercially obtainable reagents is by far the most appealing 
option in the manufacture of the marine natural products, however many marine natural products 
are complex; containing numerous sites of oxygenation and an abundance of chiral centres often 
resulting in intricate and low yielding synthetic pathways.50  However, should the complexity of 
marine natural products hinder the development of an economically viable synthetic route, marine 
natural products are often used as ‘lead’ drug compounds, where a compromise between  synthetic 
cost and loss of bioactivity is reached.42  Eribulin mesylate is a good example of how a simpler and 
synthetically more accessible analogue of a marine natural product (halichondrin B) has proceeded 
into development.         
trabectedin (Yondelis®) cyanosafriacin B 
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1.4. Conclusion 
 
Despite the numerous challenges in the development of drugs from Nature, it still remains the most 
viable cornucopia of potential drugs.44  The estimated total number of species on this planet is 
approximately 2-100 million species, with many yet undiscovered.44  The potential for these 
numerous species to produce medicinally exploitable compounds is huge.          
 
1.5. Outline of this thesis 
 
In Chapter 2 overviews are presented of firstly, the lifecycle of malaria parasite, Plasmodium 
falciparum, and secondly naturally occurring antiplasmodial marine isonitriles and isothiocyanates.  
This chapter provides an entre to the syntheses described in Chapter 3 and the in vitro haem binding 
analyses in Chapter 4.  Chapter 3’s primary focus is on improving the antiplasmodial activity of 
compounds derived from the naturally occurring botanical diterpene (+)-manool.   We proposed 
that, due to the potent antiplasmodial of marine isonitriles, the conversion of the tertiary alcohol 
functionalities contained on the tricyclic scaffold of the manool derived compounds to isonitrile 
moieties would considerably increase their antiplasmodial activity.  In Chapter 4 naturally occuring 
marine isonitriles’ ability to inhibit a well established druggable target, i.e. the detoxification of 
haem by the malaria parasite, is explored in an effort to try and shed light on a possible mode of 
action for these marine compounds.  With the technological advances in molecular modelling, we 
revisit a haem/isonitrile interaction originally proposed a decade ago in an effort to better 
understand the type of molecular forces involved.  Finally, in Chapter 5 we describe an improved 
synthesis of the natural product dexotopsentin with the use of microwave assisted organic (MAO) 
synthesis, which is quicker and higher yielding than previously reported syntheses.  Our synthesis 
offers an accessible route to structurally related bisindole alkaloids for the possible development of 
compounds as molecular probes to explore the inhibition of pyruvate kinase in methicillin resistant 
Staphylococcus aureus (MRSA).   
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2.1. Malaria 
2.1.1. Global distribution of malaria 
 
Although in the past century there have been many successful developments to eradicate the 
malarial parasite, malaria continues to be widespread. The 2011 WHO fact sheet reports that there 
were 225 million reported cases of malaria, 781 000 resulting in deaths in 2009.51  The increase in 
the spread of malaria has been attributed to several factors including, population movements to 
malaria infected areas, changes in agricultural practices such as the building of dams and irrigation 
systems or deforestation, the weakening of public health systems, global climate changes and 
resistance to antimalarial drugs and insecticides.52   With the current population growth rates in 
malaria riddled regions it has been estimated that without effective intervention the cases of malaria 
will double within the next 20 years.53   
The global distribution of malaria is centred in the tropics although not confined to this region of the 
world.  Many efforts have attempted to suppress the disease, however these only seem to have 
been successful in the temperate regions of the globe.  This is due to, among other factors, the 
decreased rate of reproduction of the plasmodial parasite at lower temperature.  As the ambient 
temperature declines, the period for development of the parasite in the mosquito vector increases.  
If the average temperature drops below 18 oC the likelihood of transmission becomes less due to the 
parasite failing to achieve maturation in the lifespan of the mosquito vector. At temperatures lower 
than 16 o C the malaria parasite ceases to develop and many species of mosquito postpone biting 
activity at these low temperatures.52  The large transmission rate within sub-Saharan Africa has been 
attributed to the vector, Anopheles gambiae, and its high preference towards anthropophily (human 
biting).  Ninety percent of all the fatal cases of malaria occuring in Africa result from Plasmodium 
falciparum.52  Infection by other plasmodia species may also cause malaria. Plasmodium malariae is 
transmitted throughout the topics and subtropics, although widespread the locations are patchy, P. 
vivax is located throughout the tropics however, this species is uncommon in most of Africa, while P. 
ovale is predominantly found in tropical Africa.54   
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2.1.2. Plasmodium biology 
2.1.2.1. Differentiation of the parasite within the mosquito 
 
The parasite enters the mosquito when it feeds on an infected host’s blood ingesting the 
Plasmodium gametocytes.  The gametocytes travel to the posterior midgut lumen, where bloodmeal 
storage, digestion and absorption occur.55  Only on the ingestion of the bloodmeal into the 
mosquito’s midgut do the gametocytes differentiate to form gametes.56  Minutes after ingestion 
exflagellation takes place whereby each male gametocyte differentiates into eight haploid motile 
gametes (microgametes).  The onset of exflagellation is brought about through a drop in 
temperature from 37 oC to 28 oC, an increase in pH and the addition of the gametocyte-activating 
factor (GAF), xanthurenic acid.57  By comparison the female gametocytes undergo very little 
morphological development, with their shape becoming rounder and enlarged to form female 
gametes (macrogametes).  Fertilization occurs within the midgut when the plasma membranes of 
the micro and macrogametes fuse, resulting in the microgamete’s nucleus travelling into the 
macrogamete’s cytoplasm and passing through the macrogametes endoplasmic reticulum to 
combine with the macrogamete nucleus to form the diploid zygote.58-60  The fertilized zygote 
undergoes transformation into motile ookinetes, little is known about what controls this 
development.  These ookinetes have to transverse two barriers; the peritrophic matrix (PM) and the 
midgut epithelium.  The PM is a chitinous network secreted by the midgut epithelial cells in response 
to the ingested bloodmeal.  In order to cross this barrier the ookinetes secrete a pro-chitinase,61 
which is assumed to cause physical damage to the PM affording access to the midgut epithelium.   
The invasion of the epithelial cells is initiated by the adhesion of the ookinetes to the mircovillar 
surface of the epithelial cell membranes.57  It appears that the ookinetes preferentially invade Ross 
cells, a specific type of epithelial cell, which has fewer microvilli and has an abundance of vesicular 
ATPase.62  After crossing the midgut epithelium, the ookinete encounters an extracellular space 
between the midgut epithelium and the basal lamina, where it develops into an oocyst.   Within 
each oocyst the parasite undergoes huge asexual amplification known as sporogony.  Once the 
oocyst is fully mature it results in the mass release of thousands of sporozoites into the hemocoel.  
Once in the hemocoel the sporozoites travel to and invade the salivary gland epithelium.  The 
sporozoites only remain within the cytoplasm of the salivary glands temporarily and soon exit into 
the secretory cavity where the sporozoites are organised into bundles (Figure 2.1 and 2.2).  Once in 
the secretary cavity of the mosquito’s salivary glands each time the mosquito feeds small numbers 
of sporozoites are injected into the vertebrae host infecting them with the plasmodial parasite.57  
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   Figure 2.1: The lifecycle of the P. falciparum in the mosquito vector.
55
  
 
 
Figure 2.2:   The lifecycle of P. falciparum within the mosquito vector.  The graph illustration parasite 
population decrease and increase with time in the mosquito.
55
 
 
2.1.2.2. Differentiation of the parasite within the human host 
 
The female Anopheles mosquito feeds it does so by either  cannulating blood from pools generated 
by damaged capillaries or directly from larger subcutaneous blood vessels.63  While feeding the 
mosquito vector releases a small number of sporozoites into the bloodstream. 
Differentiation in the human host occurs in two stages, the hepatic stage (Figure 2.3), and the 
erythrocytic stage.  Within minutes of entering the bloodstream the sporozoites reach the liver cells 
beginning the hepatic stage.64   The classic liver lobule consists of a dual blood supply consisting of 
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the portal venule and hepatic arteriole entering at the portal field, which also includes the bile duct 
(Figure 2.3A).  The blood supplies merge when entering the liver lobule, travel through the sinusoids 
and exits via the central vein.  Found within the sinusoids are Kupffer cells, these cells are 
macrophages tasked with the removal of foreign substances from the blood (Figure 2.3B).65  The 
Plasmodium sporozoites enter the liver sinusoid through the portal venule and hepatic arteriole and 
travel along the endothelia cells until coming into contact with a Kupffer cell (Figure 2.3C).66  The 
sporozoites invade and safely navigate the Kupffer cells, by surrounding themselves with a vacuole 
which does not fuse lysosomes.65,67   The sporozoites exit the Kupffer cell intact into the space of 
Disse, where the sporozoites quickly invade hepatocytes.  However, the sporozoites do not develop 
within the first invaded cell but migrate through several hepatocytes (Figure 2.3D). Little is known 
about the entry into the finial hepatocyte, or even development within the hepatocyte.  But what is 
known is the sporozoite surrounds itself with a parasitophorous vacuole inside which it develops 
into an exoerythrocytic form (EEF).68   Development into the EEF involves morphing of the elongated 
sporozoites into a spherical form (Figure 2.3E).69  The EEF is the intermediate tissue stage between 
the mosquito vector and erythrocytic stage.70  The EEF grows to several sizes larger than that of the 
host cell and undergoes multiple rounds of nuclear division and differentiate into thousands of 
merozoites which eventually initiate the erythrocytic stage (Figure 2.3F).71   The growth and 
replication of nucleic acid in the liver is far greater than schizogony experience in the blood stage.  
This is due to the large stores of glycogen found in hepatocytes i.e. a large supply of nutrients to fuel 
schizogony.65  The merozoites held together by the hosts cytoplasm swell into the sinusoidal lumen 
and eventually rupture releasing the merozoites (Figure 2.3G).72   
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Figure 2.3: A:  A healthy liver lobule, the portal venous and arterial supply blood to the liver cells entering 
the liver lobule at the portal filed. These two blood supplies merge after entering the sinusoid, 
flow along the hepatic cord and exit via the central venule.  B:  The hepatic sinusoid is lined 
with Kupffer cells, which are separated from hepatocytes by the space of Disse.  C:  A 
sporozoite (indicated by a red arrow) glides along the hepatic sinusoid until if finds a Kupffer 
cell, which it evades, passes through and enters a hepatocyte.  D:  After transmigrating several 
hepatocytes, the sporozoite will settle in a final hepatocyte and begin to grow.  E:  The 
sporozoite begins to grow displacing the hepatocyte’s organelles.  F:  The infected hepatocyte 
may contain thousands of mature merozoites.  G:  The hepatocyte finally ruptures releasing 
the mature merozoites into the sinusoid, to be transport around the body.
65
    
 
 Once released into the venule, the merozoites randomly attach themselves to cells surfaces until 
they finally come into contact with an erythrocyte surface.  Once attached to the erythrocyte surface 
the merozoite reorientates itself to bring its apical prominence into contact with the host cell.   The 
apical prominence is tightly bound to the surface via parasite receptors binding to ligands on the 
erythrocyte membrane.  The proteins required for this binding are secreted or located from or on 
the apical prominence.  The invasion of the cell is initiated by the secretion of a material which 
creates an invagination (invasion pit) in the host cell.  The parasite moves deeper into this cavity 
until the erythrocyte membrane seals itself off at the posterior of the merozoite.  This enclosure is 
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called the parasitophorous vacuole (PV), whose membrane is made up of both the erythrocyte lipid 
bilayer and the secretions of the merozoite.73  Once in the erythrocyte the merozoites loses its 
invasion organelles and begins to differentiate into a spherical trophozoite (ring stage).  The 
trophozoites increases in size and under goes multiple rounds of schizogonic division eventually 
causing the erythrocyte to rupture releasing new merozoites into the bloodstream able to invade 
further erythrocytes.74  Development of merozoites in the erythrocyte takes approximately 48 hours, 
resulting in around twenty merozoites per mature parasite.75  The merozoites only remain in the 
bloodstream momentarily, roughly 60 seconds, before infecting another erythrocyte to continue the 
cycle.76  With the rupture of each erythrocyte the parasite’s waste is also released into the blood 
stream, causing some of the clinical symptom experienced by patients, including fever, chills, 
headaches, adnominal and back pains, nausea, diarrhoea and occasionally vomiting.  During the 
maturation into trophozoites the erythrocyte loses its biconcave shape and becomes spherical77-79 
and produces adhesive proteins which allow these altered erythrocyte to stick to the lining of blood 
vessels.75,80  The purpose of the adherence to the epithelial lining is to protect the parasite from 
annihilation as free circulating infected erythrocytes are disposed of in the spleen.81  During the 
asexual cycle in the erythrocytic stages, a few merozoites develop into male and female 
gametocytes.  These are in turn released into the blood circulation where they are ingested as part 
of the bloodmeal of the mosquito, continuing the cycle of infection.82  While the parasite is in the 
erythrocyte it is greatly dependent upon the digestion of haemoglobin, for the parasite to continue 
functioning.  
 
2.1.2.3. The digestion of haemoglobin within the erythrocyte by P. falciparum 
 
The parasite, which is now contained within the erythrocyte’s cytoplasm, creates an invagination at 
the parasitophorous membrane, engulfing the host cytoplasm (which predominantly consists of 
haemoglobin) in a pinocytic fashion.  This newly formed transport vesicle delivers the haemoglobin 
to the parasites’ food vacuole.  The food vacuole is an acidic environment which contains several 
parasitic proteases, some of which are responsible for the hydrolysis of the haemoglobin into 
smaller peptide fragments essential for the parasites protein synthesis.83  The parasite has been 
shown to digest between 60% - 80% of the total haemoglobin contained within the infected 
erythrocyte.84  In the process of the catabolism of haemoglobin, ferrous haem (Fe(II)-protoporphyrin 
IX) and oxygen is released.  Free haem is highly toxic to the cells as it causes inhibition of enzymes, 
peroxidation of membranes and production of oxidative free radicals, the latter two leading to lysis 
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of both the erythrocyte and the malaria parasite.83   The reduced free haem is oxidised to its ferric 
form (FP-Fe(III)).  Due to the high concentration of oxygen and acidity within the food vacuole, 
oxygen radicals are produced via the Fenton85 and Haber-Weiss86 reactions.87  The oxygen accepts 
the electrons from the iron, contained in haem, initiating the chain of oxygen radical species 
metabolism.87   At the pH 5, as in the digestive vacuole, the superoxide anion is spontaneously 
converted to H2O2 and O2, leaving the parasite with even a greater problem of disposing of the even 
more toxic peroxide (Scheme 2.1). 
FP-Fe(II) FP-Fe(III)
O2 O2
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H+
1/2 H2O2 + 
1/2 O2
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Scheme 2.1: The ferrous iron catalysed formation of hydrogen peroxide.
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The parasite does possess an oxidant defence system consisting of superoxide dismutase and 
glutathione peroxidase,89,90 however these are thought to be predominately concentrated in the 
parasite’s cytoplasm.  A temporary solution exists in which the parasite uses the host’s enzymes, 
which the plasmodia obtains when the parasite engulfs haemoglobin, however these proteins are 
quickly degraded by enzymes within the food vacuole, leaving the vacuole vulnerable to oxidative 
damage.91  Haem can also react with H2O2, displaying both catalase-like and peroxidase-like activity.  
The hydrogen peroxide oxidises the porphyrin ring, to form an active intermediate FP-Fe(IV)* that 
participates in the catalase-like reaction of H2O2 to O2 and H2O reducing the porphyrin ring back to 
FP-Fe(III) (Scheme 2.2).  The intermediate FP-Fe(IV)* can also be involved in the peroxidise-like 
oxidation of glutathione, protein or lipids.  Alternatively the oxidation of FP-Fe(III) by H2O2 can 
destroy the porphyrin ring.88   
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Scheme 2.2: A proposed mechanism for the catalase and peroxidase-like activities of haem.
88
 
        
As previously stated the catabolism of haemoglobin yields toxic monomeric haem.  Although FP-
Fe(III) is relatively insoluble in the acidic aqueous solution that is contained within the food vacuole, 
however it can still potentially dissolve in the non-polar lipid membrane.92  In most higher organisms 
haem is processed by the enzyme haem oxidase which breaks down the porphyrin ring releasing 
carbon monoxide, ferric ions and biliverdine.93    The malaria parasite, however, uses a different 
method of detoxification, viz. forming a haem-polymer, named hemozoin.  The advantage of not 
using haem oxidase is the prevention of potential toxicity problems that may arise from the release 
of iron and carbon monoxide.94    It has been found that hemozoin contains a penta-valent iron (III) 
complex in a high spin state.  The central iron atom is coordinated to the four adjacent nitrogen 
atoms contained in the planar porphyrin ring while the fifth bond results from the oxygen contained 
in the acid side chain of another haem unit (See Chapter 4).95,96 In the past two decades there has 
been much debate on the cause of this polymerization, which will be further discussed in Chapter 4. 
Regardless of the polymerization mechanism it has been shown that hemozoin is far less active in 
causing membrane peroxidation.97  The detoxification of haem will be discussed in greater detail in 
Chapter 4.     
 
2.1.3. Chemotherapy 
 
The growing severity of malaria infection has elevated this disease to one of the top three 
commutative diseases.  Malaria is on the rise due mainly to a growing resistance of the parasite to 
antimalarials, resistance of the Anopheles mosquito to insecticide as well as the limited resources of 
many malaria-epidemic countries.  It seemed decades ago that malaria might go the same way as 
smallpox and be completely eradicated however, this is anything but the case.98  The malaria 
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parasite is showing resistance to many of the old and newer drugs on the market, this may be due to 
several factors including; the use of inferior counterfeit drugs,99,100 poor diagnosis,101,102 and/or the 
unique ability of the parasite to develop resistance to these drugs.103  Another issue, paralleling the 
crisis of resistance, is the unwillingness of major pharmaceutical companies to develop new 
antimalarials.  The antimalarial market is one of the largest medical markets to date with near to half 
a billion treatments required each year, however the majority of patients are poor and cannot afford 
to pay for treatment.  Hence there is very little appeal to the pharmaceutical companies to invest 
major amounts of money on drugs which will see them little or no return on their investment.104    
For a successful antimalarial, one needs to exploit the metabolic differences between the host and 
parasite.  The continued emergence of resistance to currently available drugs necessitates the 
urgent need for the development of new drugs, either for existing drug targets or for newly 
discovered biochemical pathways.105        
When malaria is referred to in this thesis it refers to malaria caused by the most prominent of the 
species in the infection of humans, P. falciparum, unless stated otherwise. For the purposes of this 
thesis currently available antimalarial drugs will be divided into two classes, blood schizontocides 
(Figure 2.4) and nucleic acid inhibitors (Figure 2.5), with the primary focus on blood schizontocides 
and more specifically the aminoquinolines.    
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2.1.3.1. Blood schizontocides 
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Figure 2.4: Some commonly used antimalarial drugs targeting the blood schizonts. 
 
Quinoline containing drugs are some of the most common drugs in the treatment of malaria.  
Quinolines are divided into two classes:  the aminoquinolines (e.g. chloroquine) and the aryl-amino 
alcohols (e.g. quinine) which differ in their physical properties at a neutral pH.    
The two major drugs in the aminoquinoline class are chloroquine and amodiaquine (Camoquin®).   In 
the 1940s, while testing for less toxic analogues of quinine, chloroquine was produced.106  Until the 
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development of resistance in the 1960s, chloroquine was the most widely used antimalarial,107  its 
popularity was due to chloroquine’s low cost of production and lack of side effects.  Amodiaquine is 
effective as a treatment by itself, however it is most potent in combination with chloroquine.     
Amodiaquine is only effective in parasites that have developed a low level of chloroquine 
resistance.108  In most western countries amodiaquine is no longer available due to its readiness to 
undergo biotransformation of its p-aminophenol moiety into a toxic quinoneimine, resulting in 
severe heptotoxicity and agranulocytosis .108-110  These effects seem to occur over a prolonged 
exposure to amodiaquine, thus it is still possible to safely use this drug in shortened therapeutic 
regimes.111    Chloroquine still remains a major course of treatment for malaria induced by P. vivax, 
P. malariae, and P. ovale.54  Aminoquinolines interfere with the sequestration of haem thus 
poisoning the parasite on its own metabolic waste and this mechanism will be discussed further in 
Chapter 4.    
The mechanism of action for aryl-amino alcohols is not completely understood, however it does 
differ from that of aminoquinolines.  This class of drugs also seems to interfere with the digestion of 
haem.112,113  Quinine is the earliest of all antimalarials, which has been used in one form another for 
the past 350 years.  It was first discovered in South America, where it is found in the bark of the 
Cinchona tree that the local inhabitants used as an antipyretic agent.114  In the seventieth century it 
was imported to Europe from Peru to be used as an antimalarial.115  Quinine is still used today for 
uncomplicated malaria116 and is often the only choice for life-threatening cerebral malaria.117  
Quinine has multiple side effects, most of which are not permanent, but some are severe such as its 
arrhytomogenic potential and the release of insulin which may result in hypoglycaemia.107  If quinine 
is used over a prolonged period vasculitus,118 haemolytic-uraemic syndrome,119 and 
thrombocytopaenia120 may develop.  Due to the dependence on raw materials required for the 
extraction of quinine a need arose for synthetic substitutes which led to the discovery of many new 
antimalarials.  Melfloquine has been used for more than two decades and is regarded as a 
structurally simplified version of quinine.  Melfloquine, when used as a prophylactic, results in 
neuropsychiatric side effects, such as insomnia, depression and panic attacks.  Halofantrine is 
another quinine analogue but is linked to an increase risk of cardiac arrythmias, as prolonged use 
inhibits the inward K+ ion flow.108  For this reason halofantrine has been withdrawn from several 
countries.107  Lumefantrine is less effective against malaria than halofantrine, but lacks the cardiac 
side effects.121 
Artemisinine is a natural product which is active against malaria.  Artemisinine it is derived from the 
Chinese herb ‘qinghao’ (Artemisa annua), which was traditionally used in the treatment of fevers.115  
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Many synthetic analogues of  artemisinine have been developed which have greatly decreased the 
cost of this class of antimalarials.122  Artemether is a more lipophilic molecule than artemisinine and 
is better absorbed from the gastrointestinal tract, allowing it to be taken orally.123  Due to the 
carboxylate fuctionality in artesunate, this drug is a hydrophilic molecule, requiring intravenous 
administration.  This is important in severe malaria case as the patient is often in a state where no 
other mode of administration is possible.98    Once in the body all the artemisinines are metabolised 
to the active dihydroartemisinine.  These drugs predominately target the late ring stages, but also 
act against the small ring stages present in the erythrocytes hours after infection.124  This class of 
drugs is highly active in the reduction of the parasites biomass, dropping it 10 000-fold in a single 
asexual cycle.125,126  The mode of delivery make artemisinines the most rapid and active drugs in the 
fight against malaria to date.107  The pharmacaphore in dihydroartemisinine appears to be the 
endoperoxide bridge.  This has been shown to be broken down by ferrous ions, in the parasites 
digestive vacoule, resulting in carbon-centred radicals.  These radicals in turn alkylate and oxidize 
proteins and lipids and modify haem107,127 as well as inhibit a calcium pump (PfATP6) located on the 
endoplasmic reticulum.128  Another proposed method of activation of these drugs is the reductive 
cleavage of the peroxide bond by iron-sulphur redox centres, which are commonly found in 
Plasmodium enzymes, and that the alkylation of these enzymes may result in the death of the 
parasite.129    
Many of the antibiotics show no visible effect on the first erythrocytic intracellular cycle, but rather 
on the second cycle.  The parasites are killed shortly after the second invasion of the erythrocyte.  
This is known as the ‘delayed death phenotype’ or ‘the delayed kill effect’.130,131  Antibiotics, 
therefore, show far longer fever and parasite clearance times when compared to classic antimalarial 
drugs.  Thus antibiotics are used in combination with faster acting drugs in the treatment of acute 
malaria.  The classical antimalarials rapidly reduce the number of parasites while the antibiotic 
continues to kill any remaining or resistant parasites.  Doxycycline is predominately used as a 
prophylactic but may, in combination with quinine or artesunate, be used in the treatment of 
uncomplicated or even severe malaria.132  Doxycycline’s major side effects include increased 
photosensitivity, gastrointestinal disturbances, enamel hypoplasia and depression of bone growth.  
Due to its effect on developing bones and teeth, doxycycline is unsuitable for children under eight or 
pregnant women.107  Clindamycin is used as an alternative to doxycycline in the treatment of 
malaria, since it is considered safe during pregnancy and for the use in young children.133  Antibiotics 
act on the prokaryote-like protein synthesis machinery of the mitochondria and/or apicoplast.130,134  
The antibiotics are thought to inhibit protein synthesis by binding to the 30S ribosomal subunit 
preventing the 50S and 30S units from bonding.130   
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2.1.3.2. Mechanism of resistance to chloroquine-type antimalarials 
  
For the purposes of this thesis only chloroquine resistance will be discussed in detail while a 
summary of resistance to the remaining drugs is presented in Table 2.1.  Chloroquine resistance is 
present wherever P. falciparum malaria is prevalent.  Resistance to chloroquine was first reported in 
1957 on the Thai-Cambodian border.135   However, by 1980 all of South America was affected and by 
1989 all P. falciparum located in Asia and Oceania were resistant to chloroquine.  In East Africa the 
first case of chloroquine resistance was documented in 1978, and subsequent chloroquine resistance 
spread to central and southern parts of Africa finally arriving in West Africa by 1989.136  Due to the 
high levels of chloroquine resistance many countries in Africa have changed their first-line treatment 
of malaria to sulfadoxine-pyrimethamine or a combination of chloroquine and sulfadoxine-
pyrimethamine (Figure 2.5).137  The distinguishing difference between chloroquine resistance and 
chloroquine-sensitive clones is the degree to which chloroquine accumulates in the food 
vacuole.138,139  Since drug resistance is related to the decrease in concentration of the drug in the 
food vacuole there are two possible pathways that are affected by resistance.  Firstly the parasite 
may take up less of the drug into the food vacuole and secondly the drug may be expelled from its 
food vacuole.98  If the uptake of chloroquine was totally dependent upon passive diffusion of the 
drug into the food vacuole (i.e. dependent on a pH gradient), a hindrance in the proton pumps 
should alter the pH of the food vacuole and hence the concentration of chloroquine.  However 
Geary et al.140 showed little difference in the pH, assuming then that the transport of chloroquine 
into the cell must be an active process.  The idea of an expulsion mechanism was supported by 
Krogstad et al.141 by showing that resistant parasites expel 40-50 times more chloroquine than 
chloroquine-sensitive parasites from the food vacuole of the parasite.  This removal of chloroquine 
from the food vacuole, is why the primary focus of chloroquine resistance in P. falciparum has been 
on the polymorphism of two genes, the pfcrt142 and the pfmdr1,143 which code for a membrane 
transporter protein and glycoprotein homologue 1 (Pgh1) respectively.  The major mutation of the 
pfcrt gene product in chloroquine-resistant strains is the substitution of Thr76 for Lys76 and has been 
found in resistance strains throughout Africa,142,144-146 Asia147,148 and South America.149  The mutation 
of the Thr76 has also been shown to be present in chloroquine-sensitive strains, indicating that other 
mutations of pfcrt are necessary or other genes are involved.137  Pgh1 has shown several cases of 
polymorphism associated with chloroquine resistance, the point mutation of Asp86 to Tyr86 present 
in resistant strains in Africa,142,144,150,151 Asia152 and South America.153  Other polymorphism exist 
Phe184 in South America,154 Cys1034 in South America,149 Asp1042 in South America,153 Asia155 and 
Africa151 and Tyr1246 in South America154 and Africa151 resulting in chloroquine restistant strains of P. 
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falciparum.  Amodiaquine has been shown to be effective against low level chloroquine-resistant 
strains of P. falciparum, but show little effect against high level chloroquine-resistant strains.108 
Table 2.1: A summary of resistance to the current arsenal of antimalarial drugs. 
 
Drug Introduced 
First 
reported 
resistance 
Location of 
resistance 
Parasite 
Gene 
Mechanism of resistance
156
 
      
Quinine 1632 1910
157
 SE Asia
154
 pfmdr1 
Reduced influx or increased 
efflux in the FV 
Chloroquine 1945 1957
135
 
Worldwide
144,146,1
52,154,155
 
pfcrt, 
pfmdr1 
Reduced influx or increased 
efflux in the FV 
Proguanil 1948 1949
158
 S. America
159
 dhfr Mutation at active site 
Sulfadoxine-
pyrimethamine 
1967 1967
160
 
Asia
155
, Africa,
137
 
S. America
137
 
dhps Mutation at active site 
Melfoquine 1977 1985
161
 
SE Asia,
152
 
Africa
162
 
pfmdr1 
Reduced influx or increased 
efflux in the FV 
Artemisinin 1978 2003
163
 Asia
163
 pfmdr1 Unknown 
Atovaquone 1996 1996
164
 Rare pfmdr1 Mutation at co-enzyme Q 
 
2.1.3.3. Nucleic acid inhibitors 
 
The most widely used nucleic acid inhibitors belong to the folate antagonist class of antimalarials.  
This class of antimalarial was not obtained from natural products but rather were developed from a 
comprehensive knowledge of biosynthetic pathways and synthetic organic chemistry (Figure 2.5).  
Type I antifolates (e.g. dapsone) mimic p-aminobenzoic acid (PABA) and compete for the active site 
of dihydropteroate synthase (DHPS).  DHPS is responsible for facilitating the conversion of 
hydroxymethyldihydropterin to dihydropteroate (Scheme 2.3) in the folate pathway.  Type II 
antifolates (e.g. pyrimethamine) inhibit dihydrofolate reductase (DHFR) which is responsible for the 
reduction of H2folate to H4folate (Scheme 2.3).  Inhibition of enzymes in the folate pathway results 
in a decrease in the synthesis of pyrimidine and therefore a reduction in DNA, serine and methionine 
production.  Due to the high level of asexual reproduction erythrocytic stage of the plasmodia 
lifecycle, antifolate predominately target this stage.156      
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Figure 2.5: Nucleic acid inhibitors used as antimalarials.   
 
This class of drug is often used as a combination; sulfadoxine/pyrimethamine (Fansidar®) and 
dapsone/chlorproguanil (LapDap®).   Fansidar® has now over taken chloroquine as the major first-
line antimalarial treatment.165  While this drug combination is regarded as safe for the treatment of 
malaria, a prolonged use as a prophylactic has been linked to an increased risk of agranulocytosis 
and toxic epidermal necrolysis (Steven-Johnson syndrome) resulting in blistering of the skin.108  This 
has resulted in many countries discontinuing the use of Fansidar® as a prophylactic.107  The major 
appeal of these combinations of drugs lies in their affordability and its slow elimination from the 
body, meaning only a single dose is often required for treatment.122  By using these drugs in 
combination their activity is increased as well as reducing the potential for resistance.115  The 
sulfadoxine/pyrimethamine combination has been very successful in the intermittent treatment of 
malaria during pregnancy.166 
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Scheme 2.3: The conversion of hydroxymethyldihydropterin to dihydropteroate facilitated by DHPS (above).  
The conversion of H2folate to H4folate via the NADPH dependent DHFR enzyme (below). 
 
The use of the hydroxynaphthoquinone atovaquone (Figure 2.5) as a single agent has resulted in the 
rapid onset of resistance resulting in serious therapy failure rates,167 and this resistance has lead to 
atovaquone being prescribed in combination with proguanil (Malarone®).  Malarone® is primarily 
used as a prophylactic, however due to its high cost it has yet to achieve widespread status in 
developing countries.  The main reason for the high cost is due to the complex synthetic route to 
atovaquone.115  Malarone® is also used in the treatment of uncomplicated malaria, where it is 
effective against early liver stages of the parasite.107  Malarone® has also thus far shown no severe 
side-effects.107  One putative target for atovaquone is the enzyme dihydroorotate dehydrogenase 
(DHODase),168,169 which is crucial for electron transport as well as the de novo biosynthesis of 
pyrimidine.170  Atovaquone has also been shown to bind to the ubiquinone binding site of the 
cytochrome bc1 complex, which inhibits the movement of an iron-sulphur cluster, which contains a 
protein domain essential for electron transport.107  This disruption of the electron transport chain 
results in the rapid breakdown of the mitochondrial membrane potential.107   Atovaquone works in 
synergy with the non-metabolized proguanil and chlorproguanil.   When atovaquone disrupts the 
mitochondrial membrane potential, an alternative pathway is generated involving ATP hydrolysis.  
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This pathway involves the exchange of ADP3- and ATP4- by the ATP/ADP transporter.  Proguanil 
inhibits this pathway resulting in a swift reduction in the membrane potential.171    
 
2.1.4. New approached to antimalarial drug development 
2.1.4.1. Improving therapy of existing drugs [Combination therapy (CT)] 
 
With the development of resistance to nearly all of the existing agents, as shown in Section 2.1, 
many combinations of current drugs are available.  These new dosing regiments may optimise drug 
activity.   There are two major advantages offered by CT, firstly the supplementation of additional 
antimalarials should increase efficiency or ideally act in synergy with one another.  A classic example 
of this is the proguanil/atovaquone combination; both showed failure rates when used as individual 
agents, but become a potent antimalarial when combined.  The second, and most important, reason 
for CT is the induced delay of the onset of resistance to the agents used in combination.  The use of 
CT may slow the progression of resistance to any newly developed antimalarials.   When designing 
new drugs for CT, the drugs should both show little or no resistance to the parasite and have similar 
pharmacokinetics.  By having similar pharmacokinetics diminishes the chances of having low 
concentration of either drug being present in the bloodstream reducing the likelihood of developing 
resistance.  However, it is possible to use of combination of drugs with different pharmacokinetics, 
by using a potent short-acting drug and a longer-lasting drug although, this has only proven effective 
if the short-acting drug is potent enough to sufficiently overcome the parasite-burden such that 
there are limited parasites to develop resistance to the long-lasting drug.172  A modern CT-drug 
which was in Phase III trials named LapDap+ (dapson/chlorproguanil/artesunate) showed significant 
shorter parasite clearance time when compared to the dapson/chlorproguanil combination, 
however at the time of writing GSK had ceased testing due to patient complications.107  Nowadays it 
may be important to consider the use of CT when designing drugs.  Developed drugs may show little 
promise as a single antimalarial agent but may be far more effective if used in a combination 
therapy.  
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2.1.4.2. Analogues of existing drugs 
 
The second approach to the development of new antimalarials is the improvement of current 
antimalarials through their chemical modification.  This method requires little or no knowledge of 
the mechanism of action or biological targets of the parent drug.  As previously discussed many 
drugs on the market were developed in this manner, for example: chloroquine, primaquine and 
mefloquine are all analogues of quinine or lumefantrine was developed as an alternative to the toxic 
halofantrine.173  An even more recent example of this would be the 8-aminoquinoline, tafenoquine, 
which is currently in the advanced stages of clinical trials.  This analogue shows improved activity 
against the hepatic stages of the parasite over its parent compound primaquine.174  The addition of 
the trifluoromethylphenyloxy substituent increases the antiplasmodial activity however, there still 
exists a risk of haemolysis in G6PD-deficient humans.107   
 
 
2.1.4.3. Compounds active against other diseases 
 
The third approach involves the discovery of novel antimalarials amongst drugs designed for 
treatment of other diseases.  This approach has both advantages and disadvantages.  As previously 
stated malaria is a disease of poverty, and funding for the development of new antimalarial is usually 
a major concern, however by looking at an assortment of already developed drugs all the major 
costs of safety test for human consumptions are complete and therefore, the cost of developing 
these drugs as antimalarials may be minimal.  Drugs developed for diseases in wealthier nations, 
such as cancer, often are too expensive to develop into antimalarials, but may become less 
expensive as patents expire.172  A good example of this type of approach is the development of 
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tetracyclines, such as doxycycline, which were developed for their antibacterial properties and were 
only later discovered to show activity against the malaria parasite. 172 
 
2.1.4.4. Drug resistance reversers 
 
With antimalarial drug resistance on the rise, many potent inexpensive drugs are rendered obsolete.  
A number of compounds however, have been shown to have the ability to reverse the resistance of 
P. falciparum to chloroquine.  For example the antidepressant, desipramine,175 the anthypertensive 
verapamil176 or the antihistamine chlorpheniramine177 have all shown an increase in sensitivity to 
chloroquine in the plasmodial parasite when supplemented with chloroquine.  A major downfall to 
resistance reversers is the unacceptable concentrations required to be effective.   With the design of 
new resistance reversers,178,179 chloroquine may see a resurrection and once again be used as the 
primary treatment for malaria.     
2.1.4.5. Malaria vaccines 
 
During the writing of this thesis GlaxoSmithKline (GSK) was in the process of conducting the Phase III 
clinical trial of their malaria vaccine, RTS,S.  After the success of the Phase II clinical trial,180-185 GSK 
began conducting drug trials on 15,460 infants and young children in 11 sites across seven African 
countries.  RTS,S triggers an immune response to help prevent P. falciparum from infecting, 
maturing and multiplying in the liver, while simultaneously preventing the parasite from re-entering 
the bloodstream and re-infecting erythrocytes. RTS,S fuses a circumsporozoite protein, a surface 
protein which assists P. falciparum in invading human liver cells with GSK’s hepatitis B vaccine, 
resulting in an immune response.186  The initial results of the Phase III clinical trial for 6 000 children 
aged 5 to 17 months were released in November 2011.  The children received three doses of the 
RTS,S vaccine or a non-malaria comparator vaccine over a twelve month period.  The initial results 
show a 56% and 47% decrease in risk of the children experiencing clinical and severe malaria 
respectively.187  The results of the Phase III clinical trials for infants (6 to 12 weeks old) will be 
available in the fourth quarter of 2012 while the results from the long term study of the RTS,S 
vaccine will be released in the fourth quarter of 2014.  The WHO has indicated that the RTS,S vaccine 
may become available for national immunisation programs in early 2015.188  The possible success of 
this vaccine may change the direction of antimalarial prophylactic research completely. 
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2.1.4.6. Natural products 
 
The final approach to development of antimalarial chemotherapy is natural products.  Natural 
products are responsible for two of the most widely used antimalarials to date, quinine and 
artemisinin.  In regions afflicted by malaria there often exists a traditional knowledge of medicinal 
plants and organisms, which may prove to be an invaluable resource in the development of new 
antimalarials.  The use of marine natural products in drug discovery is covered in Chapter 1.   
 
2.2. Antiplasmodial marine isocyanate, isothiocyanate and 
isonitrile terpenoids 
 
Terpenoids are common secondary metabolites found in marine organisms such as sponges and 
nudibranchs many of which show antiplasmodial activity.189 For the purposes of this review and in 
the context of research described later in this thesis, only isonitriles and isothiocyanates marine 
secondary metabolites which exhibit antiplasmodial activity will be discussed here (Table 2.2).  The 
first reported isolation of a marine isonitrile-containing metabolite occurred in 1973 when 
axisonitrile-1 (2.1) was isolated from the sponge Axinella cannabina,190 shortly afterwards other 
isonitrile and isothiocyanate-containing sesquiterpenoids (2.2, 2.3 and 2.5) as well as axisonitrile-3 
(2.4) where isolated from the same source.191,192  Nearly two decade later 2.4 and 2.5 was once again 
isolated, this time from the North Eastern Australian sponge Acanthella klethra (Figure 2.6, Left) 
along with the isothiocyanates 2.6-2.8.  
 
Figure 2.6:   Underwater photographs of Acanthella sp. sponge (left) and Phyllidia sp. nudibranch (right).
193
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 Angerhofer et al.194  first described the antiplasmodial activity of compound 2.4-2.8, with the most 
active compound being 2.4 which exhibited antiplasmodial activity of  71 nM.194  With the 
conversion of the isonitrile to the isothiocyanate the antiplasmodial activity was shown to be 
reduced by 500 fold.194  This discovery indicated that activity of the compound was dependent upon 
the presence of isonitrile functional group.  The discovery of antimalarial potential in marine 
isonitriles sparked in-depth research into sponges of the Axinellidae and Halicondridae families.  A 
series of isonitrile, isothiocyanate and isocyanate diterpenes consisting of isocycloamphilectane (2.9-
2.13), cycloamphilectane (2.14 and 2.15), amphilectane (2.16-2.21) and isoamphilectane (2.22) 
backbones  and 2.23 were isolated from the halichondrid sponge Cymbastela hooperi.195  Generally 
all these molecules showed good antimalarial activity.  Of the isocycloamphilectanes, compound 
2.12 showed the most potent antiplasmodial activity of (7 nM).196  When comparing this compound 
with the amphilectanes and isocycloamphilectanes there was a general decrease in antiplasmodial 
activity with the exception of 2.19 which showed antiplasmodial activity (31 nM).196    In more recent 
years Wattanapiromsakul et al.197 isolated four tricyclic diterpene isonitriles (2.24-2.27) from the 
Ciocalapata sp. sponge collected off the coast of Kho-Tao, Thailand, which showed antiplasmodial 
activity.  A recent study of a Puerto Rican sponge Hymeniacidon sp. has yielded monamphilectine A 
(2.28), a new β-lactam containing isonitrile which shows promising antiplasmodial activity.198   A 
series of kilihinane diterpenoids (2.29-2.33) were discovered from the Okinawan sponge Acanthella 
sp.  These kilihinane diterpenoids are known for their anthelmintic, antibacterial and antifouling 
abilities, in addition they showed potent antiplasmodial capabilities.199  The most active in the series 
was kalihinol A 2.29 which exhibited a very significant antiplasmodial activity (1 nM). The bicyclic 
isothiocyanate (2.34) was isolated from a Halichondria sp. sponge collected off the Hawaiian island 
Oahu.200   While compound 2.35 has not been tested for its antiplasmodial activity it is worth noting 
as it will be discussed further in Chapter 4.  3-Isocyanotheonellin (2.35) was isolated from the Sri 
Lankan Phyllidia sp. nudibranch201 (Figure 2.6, Right) and displayed moderate antiplasmodial 
activity.202  The reported antiplasmodial activity of marine isonitriles, isocyanates and 
isothiocyanates are presented in Table 2.2.   
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Table 2.2: Antiplasmodial activity of marine isonitriles 2.4-2.35 
 
Compound 
IC50  
*μM+ 
Compound 
IC50  
*μM+ 
Compound 
IC50  
*μM+ 
      
2.4 0.61
a
 / 0.071
b
 2.15 0.25
a
 / 0.081
b
 2.26 0.44
c
 
2.5 46.89
a
 / 11.8
b
 2.16 1.02
a
 / 0.45
b
 2.27 0.98
c
 
2.6 8.51
a
 / 2.32
b
 2.17 1.75
a
 / 0.81
b
 2.28 0.04
b
 
2.7 15.20
a
 / 2.09
b
 2.18 1.32
a
 / 0.31
b
 2.29 0.001
d
 
2.8 38.0
 a,b
 2.19 0.047
a
 / 0.031
b
 2.30 1.8
d,e
 
2.9 0.015
a
 / 0.013
b
 2.20 0.20
a
 / 0.086
b
 2.31 2.6
d,e
 
2.10 0.13
a
 / 0.08
b
 2.21 2.31
a
 / 1.23
b
 2.32 0.01
d,e
 
2.11 0.22
a
 / 0.16
b
 2.22 0.30
a
 / 0.10
b
 2.33 0.08
d,e
 
2.12 0.009
a
 / 0.007
b
 2.23 30.19
a,b
 2.34 5.7 
2.13 0.21
a
 / 0.066
b
 2.24 0.09
c
 2.35 ND 
2.14 0.29
a
 / 0.08
b
 2.25 1.07
c
 Chloroquine 0.29 
 
a
  Tested against the Serra Leone chloroquine-sensitive P. falciparum clone D6 
b
  Tested against the Indochinese chloroquine-resistant P. falciparum clone W2 
c
  Tested against the Loatian chloroquine-resistant P. falciparum clone K1 
d
  Tested against the Gambian chloroquine-resistant P. falciparum clone FCR-03  
e
  Values quoted as EC50  
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2.3. Putative mechanism of marine isonitrile antiplasmodial 
activity 
 
Based on a series of spectroscopic experiments (e.g. UV/vis and mass spectroscopy), Wright et al.196 
concluded that marine isonitriles (2.4 and 2.9-2.23) have the ability to form ligand-haem complexes.   
They continued to elaborate on the binding motif of the isonitrile-haem by creating a generated 3D 
pseudoreceptor envelope based on the proposed pharmacophore calculated on the marine 
isonitrile/isothiocyanate haem interaction through force field molecular dynamics.  An averaged 
receptor surface was generated by surrounding the inhibitor models with envelope-defining virtual 
particles possessing physiochemical descriptors, such as hydrophobicity, partial charge, electrostatic 
potential and hydrogen-bonding affinity.  The outcome of this pseudoreceptor suggested the 
electrostatic interaction between the axial isonitrile/isothiocyanate at C-7 or C-20 and the iron atom 
within the porphyrin of haem (Figure 2.7, Left).  Wright et al.196  therefore, proposed that the 
antiplasmodial activity of 2.4 and 2.9-2.23 was a result of the parasites inability to successfully 
sequester haem into hemozoin. A toxic build-up of haem results in the irreversible damage to 
parasite proteins and membranes resulting in the death of the plasmodia.  The major criticism of the 
use of a pseudoreceptor model is the assumption that these compounds inhibit one target and the 
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compounds corresponding IC50 value is directly related to the compounds ability to better bind to 
the pseudoreceptor.  When in fact the pseudoreceptor may describe, for example a transport 
protein responsible for the accumulation of the compound at the active site and therefore the IC50 
value may be related to a higher availability of the compound at the active site as opposed to a 
higher affinity for the active site.203 
Ten years later Wright and co-workers204 revisited the biological effect of marine isonitriles by 
evaluating 2.4, 2.9, 2.15, 2.19 and 2.20 for anti-algal, anti-tubercular, anti-bacterial anti-
photosynthetic and anti-fouling activities.  The initial success shown by these compounds to inhibit 
the growth of the freshwater algae Chlorella fusca led them to the hypothesis that the mode of 
action may lie in the interference with the photosynthetic process within symbiotic organism that 
reside in the algae and would account for a decrease in algal growth.  Therefore, these isonitriles 
where further analysed for their ability to inhibit photosynthesis, which 2.9, 2.19 and 2.20 showed a 
decrease in photosynthesis of 37, 45 and 69% respectively at a test concentration of 0.2 mg.mL-1.  
Wright and co-workers postulated that the antiplasmodial and anti-photosynthetic activity may be 
related through the inhibition of haem-containing proteins such as cytochromes b and f both of 
which are involved in the carbon fixation cycle of photosynthesis and promulgation of malaria.  They 
therefore docked 2.4, 2.9, 2.15, 2.19 and 2.20 into deoxy-human haemoglobin and plant cytochrome 
CYP74A as representations of haem-containing proteins.  They observed that 2.4, 2.9, 2.15, 2.19 and 
2.20 had an affinity for a cavity directly adjacent to haem, which was contained in both proteins.   
They consequently named this cavity the “heme trench”.  The binding motif of 2.4, 2.9, 2.15, 2.19 
and 2.20 showed the hydrophobic scaffold occupies the heme trench while the isonitrile moiety 
interacts with one of the carboxylic acid side chains of haem (Figure 2.7, Right).  While this new 
description of the antiplasmodial activity in the inhibition of haem-containing proteins is feasible the 
original hypothesis of the inhibition of hemozoin is far more attractive as a drug target and 
motivated us to revisit isonitriles binding to haem in Chapter 4.      
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Figure 2.7: The proposed docking conformation of 2.9 and free haem (left).
196
  The  docked conformation 
of 2.9 and deoxy-human haemoglobin (PDB code 2DN2). Compound 2.9 is represented as 
sticks and coloured by atom; the haem molecule is represented as sticks coloured yellow and 
by heteroatom type. The “heme trench” is represented as partial solid surface and coloured by 
hydrophobicity (Right).
204 
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3.1. Background 
3.1.1. A review of naturally occurring antiplasmodial diterpene natural 
products 
 
The diterpene class of compounds contains a plethora of structures and functionalities and they 
have been isolated from a multitude of marine and terrestrial sources.  In this section we will review 
the chemical literature published in the past decade, focusing on diterpene compounds which 
displayed antiplasmodial activity (Table 3.1 and Table 3.2).    
3.1.1.1. Isolation of antiplasmodial diterpenes from a terrestrial source 
 
In the past decade numerous diterpenes and triterpenes have been isolated from natural sources, 
many of which have shown antiplasmodial activity.  Numerous furanocassane and furanonorcassane 
diterpenes (3.1-3.50)205,206 extracted from the seed kernels of Caesalpinia crista, have shown 
antiplasmodial activity against P. falciparum, with IC50 values ranging from 0.1->10 µM.
205  
Caesalpinia crista is a plant found in the tropical and subtropical regions of Southeast Asia and is 
widely used by the local population for its medicinal properties.206  All furanocassane-type 
diterpenes showed antiplasmodial activity with the most potent of the series, norcaesalpinin E (3.4), 
displayed an IC50 value of 90 nM cf. chloroquine (290 nM).
205  Other furan-containing diterpenes 
have shown antiplasmodial activity such as gromphosten and gromphosten A (3.51 and 3.52) 
isolated from Gomphostemma niveum207 and hautriwaic acid lactone and viscidone (3.53 and 3.54) 
isolated from Baccharis dracunculifolia.208   
A triad of diterpene lactones (3.55-3.57), isolated from Parinari capensis, showed promising 
antiplasmodial activity (IC50 of 1.6, 2.0 and 5.0 µM) against chloroquine-resistant strains of P. 
falciparum.209  The South American shrub Azorella compacta afforded the mulinane-type diterpenoid 
(3.58-3.62) with antiplasmodial activity against P. berghei in vivo.210  Two new diterpenoids (3.63 and 
3.64) containing a similar scaffold to the mulinane-type diterpenes were isolated from the leaves of 
the Southern African plant Croton steenkampianus211 and an additional four rearranged mulinane 
diterpenes (3.65-3.68) were obtained from the roots of the Thai plant Jatropha integerrima.212   
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Figure 3.1: Antiplasmodial terrestrial plant diterpenes: furanocassane and furanonorcassane diterpenes 
(3.1-3.50), gromphosten and gromphosten A (3.51 and 3.52), diterpene lactones (3.55-3.57) 
and mulinane-type diterpenoid (3.58-3.68). 
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Clerodane diterpenoids (3.69-3.75) were isolated from the tree bark of Laetia procera with 
significant antiplasmodial activities against P. falciparum with IC50 in the low (0.5 µM) range.
213 A 
totarane (3.76) and an abietane (3.77) diterpene were isolated from the Southern African plant 
Harpagophytum procumbens (Devil’s Claw) both of which showed antiplasmodial activity.214  The 
extraction of the leaves of Hyptis suaveolens led to the isolation of an abietane-type diterpanoid 
endoperoxide (3.78) (IC50 of 0.3 µM).
215  Diterepene 3.78 was later re-isolated from aerial parts of 
Anisochilus harmandii along with the new diterepene (3.79) and the quinone-containing diterpenes 
(3.80 and 3.81).216  A study of five Plectranthus species provided seven known abietane-type 
diterpenes (3.82-3.88) all showing antiplasmodial activity.217  Six new pimarane-type diterpenes 
(3.89-3.94) were isolated from the Thai medicinal plant Kaempferia marginata with only compound 
3.90 and 3.92 showing an IC50 antiplasmodial activity of 28.9 and 10.5 µM respectively.
218  The 
Butanese medical planted Aconitum orochryseum afforded atisinium chloride (3.95),219 while 
Scoparia dulcis afforded scopadulcic acid A (3.96)220 both with antiplasmodial activity.   
The anti-plasmodial activity of the plant derived diterpenes (3.1-3.96) is presented in Table 3.1.  Of 
interest is the variety of P. falciparum clones used in the various screening assays.  Interestingly, only 
14 of the 96 compounds presented in Table 3.1 have been screened against more than one P. 
falciparum clone.  The variation in antiplasmodial activity of individual compounds e.g. 3.63 and 3.74 
against different clones is noteworthy.    
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Figure 3.2: Antiplasmodial terrestrial plant diterpenes: clerodane diterpenoids (3.69-3.75), totarane 
diterepene (3.76),  abietane diterpene (3.77), abietane-type diterpanoid endoperoxide (3.78), 
quinone containing diterpenes (3.80 and 3.81), abietane-type diterpenes (3.82-3.88), 
pimarane-type diterpenes (3.89-3.94), atisinium chloride (3.95) and scopadulcic acid A (3.96).     
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Table 3.1:  Antiplasmodial activity of terrestrial diterpenes 3.1-3.96 
 
Compound 
IC50 
*μM+ 
Compound 
IC50 
*μM+ 
Compound 
IC50                
*μM+ 
Compound 
IC50      
*μM+ 
        
3.1 5.0
a 
3.25 >10
 a
 3.49 3.6
 a
 3.78 0.31 
3.2 0.8
 a
 3.26 0.1
 a
 3.50 0.7
 a
 3.79 15.6
 a
 
3.3 2.0
 a
 3.27 >10
 a
 3.51 126.4
b 
3.80 6.5
 a
 
3.4 0.09
 a
 3.28 0.6
 a
 3.52 9.9
b 
3.81 17.7
 a
 
3.5 0.8
 a
 3.29 >10
 a
 3.53 2.5
c
/7.0
d
 3.82 4.6
 a
 
3.6 0.3
 a
 3.30 1.9
 a
 3.54 9.0
c
/7.8
d
 3.83 29.2
 a
 
3.7 0.2
 a
 3.31 3.1
 a
 3.55 1.6
 a
 3.84 5.3
 a
 
3.8 ND 3.32 1.0
 a
 3.56 2.0
 a
 3.85 3.1
 a
 
3.9 0.098
 a
 3.33 0.8
 a
 3.57 5.0
 a
 3.86 6.0
 a
 
3.10 4.0
 a
 3.34 0.7
 a
 3.63 91
c
/28.5
e
 3.87 14.7
 a
 
3.11 6.5
 a
 3.35 1.0
 a
 3.64 72.2
c,e
/25
d
/43.4
f 
 3.88 4.7
 a
 
3.12 0.8
 a
 3.36 1.7
 a
 3.65 13.2
g 
3.89 -
 g
 
3.13 ND 3.37 0.1
 a
 3.66 -
 g
 3.90 28.9
 g
 
3.14 0.8
 a
 3.38 3.4
 a
 3.67 18.4
 g
 3.91 -
 g
 
3.15 >10
 a
 3.39 0.2
 a
 3.68 -
 g
 3.92 10.5
 g
 
3.16 6.5
 a
 3.40 2.9
 a
 3.69 0.6
h
/0.5
i
 3.93 -
 g
 
3.17 0.6
 a
 3.41 >10
 a
 6.70 0.6
h
 /0.7
i
 3.94 -
 g
 
3.18 0.7
 a
 3.42 >10
 a
 3.71 4.4
h
/6.1
i
 3.95 3.6
 g
 
3.19 3.5
 a
 3.43 >10
 a
 3.72 4.7
h
 / 5.4
i
 3.96 27.0
c
/19.0
d
 
3.20 4.1
 a
 3.44 0.8
 a
 3.73 0.6
h
 / 0.6
i
 
  
3.21 2.5
 a
 3.45 >10
 a
 3.74 6.0
h
 / 3.8
i
 
  
3.22 7.0
 a
 3.46 >10
 a
 3.75 57.6
h
 / 2.8
i
 
  
3.23 2.1
 a
 3.47 >10
 a
 3.76 2.5
f
/ 2.7
g
 
  
3.24 0.4
 a
 3.48 0.8
a
 3.77 3.3
f
/ 2.2
g
 
   
a
  Tested against the Gambian chloroquine-resistant P. falciparum clone FCR-03  
b
  Tested against the chloroquine-sensitive clone P. falciparum  MRC-02  
c
  Tested against the Serra Leone chloroquine-sensitive P. falciparum clone D6 
d
  Tested against the Indochinese chloroquine-resistant P. falciparum clone W2  
e
  Tested against the Loatian chloroquine-resistant P. falciparum clone Dd2  
f
  Tested against the Papua New Guinean chloroquine-sensitive P. falciparum clone D10 
g
  Tested against the Loatian chloroquine-resistant P. falciparum clone K1 
h
  Tested against the Tanzanian chloroquine-sensitive P. falciparum clone F-32 
i
  Tested against the Columbian chloroquine-resistant P. falciparum clone FcB1 
-   Not active 
ND  Not determined 
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3.1.1.2. Isolation of antiplasmodial diterpenes from a marine source 
 
Terpenoids are a common secondary metabolite found in marine organisms such as sponges, soft 
corals, gorgonians and nudibranchs many of which show antiplasmodial activity.189,221 Marine 
antiplasmodial diterpenes bearing isonitrile, isocyanate and isothiocyanate functionalities have been 
presented in Chapter two.  Three purine-substituted diterpenes (3.97-3.99) were isolated from a 
marine sponge (Agelas sp.) collected from the Solomon Islands, all of which displayed activity against 
P. falciparum with IC50 values of 6.6, 8.3 and 18.0 µM respectively.
222  Previous studies of the genus 
Agelas have afforded structurally similar compounds (3.100 and 3.101).223,224  More recently ten 
novel eunicellin-type diterpenes (3.102-3.113) were isolated from Briareum polyanthes.  It was 
found that compounds containing an alkene at C-7 and compounds containing –OR functional group 
(R = H, OH or Ac) at C-6 (3.103-3.107) displayed the highest antiplasmodial activity of this class of 
diterepenes with IC50 values of 39, 22, 21, 18 and 32 µM respectively.
225   
Studies of the Pseudopterogorgia species of gorgonian afforded the novel bielschowskysin (3.114)226 
as well as six new diterpenoids, caucanolides A-F (3.115-3.120),227 from Pseudopterogorgia kallos 
and Pseudopterogorgia bipinnata.  The West Indian sea whip Pseudopterogorgia elisabethae 
afforded a previously undescribed aberrarane diterpene scaffold with the isolation of aberrarone 
(3.121).228  This same Rodriguez research group previously isolated the tetra cyclic colombiasin A 
(3.122) from the same organism, Pseudopterogorgia elisabethae.229  In 2010 Rodriguez and co-
workers,  isolated ten new (3.123-3.132)230 and eight known diterpenes (3.133-3.140)231 containing a 
dolabellane skeleton from the Colombian gorgonian octocoral of the Eunicea genus.  The most active 
compound against P. falciparum in vitro proved to be 3.131 with an IC50 of 9.4 μM while the 
remaining dolabellane diterpenes exhibited activity up to ca. 60 μM.230   The specific antiplasmodial 
activities of 3.123-3.130 and 3.132-3.140 were not reported and thus omitted from Table 3.2.  
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Figure 3.3: Antiplasmodial marine diterpenes: purine-substituted diterpenes (3.97-3.101), eunicellin-type 
diterpenes (3.102-3.113), bielschowskysin (3.114), caucanolides A-F (3.115-3.120), aberrarone 
(3.121), colombiasin A (3.122) and dolabellane type diterpenes (3.123-3.140).     
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A series of brominated diterpene-benzoate macrolides (3.141-3.158)232 as well as callophycolide A 
(3.159)233 were isolated from the Fijian red alga Callophycus serratus some of which exhibited 
antiplasmodial activity (<1 μM).232  The antiplasmodial activity of 3.97-3.122, 3.131 and 3.141-3.159 
are summarized in Table 3.2.  There are no examples of the same marine natural product being 
screened against multiple P. falciparum clones.  This trend may reflect the paucity of marine natural 
products generally isolated from marine organisms.   
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Figure 3.4:   Antiplasmodial marine diterpenes:  brominated diterpene-benzoate macrolides (3.141-3.158) 
and callophycolide A (3.159)   
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Table 3.2:  Antiplasmodial activity of marine diterpenes 3.97-3.122, 3.131 and 3.141-3.159. 
 
Compound IC50 *μM+ Compound IC50 *μM+ Compound IC50 *μM+ Compound IC50 *μM+ 
        
3.97 8.3
a 
3.109 ND 3.121 30.3
c 
3.150 4.8
d
 
3.98 ND 3.110 52.8
b 
3.122 31.8
c 
3.151 56.0
d
 
3.99 ND 3.111 29.9
b 
3.131 9.4
c 
3.152 0.3
d
 
3.100 6.6
a 
3.112 43.9
b 
3.141 2.7
d 
3.153 0.8
d
 
3.101 18.0
a 
3.113 49.7
b 
3.142 44.0
d
 3.154 18.0
d
 
3.102 >132.9
b 
3.114 23.0
b 
3.143 9.8
d
 3.155 14.0
d
 
3.103 39.7
b 
3.115 45.0
c 
3.144 0.5
d
 3.156 0.9
d
 
3.104 22.8
b 
3.116 >100
c 
3.145 1.4
d
 3.157 2.5
d
 
3.105 21.3
b 
3.117 >100
c 
3.146 1.4
d
 3.158 >100
d
 
3.106 17.8
b 
3.118 40.0
c 
3.147 2.9
d
 3.159 5.2
d
 
3.107 32.0
b 
3.119 >100
c 
3.148 1.4
d
 
  
3.108 51.6
b 
3.120 >100
c 
3.149 0.9
d
 
  a
  Tested against the Columbian chloroquine-resistant P. falciparum clone FcB1 
b
  Tested against the Tanzanian chloroquine-sensitive P. falciparum clone F-32 
c
  Tested against the Indochinese chloroquine-resistant P. falciparum clone W2  
d
  Tested against the African chloroquine-sensitive P. falciparum clone 3D7 
ND  Not determined  
 
3.1.2. Diterpenes ability to alter erythrocyte morphology 
 
The red blood cell membrane consists of a lipid bilayer supported by an underlying protein network.  
The membrane is responsible for the shape and elasticity of the erythrocyte cells.234  Under normal 
conditions the erythrocytes exist as discocytes (disc-shaped).  Erythrocytes are highly deformable 
cells, in which shape changes may be induced by a range of compounds, including many semi-polar 
natural products.  These shape changes may result in either stomatocytic (cup-shaped) or 
echinocytic (speculated) forms of red blood cells.235  In the past, a number of compounds which have 
shown antiplasmodial activity have had the ability to induce echinocytic or stomatocytic change to 
the red blood cells membrane and in some cases cause lysis of the erythrocyte.236  Sheetz and 
Singer237 have postulated that such compounds incorporate into the erythrocytic membrane causing 
the change to these cells’ membrane.  In general, alterations to the erythrocyte morphology appear 
to be induced by amphiphillic and lipophillic compounds which can be incorporated into the lipid 
bilayer.  Sheetz and Singer explained this change in the red blood cell membrane in their bilayer 
couple hypothesis,237,238 which postulates that the formation of stomatocytes or echinocytes is due 
to the expansion of one of the two monolayers.  Echinocytogenic amphiphiles are thought to be 
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trapped in the outer monolayer thus expanding it relative to the inner monolayer.  Conversely 
stomatocytes are induced through incorporation of the amphiphile into the inner monolayer causing 
expansion of this layer relative to that the outer layer.           
Once the malaria parasite has entered the erythrocyte, the successful development of the parasite is 
dependent upon the integrity of the membrane of the red blood cell remaining intact.  It is therefore 
thought that the antiplasmodial activity of many naturally occurring compounds lies in their ability to 
alter the shape of the red blood cells thus hindering the growth of the parasite.239  Plasmodia species 
are dependent upon the functioning of the erythrocyte membrane and are able to alter its 
permeability in order to obtain nutrients.  Any modifications to the erythrocyte membrane would 
seriously hinder the parasites growth.239   Therefore, compounds that alter erythrocyte membrane 
integrity are responsible for an indirect toxic effect on the malaria parasite and cannot be regarded 
as inducing genuine antiplasmodial toxicity.236   The desirability of a malarial prophylactic that 
induces possibly irreversible change in erythrocyte membrane morphology is questionable.    
Many natural products (and their synthetic analogues which have shown promising antiplasmodial 
activity), have also altered the ethrocyte’s membrane shape e.g.  the series of triterpenoids 
(3.160-3.168),235,240,241 abietane-type diterpene (3.169),242 norditerpenoids (3.170-3.175),236 
labdanes and isopimaranes (3.176-3.186).236  A summary of the eyrthrocyte shape transformation, 
induced by antiplasmodial natural compounds 3.160-3.185 in erythrocyte is presented in Table 3.3.    
At equilibrium anionic amphilphiles tend to be echinocytogenic while cationic amphiphiles tend to 
be stomatocytogenic.237,238,243  This observation was confirmed when a series of synthetic long chain 
anionic, cationic and zwitterion amphiphiles (structures not shown here) were tested for erythrocyte 
deformation.240  All the triterpenoid compounds (3.160-3.168) tested for their ability to change cell 
membrane morphology showed concentration dependent changes in the shape of the erythrocytes.  
The triterpenoids 3.160, 3.163 and 3.165 induced formation of echinocytes and the triterpenoid 
compounds 3.161, 3.162, 3.164, 3.166, 3.167 and 3.168 transformed the healthy erythrocytes into 
stomatocytes.   The former group of compounds initially formed exovesicles on the erythrocyte 
membrane, due to the compounds incorporation into the outer layer of the red blood cell leading to 
the formation of echinocytes.  These compounds all have a functional group at C-18 with the ability 
to act as a hydrogen bond donor (COOH, CONH2, CH2OH), with the amide 3.160 being the most 
active echinocytogenic compound.  The stomatogenic compounds 3.161, 3.162 and 3.164 also 
contain functional groups at C-18 (CH3, CHO, and COOCH3) which are not hydrogen bond donors.  
This result suggests that hydrogen bonding in pentacyclic triterpenes is important in facilitating their 
incorporation into the red blood cells' membrane.235   It is interesting to note that compounds 3.166, 
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3.167 and 3.168 induced cell lysis at high concentration.241  The abietane-type diterpene 
dehydroabietinol 3.169 was incorporated into the inner monolayer of the erythrocytes thus causing 
the formation of stomatocytes at concentrations close to the IC50 values for the inhibition of P. 
falciparum.242  The norditerpenoids 3.171, 3.172 and 3.175 showed stomatogenic effects on the 
erythrocytes and eventually lead to the lysis of the red blood cell at a concentration range of 
100-200 µg.mL-1.  Compound 3.173 induced a modest increase in echinocytes while interestingly 
compounds 3.170 and 3.174 demonstrated no change to the erythrocytes shape (Figure 3.6).244  The 
three isopimaranes (3.183-3.185) caused the formation of echinocytes.  Compound 3.183 showed 
the lowest IC50 value but showed significant echinogenic behaviour at very low concentrations, 
whereas the remaining two isopimaranes only started inducing the echinocytic formation at higher 
concentrations.  Compound 3.183 differs from compounds 3.184 and 3.185 in that it contains only a 
single oxygen functional group and thus has the most significant amphiphillic character.  Compound 
3.185 contains a polar group situated on one end of the molecule and showed echinocytosis at low 
concentrations and induced cell lysis at higher concentrations.   Less pronounced membrane effects 
were seen in solutions containing compounds 3.178, 3.180 and 3.181, all of which contain two 
hydroxyl groups located at opposite ends of the molecule.  The methyl ester 3.176 was a more 
potent stomatogenic compound than its corresponding carboxylic acid 3.177.   Haemolysis occurred 
at a concentration of 100 µg.mL-1 for compounds 3.176-3.179, 3.182 and 3.185.236      
A structural comparison of erythrocyte altering antiplasmodial diterpenes (Figure 3.5), shows that 
many of the compounds contain functionalities that may act as hydrogen bond donors as well as 
containing terminal or unhindered alkenes.  This would suggest that alteration of the red blood cell 
membrane may result from the presence of these functionalities in combination with other factors 
which have yet to be established.   
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Figure 3.5:  Antiplasmodial diterpene (3.169-3.186) and triterpenoids (3.160-3.168) natural products 
responsible for the erythrocyte morphology changes summarized in Table 3.3. 
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Table 3.3:   The shape transformation induced by antiplasmodial natural compounds 3.160-3.185 in 
erythrocytes. 
 Compound 
 3.160235 3.161235 3.162240 3.163235 3.164235 3.165235 3.166241 3.167241 3.168241 
Source Zataria 
multiflora 
Zizyphus 
vulgaria 
Rinorea 
ilicifolia 
Synthetic Synthetic Synthetic Caloncoba 
echinata 
Caloncoba 
echinata 
Caloncoba 
echinata IC50 [µM] 13.9
a
 14.0
a
 27.7
a <27
 a
 7.0
a
 14.1
a
 <30
a
 <30
a
 <30
a
 
Conc. 
[µg.mL-1]  
         
200 - - SS E1, D - -  S1, S2, SS* S1, S2, SS* S1, S2, SS* 
100 - - SS - - -  S1, S2, SS* S1, S2, SS* S1, S2, SS* 
50 E2 S2, SS SS E2 - E3 S1, S2, SS* S1, S2, SS* S1, S2, SS* 
25 - - SS E2 S2  - S1, S2, SS* S1, S2, SS* S1, S2, SS* 
12.5 E2 S2, SS S1, SS - - E3 S1 S2 S3 
6.25 E1 S1 D, S2 E1, D S1 E1 D, S1, S2 D, S1, S3 D, S1, S4 
3.13 D, E1 S1 D, S1 D D, S1 E1 - - - 
  
 Compound 
 3.169244 3.170244 3.171244 3.172244 3.173244 3.174244 3.175244 3.176236 3.177236 
Source Salvia 
pomifera 
Synthetic Synthetic Synthetic Synthetic Synthetic Synthetic Playcladus 
orientalis 
Playcladus 
orientalis IC50 [µM] 25.6
a
/27.4
b 36.6
a
 17.0
 a
 11.7
a
 58.6
a
 45.2
a
 36.2
a
 53.4
a
 163.9
a
 
Conc. 
[µg.mL-1] 
          
200 * - * * - - * - -  
100 * D S2 S3 E1 D S3 SS* S2* 
50 * D - - D D - S2, S3 D, E1 
25 S2 D - - D D - D, S2 D 
12.5 S1, S2 D - - D D - D D 
6.25 S1, S2 D - - D D - -  - 
3.13 D, S1 D - - D D - - -  
  
 Compound 
 3.178236 3.179236 3.180236 3.181236 3.182236 3.183236 3.184236 3.185236 
Source Playcladus 
orientalis 
Playcladus 
orientalis 
Playcladus 
orientalis 
Playcladus 
orientalis 
Playcladus 
orientalis 
Playcladus 
orientalis 
Playcladus 
orientalis 
Playcladus 
orientalis IC50 [µM] 104.5
a
 130.2
a
 84.1
a
 145.2
a
 76.3
a
 24.6
a
 80.9
a
 93.3
a
 
Conc. 
[µg.mL-1] 
        
200 - - - - - - - - 
100 S2* S2* D, E1 D, E1 SS* E3 E1 SE2* 
50 D, E1 D, S1 D, E1 D SS E3 D SE1, E2 
25 D D D D D E2 D E3 
12.5 D D D D D E1 D E1 
6.25 - - - - - - - - 
3.13 - - - - - - - - 
 
Dominating erythrocyte shapes in bold;  D, discocyte; E1, E2, E3, echinocyte types 1, 2 and 3; SE1, SE2, spheroechinocyte type 1 and 2; S1, S2, S3, 
stomatocyte types 1, 2 and 3; SS1, SS2, spherostomatocyte type 1 and 2; (*) designates haemolysis, (-) indicates not determined at that concentration.   
 
a
  Tested against the African chloroquine-sensitive P. falciparum clone 3D7 
b
  Tested against the Loatian chloroquine-resistant P. falciparum clone Dd2 
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Figure 3.6:  A: Erythrocytes incubated with media alone, B: 100 µg.mL
-1
 of compound 3.170, C: 3.171,  
 D: 3.172, E: 3.173, F: 3.174, G: and 3.175.  Small arrows represent stomatocytes type 2.  Large  
 arrow denotes echinocytes type 1. Reproduced with permission from van Wyk et al.
244
 
3.2. Research aims 
 
As discussed in Chapter 2 and Section 3.1, both diterpene isonitriles and diterpene alcohols have 
shown antiplasmodial activity.  In this Chapter, we discuss the synthesis of a series of tricyclic 
podocarpane type diterpenes for the possible development of new antiplasmodial compounds 
(Figure 3.7).  In the past our laboratory has successfully synthesized podocarpanes, through a series 
of transformations of the naturally occurring diterpene (+)-manool (3.187).  Since these types of 
antiplasmodial compounds have been synthesized before, e.g. 3.170,244 we thought a structural 
activity relationship (SAR) study involving the addition of a variety of functionalities at the chiral 
centre C-13, would afford some insight into how the antiplasmodial activity may be increased while 
simultaneously reducing the haemolytic activity also observed in this series of compounds.  Due to 
the potency of the tricyclic marine isonitriles against the plasmodium parasite, we also hypothesized 
that the conversion of the tertiary alcohols to isonitriles moiety would possibly significantly increase 
the antiplasmodial activity of these synthetic compounds. 
OHH
OH
R13
 
Figure 3.7: General podocarpane scaffold for proposed synthetic diterepenes. 
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3.3. Synthesis of antiplasmodial podocarpanes 
3.3.1. Synthesis of the tricyclic ketone (3.188) 
 
The pyridium chlorochromate (PCC) oxidation of (13R)-manool245 (3.187) involves the migration of 
the Δ14 olefin to Δ13 with concurrent oxidation of the transposed alcohol functionality to yield the 
aldehydes (E)-labda-8(17)dien-15-al (3.189) and (Z)-labda-8(17)dien-15-al (3.190).  We proposed that 
this transformation proceeds through a mechanism in which 3.187 forms a π complex with PCC 
(3.191) that can rearrange to form the chromate ester (3.192).  The chromate ester undergoes 
ionization to form the ion pair (3.193), which is facilitated through steric crowding in the chromate 
ester.  Sundararaman and Herz showed that this mechanism is favoured with the addition of bulky 
ligands on the chromium atom.246  
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Scheme 3.1: Proposed mechanism for the oxidation rearrangement 3.187 facilitated by PCC.   
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The 1H NMR spectrum of the PCC oxidation product immediately revealed the presence of two pairs 
of deshielded doublets (δH 9.97 and δH 9.82) which correspond to the aldehyde protons of the E and 
Z isomers (3.189 and 3.190) (ratio 2:1).  The mixture of aldehydes was purified by silica flash 
chromatography to afford a combined isolated yield of 88%.  The 1H and 13C NMR data of the 
mixture of aldehydes were consistent with those published in literature.246,247  The aldehydes 3.189 
and 3.190 were found to be unstable and thus ozonolysis was performed immediately.248   
Following the oxidation rearrangement (Scheme 3.1), reductive ozonolysis of the Δ8 and Δ13 olefins 
was performed to afford the diketone 3.194 (Scheme 3.2).  A constant stream of ozone was bubbled 
through a cooled dichloromethane solution of a mixture of the E and Z isomeric aldehydes 3.189 and 
3.190.  Ozone was continuously administered until the solution had turned a pale blue colour 
indicating ozone saturation.  The ozone was purged by bubbling nitrogen through the solution and 
the ozonide (3.195) intermediate was reduced by the addition of triphenylphosphine.  Once the 
completion of the reaction had been confirmed by TLC, hydrogen peroxide was added in order to 
precipitate excess triphenylphosphine as triphenylphosphine oxide (3.196) which could be removed 
via filtration through a silica plug.  The mechanism of ozonolysis of 3.189 and 3.190 is illustrated in 
Scheme 3.2. 
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Scheme 3.2: Mechanism of ozonolysis of 3.189 and 3.190 to afford the diketone 3.194.
249
 
 
Ozonlysis is a 1,3-dipolar cycloaddition, involving the cleavage of π bonds in an oxidative fashion 
resulting in two new carbonyls per alkene.  Ozone is a symmetrical bent molecule consisting of a 
positively charged central oxygen with two negatively charged terminal oxygen atoms.249  The 1,3-
dipole cycloaddition yields (3.197) which immediately decomposes by reverse 1,3-dipole 
cycloaddition, resulting in a simple aldehyde and an unstable carbonyl oxide (3.198).  The carbonyl 
oxide now adds to the aldehyde by attacking its carbonyl carbon through an oxyanion nucleophillic 
attack, for a third cycloaddition step to afford the ozonide (3.195).  The ozonide is the first stable 
product of this reaction, but is removed with the addition of triphenylphosphine to yield a ketone 
functionality (3.194) and triphenylphosphine oxide (3.196).    
The crude yellow oil was purified further by flash silica chromatography (50% EtOAc, 50% hexane) to 
afford 3.194 in 76% yield.  The diketone 3.194 could be easily distinguished from the aldehyde 
precursors with the appearance of a methyl singlet in the 1H NMR spectrum (δH 2.07) and the 
disappearance of the deshielded doublets (δH 9.97 and δH 9.82).  The 
13C NMR spectrum further 
supported the successful synthesis of 3.194 with the appearance of two singlets downfield (δC 212.3 
and δC 209.2) corresponding to the formation of two new carbonyl carbons. 
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With the addition of the base sodium hydride to an anhydrous solution of the diketone 3.194 in 
tetrahydrofuran an intramolecular aldol condensation was initiated (Scheme 3.3).  The hydride ion 
removes a proton from the terminal methyl group adjacent to the carbonyl carbon resulting in a 
carbanion.  The carbonyl at C-8 can now undergo nucleophilic attack by the carbanion resulting in 
cyclization as shown in Scheme 3.3.  After 4 hours the reaction was quenched with a saturated 
solution of ammonium chloride, as it was found that the addition of acid resulted in dehydration of 
the tertiary alcohol at C-8.  Normal phase HPLC (10% EtOAc 90% hexane) proved to be very time 
consuming when trying to purify 3.188 as this compound was the final product to elute off the 
column (tR = 40 min).  As a result other methods of purification were pursued.  Many solvents and 
combinations of solvents were tried in order to purify this product through recrystalization.  
Eventually it was found that a hot 20% dichloromethane 80% hexane solvent system, cooled slowly 
on ice, resulted in an 80% isolated yield of pure white needle-like crystals of 3.188.      
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Scheme 3.3:  Hydride induced intramolecular aldol condensation of 3.194 
 
The cyclization of 3.194 was deemed successful as the deshielded peak (δC 212.3) corresponding to 
the carbonyl carbon on C-8 of the ketone in 3.194 disappeared from the 13C NMR spectrum of the 
product while a new carbon signal (δC 75.5) corresponding to an oxy-quaternary carbon was 
detected in the 13C NMR spectrum.  This observation was confirmed by 1H NMR and DEPT135 NMR 
experiments revealing the loss of a methyl resonance (δH 2.07 and δC 14.5) and the addition of a 
methylene signal (δH 2.53, 2.23 and δC 57.3) in the 
1H and DEPT135 spectra of 3.188 respectively.  
Interestingly, we discovered that the optimal time for this reaction was 4 hrs as an increased 
exposure of compound 3.188 to basic conditions resulted in the dehydration of the C-8 alcohol.   
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3.3.2. Grignard addition to 3.188 
 
As previous work had highlighted the antiplasmodial activity of podocarpane 3.170,244 the ketone on 
C-13 of 3.188 afforded us an opportunity to conduct a SAR study, through the convenient addition of 
a series of different functionalities to C-13 via standard Grignard methodology.  Grignard reagents 
are organometallic compounds with the general formula RMgX, and are one of the most versatile 
group of reagents for the alkylation of ketones and aldehydes.  The magnesium-carbon bond is 
polarised resulting in an alkyl nucleophile, which is highly unstable and thus moisture and air 
sensitive.  Therefore all Grignard reactions are required to be conducted under inert and anhydrous 
conditions.  Unfortunately, the Grignard reaction’s desired product is often isolated with side 
products such as reduction products (from β-hydride transfer from the alkyl group),250  aldol 
products (from the enolization of the ketone as a result of the strong basicity of the Grignard 
reagent),250 as well as side products involving conjugate addition, condensation and pinacol 
coupling.251  In some cases these abnormal adducts are the major products in the reaction prevailing 
over the formation of the desired tertiary or secondary alcohol.250 
The mechanism by which Grignard alkylation of the ketone (3.199) proceeds is one of two pathways 
either through a polarised intermediate (3.200) or via a single electron transfer (SET) and the 
formation of radical species (3.201 and 3.202, Scheme 3.4).  The preferred pathway is dependent 
upon the reduction potential of the ketone, the oxidation potential of the Grignard rearrangement, 
the nature of the solvent system and the nature of the halogen.252     
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Scheme 3.4:   The two proposed mechanistic pathways of Grignard synthesis.
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 Fortunately, the addition of equal or greater equimolar amounts of anhydrous cerium chloride 
enhances the carbonylophilicity of Grignard reagents while suppressing the formation of the 
undesirable side products.  Cerium is a member of the rare earth metals which possess f-orbitals 
with exploitable electronic and sterochemical properties, making cerium useful as a reagent or 
catalyst for organic synthesis.253  Cerium chloride possesses great oxophilicity and has shown 
promise in its ability to activate carbonyl functionalities via coordination.254  This activation may be 
the driving force in the promotion of carbonyl nucleophilic addition reaction by CeCl3.  It is also 
interesting to note that the Gignard reagents basicity is lower on mixing with cerium chloride.251  
Although the use of CeCl3 for organometallic alkylation is widely used the mechanism is poorly 
understood.255  A putative mechanism has been described by Hatano et al.250 detailing the ability of 
CeCl3 to act as a Lewis acid activating the carbonyl compound or the additives ability to increase the 
nucleophilicity of the alkylating agent via metal complexations of transmetalations.  In the past CeCl3 
has been used as an additive to suppress undesired side products and synthesize key intermediates 
of highly hindered natural products.256  For this reason CeCl3 was used in the synthesis of the 
podocarpane derivatives (3.203-3.207, Scheme 3.5).      
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Scheme 3.5: The Grignard addition of 3.188. (X = Br, Cl) 
 
All the alkylation reactions of C-13 of 3.188 were carried out in the absence of CeCl3 resulting in 
none or in very poor yield of the desired tertiary alcohol (Table 3.4).  The addition of CeCl3 to the 
reaction mixture via the procedure laid out by Imamoto et al.257 resulted in the formation of the 
desired product and an increase in yield, most notably in 3.203 with an increase in yield from 17 to 
57%.  Reduced amounts of CeCl3 (< 1.5 equiv.) resulted in poor yields and 1.5 equivalents (relative to 
3.188) was established as the most suitable equivalency and used in all our Grignard reactions.  The 
use of THF or a THF/ether solvent system produced the highest yield while a pure ether system 
resulted in a poorer yield.251  All reactions were therefore carried out in an anhydrous THF solvent 
system.    
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Table 3.4:  Yields of Grignard addition products 3.203-3.207 in the presence and absence of CeCl3 
 
 Yield [%] 
 
Compound Absence of CeCl3 CeCl3 
3.203 17 57 
3.204 19 34 
3.205 0 20 
3.206 2 27 
3.207 ND 19 
All reactions were carried out under standard conditions outlined in Chapter 6.   
The success of the alkylation with the use of Grignard reagents was easily determined from the 13C 
NMR spectra, in which the loss of the signal at δC 210.7 in 3.188 and the appearance of a signal 
around δC 67 indicate the reduction of the ketone carbonyl to a tertiary alcohol carbon (C-13 in 
3.203-3.207, Figure 3.8).  In addition two broad signals (δH 2.5-4.0) in 
1H NMR spectra (Figure 3.9) 
corresponding to the hydrogen on the hydroxyl functionality confirming the successful addition of 
the carbon nucleophile to C-13.  The Grignard reaction involving the addition of an iso-butyl 
nucleophile to 3.188 resulted in formation of the reduction side product 3.207.  Tert-butyl 
magnesium bromide is a strong reducing agent258 and perhaps iso-butyl magnesium bromide 
behaves in a similar way accounting for the formation of 3.207.     
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Figure 3.8:   The 
13
C NMR (CDCl3, 150 Hz) spectra obtained for compounds 3.188 (top, Shown inset) and 
3.203 (bottom, Shown inset).   
 
 
Figure 3.9:  The 
1
H NMR (CDCl3, 600 MHz) spectra of 3.207 (shown inset).  The proton signal attached to 
the oxygen of the hydroxyl functionality at positions 8 and 13 is indicated.  
 
3.3.3. Determination of the absolute configuration of 3.203-3.207 
 
While the absolute configuration of the diterpene ring of (+)-manool has been previously 
reported,244 the Grignard alkylation created a new chiral centre at C-13.  We therefore wanted to 
determine the absolute configuration of this carbon and thus submitted two podocarpanes (3.204 
and 3.207) for X-ray crystal structure analysis.  The orthorhombic crystal of 3.204 contained the 
space group P212121 and the asymmetric unit comprised a single molecule.  Given that the absolute 
configurations at C-5, C-8, C-9 and C-10 were known: C-5: (S), C-8: (R), C-9: (R), C-10: (S) and C-13: 
(R). The X-ray crystal structure established an (R) configuration at C-13.   
 
Figure 3.10:   An ORTEP diagram of the perspective view of a molecule of 3.204 from the crystal structure.  
Thermal ellipsoids for the non hydrogen atoms are shown at the 50% probability level. Only 
the intramolecular O-H∙∙∙O hydrogen bond is shown.  
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Interestingly, hydrogen bonding patterns were evident from the X-ray crystal structure of 3.204, 
where there is an intramolecular O-H•••O hydrogen bond linking the two hydroxyl groups across the 
ring.  The H atom attached to the acceptor oxygen atom then forms an intermolecular hydrogen 
bond with a neighbouring molecule.  This hydrogen bonding leads to infinite chains of screw-related 
molecules running parallel to the crystal α-axis.259 
 
 
 
Figure 3.11:  Hydrogen bonding in the crystal of 3.204.  Alternating intra- and intermolecular O-H∙∙∙O 
hydrogen bonds form infinite spirals running parallel to the crystal a-axis.    
 
We were also interested in the absolute configuration at C-8 and C-13 in the side product 3.207.  The 
formation of the hydroxyl at C-13 allows for the carbon-oxygen bond to form in either an axial or an 
equatorial position i.e. the alkylating nucleophile may attack the sp2 hybridized carbonyl from either 
the si of the re face. We initially assumed that an equatorial orientation of the hydroxyl moiety 
would be favoured.  On purification of 3.207 with HPLC only a single peak was identified with 
refractive index (RI) detection.  To ensure that the steroisomers did not have identical retention 
times, and that a pure sample of 3.207  had been obtained, 3.188 was reduced using LAH to yield a 
2:1 mixture of the two epimers 3.207 and 3.208.  Comparison of the 1H NMR spectra of the mixture 
of 3.207 and 3.208 with that of 3.207 obtained from the Grignard reaction showed that only one 
isomer was produced in the reaction involving isobutylmagnesium (Figure 3.12).      
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Figure 3.12:  The 
1
H NMR (CDCl3, 600 MHz) spectra of 3.207 obtained from the Grignard reaction (top, 
shown inset) and the reaction mixture of 3.207 and 3.208 (bottom, shown inset) after 
reduction of 3.188 with LAH.   
 
The absolute configuration of 3.207 was established by X-ray crystallography.  The crystals of 3.207 
were monoclinic, containing the space group C2 (which was transformed to the alternative setting I2 
for technical reasons)259 and it contained two molecules in the asymmetric unit with common 
configurations at the chiral centres.  A quantitative comparison of these molecules yielded a root 
mean square fit of 0.077Å, indicating that they are virtually superimposable.  Again it was assumed 
that the absolute configurations at C-5, C-8, C-9 and C-10 had been correctly assigned from other 
data and the molecules comprising the respective asymmetric units in the crystal were therefore 
chosen to be consistent with those assignments. The configurations at the chiral centres of 3.207 
from the crystal structure are: C-5: (S), C-8: (R), C-9: (R), C-10: (S) and C-13: (R). 
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Figure 3.13:   ORTEP diagram for 3.207 showing the two independent molecules A and B in the asymmetric 
unit as well as the unique hydrogen bonds associated with this unit. 
       
Interesting hydrogen bonding patterns were also evident in the crystal structure of 3.207. There is 
an intramolecular O-H∙∙∙O hydrogen bond linking the two hydroxyl groups of each molecule (Figure 
3.13). The H atom attached to the acceptor oxygen atom then forms an intermolecular hydrogen 
bond with a neighbouring molecule.  In the crystals of 3.207, molecules A and B are linked to one 
another and to a pair of molecules A', B' related to the former by a twofold rotation axis, which 
results in the formation of a closed, tetrameric motif (Figure 3.14).259  
 
A 
B 
A 
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Figure 3.14: Tetrameric motif in the crystal of 3.207 formed by alternating intra- and intermolecular H-
bonding and involving molecules A and B and their counterparts (the latter related to A and B 
by a twofold rotation axis running approximately normal to the page). Note the formation of a 
ring of homodromic hydrogen bonds involving six of the hydroxyl groups. 
 
3.3.3.1. Spectroscopic characterization of the podocarpanes 3.204-3.207 
 
The orientations of the hydrogens around the ring were assigned after careful analysis of the proton-
proton coupling constants.  A representative example of the way in which we assigned the NMR data 
in these compounds will be discussed here.  In the 1H NMR spectrum of 3.207 a doublet of triplets 
can clearly be seen at 1.81 ppm (Figure 3.15).   
 
 
Figure 3.15:  The 
1
H NMR (CDCl3, 600 MHz) spectrum of 3.207.  A doublet of triplet can be seen, corresponding 
to H-14a. 
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This chemical shift corresponds to one of the protons on C-14.  The large coupling constant 
corresponds to the coupling of one of the protons on C-14 to its geminal partner (J ≈ 14 Hz).  Since 
the only other adjacent proton is on C-13 the expected splitting pattern of H-14 is a doublet of 
doublets with a smaller coupling constant of approximately 5-6 Hz due to the approximate 45o angle 
between the protons.  However, the HSQC spectrum of 3.207 indicates two different proton signals 
on C-14, a multiplet (δH 1.39) and a doublet of triplets (δH 1.81).  Inspection of the COSY spectrum of 
3.207 (Figure 3.16) shows the signal at 1.81 ppm coupling to a proton on C-12 (δH 1.94), this was 
unusual as coupling between spins separated by four or more bonds is rare.  However, in cyclic or 
sterically constrained environments, 4J coupling or ‘W-coupling’ is often observed.  It is called ‘W-
coupling’ because the four bonds between the two coupling protons are all coplanar and form the 
shape of a W (Figure 3.16).  The coupling constant of this type of 4J coupling rarely exceeds 2-3 Hz.260  
‘W-coupling’ would account for the splitting pattern observed (Figure 3.17).  Since the hydroxyl on C-
13 is β-axial the two adjacent hydrogens on C-12 are β-equatorial and α-axial, therefore in order for 
‘W-coupling’ to occur the β-equatorial H-12 must couple with a hydrogen aligned in the same plane.  
We therefore concluded that the signal at 1.81 ppm corresponded to the β-equatorial hydrogen on 
C-14.  This was supported by the lack of coupling, seen in the COSY spectrum, between the two α-
axial hydrogens on C-12 and C-14.  The 
1H NMR chemical shifts of remaining hydrogen atoms were 
assigned with similar rigour except where there was extensive signal overlap in the methylene 
envelope.            
 
Figure 3.16:  COSY spectrum (CDCl3, 600 MHz; relaxation time *d1+ = 1.00 sec; F1 and F2 = δH 0.65 – 2.10) 
obtained for 3.207.  The broken line indicates the COSY correlation between H-12 and H-14a.  
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Figure 3.17:   A graphical representation of the ‘W-coupling’ experienced by compound 3.207.  The red 
outline of the structure of 3.207 (left) show the protons involved in the W-coupling.  The image 
on the right is a schematic diagram explaining the splitting pattern experienced by H-14β. 
 
3.3.4. Structural activity relationship study of the podocarpanes 
 
The compound with the strongest antiplasmodial activity in the first series of podocarpanes 
synthesised was the phenyl ring containing compound 3.204 (IC50 6.6 μM) and 3.204 also did not 
appear to alter the shape of the erythrocyte.  Due to the many examples of antimalarial drugs 
containing halogens (e.g. chloroquine and halofantrine) we proposed that by halogenating the 
phenyl ring of 3.204 we may improve the antiplasmodial activity.  While several methods exist261-263 
for the halogenation of a phenyl ring the 4/3-chlorophenyl magnesium bromide, 4-chloro-2-
methylphenyl magnesium bromide and 4-fluorophenyl magnesium bromide Grignard reagents were 
all commercially available, enabling us to synthesize 3.209-3.212 by Gringard methodology (Scheme 
3.6).  Using the CeCl3 mediated Grignard addition method we had optimized earlier we were able to 
synthesize 3.209-3.212 in 32-64% yield.      
H
O
OH
H
OH
OH
R
RMgX, CeCl3
3.188
THF, 0 oC
Cl
Cl
F
Cl
3.209
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R R
 
Scheme 3.6: The synthesis of halogenated phenyl containing podocarpanes 3.209-3.212 via a Grignard 
addition. 
 
Interestingly, the 1H and 13C NMR spectra of compound 3.211 (Figure 3.18) clearly shows the fluorine 
atom in the para position of the phenyl ring coupled to the surrounding carbons and protons.  The 
magnitude of the JF,C and JF,H coupling constants decrease over two, three and four bonds as 
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expected (Figure 3.18)264 and proved useful in assigning the aromatic 1H and 13C chemical shifts in 
3.211.  The assignment of the 1H and 13C NMR data for 3.209-3.212 were made from careful analysis 
of both the 1D and 2D NMR spectra and are reported in Chapter 6.   The antiplasmodial activity and 
conclusions made about structural activity relationships are presented in Section 3.5.    
     
 
 
 
 
 
 
 
Figure 3.18: 
1
H (CDCl3, 600 MHz) and 
13
C (CDCl3, 600 MHz) spectra obtained for 3.211.  The inset describes 
the fluoride splitting experiences by the protons and carbons respectively.   
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3.4. Attempted synthesis of podocarpane isonitriles 
 
The nanomolar antiplasmodial activity of Wright and Wattanapiromsakul’s tricyclic marine isonitriles 
(2.16-2.21 and 2.24-2.27) inspired us to attempt to convert the tertiary alcohols on C-8 and C-13 of 
3.188, 3.204-3.207 and 3.209-3.212 to isonitrile functionalities, thus hopefully increasing the 
potency of the podocarpanes’ antiplasmodial activity.     
3.4.1. Isonitrile synthesis in a model compound 
 
Kintano et al.265 originally describe a method for the conversion of tertiary alcohols to isonitriles 
facilitated by zinc halides.  This method also required trimethyisilyl cyanide (TMSCN), which will 
produce the highly toxic hydrogen cyanide on contact with water, thus the use of hygroscopic zinc 
halides would be problematic.  Kintano et al.266,267 later improved their method by substituting zinc 
halides with silver salts, the most notable being anhydrous silver perchlorate (AgClO4), thus 
increasing safety while apparently simultaneously reducing reaction times in converting alcohols to 
isonitriles in near quantative yield.  We hoped to extend Kintano’s capricious method to the 
synthesis of isonitrile containing podocarpanes and set about first testing this method on a simpler 
compound i.e. 3.213.   
O HO CN
i. ii.
3.214 3.2153.213  
 
Scheme 3.7: The synthetic scheme for the synthesis of the model isonitrile compound 3.215. Reagents and 
conditions:   i) MeLi, THF, -78 ˚C, 76%; ii)  TMSCN, AgClO4, DCM, 68% 
 
The commercially available α-tetralone (3.214) was reduced using methyl lithium to afford a racemic 
mixture the tertiary alcohols (3.213).  The protocol outlined by Kintano267 dictates the addition of the 
TMSCN to a DCM solution of the tertiary alcohol, followed by the addition of the silver salt.  
However, we had no way of adding the insoluble silver salt without perturbing the sealed system, 
thus possibly exposing ourselves to highly toxic hydrogen cyanide gas.  Therefore, we added the 
silver salt to the reaction mixture prior the addition of TMSCN, resulting in no detection of the 
isocyanide.  We subsequently modified a three-necked round bottom flask to allow the addition of 
the silver salt to the alcohol-TMSCN mixture without disrupting the closed system.  TMSCN followed 
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by anhydrous AgClO4, using our modified apparatus, was carefully added to a solution of 3.213 in 
anhydrous dichloromethane to yield the isonitrile 3.215 in 68% yield after normal phase HPLC 
(22.5% EtOAc  87.5% hexane) purification (Scheme 3.7).  After two hours, the reaction was quenched 
with saturated NaHCO3 solution and allowed to stir and vent in a sealed fumehood for 10 minutes to 
remove any unreacted TMSCN.  The highest safety precautions were taken when carrying out this 
reaction, a cyanide antidote kit was always close at hand.  In addition immediately after the reaction 
was completed all experimental apparatus was soaked in solution of saturated NaHCO3 followed by 
subsequent addition of HClO4 to convert all cyanide to harmless cyanates for safe disposal.  The 
13C 
NMR spectrum of 3.215 clearly showed the removal of the hydroxyl moiety on C-9, however, the 
appearance of a new signal corresponding to the carbon of the isonitrile was not apparent (δC 150-
170 ppm, Figure 3.19) and the 13C NMR data required further interrogation.    
 
Figure 3.19: 
13
C (CDCl3, 150 MHz) spectra obtained for 3.215 (top), 3.216, (middle) and 3.214 (bottom).  The 
structures are shown inset.   
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3.4.1.1. Optimization of the 13C NMR acquisition parameters to detect the isonitrile 
functionality              
 
The 13C NMR spectrum of the comerically available tert-butyl isocyanate 3.216 (Figure 3.20) revealed 
a 13C-14N triplet at δC 152.4.  
 
 
 
Figure 3.20:  The 
13
C NMR (CDCl3, 150 MHz) of tert-butyl isocyanide (3.216, shown inset), with an enlarged 
view of the isonitrile signal.  [d1] = 5.00 sec 
 
The carbon is split into a triplet due to the coupling of the 13C – 14N, since 14N has a quantum spin 
number (I) of 1 which results in a 2nI + 1 splitting pattern, where n = total number of coupling 
neighbouring nuclei.  There was no triplet signal (1JN,C = 4.5 Hz) observed in this region for compound 
3.215, possibly due to the long relaxation time of the isonitrile carbon.  The relaxation time of a 
saturated CDCl3/ tert-butyl isocyanide (3.216) solution was used to investigate the relaxation time of 
this carbon.  An increase of the d1 delay time from one to five seconds and a prolonged acquisition 
time resulted in an increase in the signal to noise ratio.  These data aquistion parameters were used 
to acquire a 13C NMR spectrum of 3.215 in CDCl3 resulting in a triplet signal appearing at δC 167.9 
(Figure 3.21) indicating the presence of an isonitrile carbon.  The presence of an isonitrile 
functionality was also supported by IR data in which a peak at 2190 cm-1, corresponding to the N≡C 
stretching frequency was observed.268  
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Figure 3. 21: The 
13
C NMR (CDCl3, 150 MHz) of 3.215, (shown inset), with an enlarged view of the isonitrile 
signal.  [d1] = 5.00 sec.  Number of scans = 20480 (Total time 34 hrs) 
 
3.4.2. Attempted conversion of 3.188, 3.204-3.207 and 3.209-3.212 to 
isonitriles. 
 
With the successful conversion of 3.213 to 3.215, we attempted to convert the tertiary alcohols of  
3.188, 3.204-3.207 and 3.209-3.212 into isonitriles (Scheme 3.8).   We attempted to synthesize the 
isonitriles using two different silver salts (AgClO4 and AgBF4), however on inspection of the 
13C NMR 
spectrum of the reaction product of 3.188, no triplet was observed in the δC 150-170 ppm region 
although the C-OH signals at 75.5 (q, C-8) ppm and 57.3 (CH, C-14) ppm had disappeared while two 
new signals at 125.8 (CH, C-8) ppm and 165.9 (C, C-14) ppm had appeared in the downfield region, 
suggesting the dehydration of 3.188  to afford 3.217 (Figure 3.22).   We explained this dehydration 
after carefully considering permutations around the proposed mechanism of isonitrile formation 
presented in Scheme 3.9.  This mechanism is based on an SN1 nucleophilic substitution reaction via a 
carbocation intermediate (3.218).  The cyanide anion (3.219) usually favours alkylation at the 
cyanide carbon forming the nitrile as opposed to the isonitrile.  However, should the cyanide ion be 
‘complexed’ with a heavy-metal counter-ion such as silver (3.220), alkylation preferentially occurs 
via the nitrogen atom.  The use of the aprotic solvent DCM, which does not have the ability to form 
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 ppm
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hydrogen bonds that hinder nucleophilic attack via the nitrogen atom allows for the formation of the 
isonitrile.   
 
 
Figure 3.22:   
13
C NMR spectra (CDCl3, 150 MHz) spectra of 3.188 (bottom) and 3.217 (middle) and DEPT135 
(CDCl3, 150 MHz) spectrum of 3.217 (top).  Structures shown as insets.   
 
The proposed mechanism (Scheme 3.9) starts with the TMSCN (3.221) removing the tertiary alcohol 
moiety (3.222) by forming the trimethyl silate (3.223), simultaneously releasing the cyanate anion 
into the solution.  This initial step may account for why the reaction failed when the silver salt was 
added prior to the addition of TMSCN.  The carbocation (3.218) formed with the loss of the 
trimethylsilyl leaving group 3.223 and is a bulky highly hindered carbocation.  Steric hindrance may 
therefore account for the failure of the cyanate anion to attack the carbocation 3.224.  Quenching of 
the carbocation through the loss of a proton (Scheme 3.10) to yield the α,β-unsaturated ketone 
(3.217) appears to be preferable.  A similar result was obtained for all podocarpanes (3.204 - 3.207).             
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Scheme 3.8:  The synthesis of a isonitrile from tertiary alcohol 3.188 using silver perchlorate and TMSCN. 
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Scheme 3.9:   The proposed mechanism of the formation of an isonitrile from a tertiary alcohol 3.222 
facilitated by TMSCN and AgOCl4 
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Scheme 3.10: Proposed mechanism for the formation of 3.217.  Reagents and conditions: i)  TMSCN, AgOCl4, 
DCM, RT 
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3.5. Antiplasmodial and haemolytic activity of 3.188, 3.204-3.207, 
3.209-3.212 and 3.213-3.215 
 
Although, podocarpanes 3.188, 3.204-3.207 and 3.209-3.212 all displayed, moderate antiplasmodial 
activity, none showed antiplasmodial activity within the range of the currently available drugs used 
for the treatment of malaria (Table 3.5).  The most active of the cohort of compounds screened were 
the podocarpanes containing an aromatic phenyl ring at C-13 i.e. 3.204, 3.209-3.212 and the ketol 
3.188.    The antiplasmodial activity for all the halogenated compounds 3.209-3.212 was improved 
when compared to the activity of 3.204.  The antiplasmodial results (Section 3.5) show three 
structural activity relationships.  Firstly the substitution of the chlorinated C-4 aromatic ring (3.209) 
and not C-3 (3.210) enhances antiplasmodial activity. Secondly the fluorinated compound (3.211) 
has a moderately lower IC50 value than that of its chlorinated counterpart (3.209) and finally a 
disubstituted phenyl ring (3.212) shows relatively better antiplasmodial activity compared to all the 
halogenated compounds.  These results would suggest that the position of the substituent as well as 
the electronegativity plays a role in these compounds’ bioactivity. Since the phenyl containing 
podocarpanes are the most active, this may suggest the activity of these compounds resides in their 
ability to fit into and possibly π-stack into a hydrophobic pocket in the active or effector site of an 
unidentified enzymatic target. 
All the podocarpane derivatives were tested for their ability to alter erythrocyte membrane shape.  
No formation of echinocytes or stomatocytes was observed.  This suggests that none of these 
compounds were incorporated into the red blood cells lipid bilayer.  At a drug concentration of 100 
µM, only a very small percentage of erythrocytes underwent lysis (Table 3.5).  It would appear that 
the removal of the alkene functionality attached to C-13 present in 3.170-3.172, 3.175 and 3.183-
3.186 eradicates the compounds ability to change erythrocyte morphology.    
The synthetic isonitrile (3.215) caused total haemolysis of the erythrocytes at both 50 and 100 μM 
concentrations (Table 3.5).  The precursors 3.213 and 3.214 were tested for haemolytic activity in 
order to gauge the role the isonitrile moiety plays in the disruption of the erythrocytes membrane.  
α-Tetralone 3.214 and the tertiary alcohol 3.213, both showed 0.2 % lysis at 50 μM and 0.2 and 0.3% 
lysis at 100 μM respectively.  We can thus conclude that the isonitrile functionality in 3.215 plays a 
direct role in haemolysis.  
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Table 3.5:   The antiplasmodial and haemolytic activity of compounds 3.188, 3.204-3.207, 3.209-3.212 and 
3.215.   
 
Compound Antiplasmodial activity 
(μM) 
Haemolytic activity at 
100μM 
Haemolytic activity at           
50μM 
IC50 s.d. n % Haemolysis s.d. n % Haemolysis s.d. n 
3.188 7.2 1.2 5 0.6 0.3 5 0.7 0.2 5 
3.203 29.1 1.2 4 1.0 0.4 3 0.5 0.1 3 
3.204 6.6 0.3 4 0.6 0.3 5 0.7 0.2 4 
3.205 22.3 1.6 4 0.5 0.3 4 0.4 0.2 6 
3.206 26.1 0.8 4 0.8 0.4 5 0.5 0.2 3 
3.207 21.3 2.9 4 0.6 0.3 3 0.6 0.3 3 
3.209 4.1 0.5 4 0.1 0.1 3 0.001 0.001 3 
3.210 8.2 1.7 3 0.5 0.2 3 0.06 0.02 3 
3.211 3.5 0.4 4 0.2 0.1 3 0.02 0.02 3 
3.212 1.4 0.2 3 0.4 0.2 3 0.03 0.003 3 
3.215 3.1 0.6 4 105.2 2.1 3 103.8 3.4 3 
Chloroquine 0.07 0.01 3 0.2 0.1 5 0.06 0.04 4 
Quinine 0.1 0.01 5 0.5 0.3 6 0.6 0.1 5 
Primaquine 0.6 0.04 5 0.6 0.3 6 0.3 0.2 5 
Pyrimethamine 0.1 0.02 4 0.4 0.2 6 0.4 0.3 5 
Cycloproguanil 11.3 1.9 7 0.07 0.05 5 0.2 0.2 4 
 
3.6. 1-Deoxy-D-xylulose-5-phosphate (DOXP) reductase (DXR) 
inhibition 
 
Once 3.209-3.212 were synthesized, these compounds were submitted to a P. falciparum and E. coli 
DXR inhibition assays.269 
 
3.6.1. Background  
  
Isoprenoids constitute the largest single class of natural products with over 35 000 compounds being 
described to date.270   This class represents a large collection of bioactive compounds, comprising 
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many primary and secondary metabolites.  Many isoprenoids carry out biological functions essential 
to the functioning and development of living organisms.  Despite the plethora of biological functions, 
they all stem from two C5 precursors, isopentenyl diphosphate (3.225, IPP) and its isomer 
dimethylally diphosphate (3.226, DMAPP).  The non-mevalonate pathway consists of seven 
enzymatically controlled steps (Scheme 3.11) resulting in the precursors 3.225 and 3.226.271  The 
initial step consists of the condensation of pyruvate (3.227) and glyceraldehyde-3-phosphate (3.228) 
forming DOXP (3.229), mediated by DOXP synthase (DXS).272  The DOXP is converted to 2-C-methyl-
D-erythritol-4-phosphate (3.230, MEP) by an intramolecular rearrangement and reduction in a single 
step catalysed by DXR.273  This mechanism of conversion of 3.229 to 3.230 is not clearly understood, 
two proposed hypothesises are discussed below in Section 3.6.2.  The conversion of MEP to 4-
diphosphocytidyl-2C-methyl-D-erythritol (3.231, CDP-ME) is CTP dependent and catalyzed by CMS.274  
4-Diphosphocytidyl-2C-methyl-D-erythritol-2-phosphate (3.232, CDP-MEP) is formed by the 
phosphorylation of 3.231 at the 2-hydroxyl position, and is mediated by 4-Diphosphocytidyl-2-C-
methyl-D-erythritol kinase (CMK).275  The two phosphates on either end of 3.232 are joined by the 
enzyme MCS, resulting in the formation of 2C-methyl-D-erythritol-2,4-cyclodiphosphate (3.233, 
MEcPP) and the removal of cytidine monophosphate (CMP).276  The formation of 1-hydroxy-2-
methyl-2-(E)butenyl-4-diphosphate (3.234, HMD-PP) requires the cleavage of two carbon oxygen 
bonds and this is thought to be facilitated via a 2e- transfer from the iron-sulphur cluster of HMDPP 
synthase.277  In the final step HMDPP is converted to a mixture of DMAPP and IPA (usually 5:1 or 3:1) 
catalyzed by the NAD(P)H dependent HMBPP reductase.278              
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Scheme 3.11:   The non-mevalonate pathway in P. falciparum.
277
 Abbreviations:  DXS, DOXP synthase; DXR, 
DOXP reductase; CMS, 4-diphosphocytidyl-2-C-methyl-D-erythritol synthase; CTP, cytidine 
triphosphate; CMP, cytidine monophosphate; MCS, 2-C-methyl-D-erythritol 2,4-
cyclodiphosphate synthase; HDS, (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate synthase; 
HDR, (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate reductase    
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3.6.2. DOXP reductase (DXR) 
 
DOXP reductase (DXR) is the second enzyme in the non-mevalonate cascade, and exists as a 
homodimer of a molecular weight of 42-45 kDa.  The optimum pH range is 7-8 for the function of 
this enzyme with a maximum temperature range of 50-60 °C.279   DXR requires the assistance of a 
divalent metal ion for catalysis, usually Mg2+, Mn2+ or Co2+.  The addition of other divalent metal 
(Ca2+, Ni2+ or Zn2+) in vitro resulted in a reduction or loss of activity.273,280  Due to the abundance of 
Mg2+  in vivo it has been suggested that Mg2+ is the relevant cation used for the transformation of 
DOXP to MEP (Scheme 3.12).280   Each PfDXR subunit contains a single NADPH molecule and a 
divalent metal ion (Figure 3.23).  These subunits each contain two large domains, a linker region and 
a small C-terminal domain.  The one large domain is responsible for NADPH binding while the other 
is responsible for metal and substrate binding and thus catalysis.281    
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Scheme 3.12: Proposed mechanisms of the rearrangement of DOXP (3.229) to form the intermediate 2-C-
methyl-D-erythrose-4-phosphate (3.235).  Above:  α-ketol rearrangement; below: sequential 
retro-aldol/aldol reactions.  Reproduced from Proteau.
279
 
 
2-C-methyl-D-erythrose-4-phosphate (3.235) was proposed as an intermediate for the conversion of 
3.229 to 3.230.282  The two proposed mechanisms involve either a α-ketol rearrangement or a 
sequential retro-aldol/aldol synthesis (Scheme 3.12).  The α-ketol rearrangement requires the 
divalent metal directed deprotonation of the hydroxyl on C-3 of DOXP (3.229), assumedly via a basic 
residue on DXR, initiating the migration of the phosphate bearing C2 subunit to afford 3.235.  The 
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second mechanism requires the basic deprotonation of the alcohol on C-4, followed by the cleavage 
of the bond between C-3 and C-4 to afford the enolate, hydroxyacetone (3.236) and glycoaldehyde 
phosphate (3.237).  Recombination of the two moieties via an aldolization, forms a carbon-carbon 
bond between C-2 and C-4 of 3.229, resulting in 3.235.283        
 
 
Figure 3.23:  The ribbon representation of the crystal structure of the homodimer of P. falciparum DXR (PDB 
3AUA) and co-factors.
281
  The α-helices coloured in red, the β-sheets in blue.  The co-factor 
NADPH in the active site is displayed in stick representation and Mg
2+
 displayed in yellow in 
CPK representation.   
 
The formation of MEP is under strict stereochemical control.279  The stereospecific delivery of a 
hydride from NADPH occurs from the proS hydride,280 which attacks the aldehyde intermediate 
3.235 at the re face.284  This results in the formation of 2-C-methyl-D-erythritol-4-phosphate 3.230.  
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Scheme 3.13: The stereochemical formation of 3.230 in DXR.  The proS hydride of NADPH attacks the 
aldehyde of 3.235 at the re face.  Reproduced from Proteau.
279
 
 
3.6.3. Current DXR inhibitors 
 
The natural antibiotic fosmidomycin (3.238) was isolated from Streptomyces lavendulae285 and  
identified as a DXR inhibitor.286  Another related natural product FR900098 (3.239) was also shown 
to be a potent inhibitor of DXR.287  The bound crystal structures of these compounds indicate a 
similar binding fashion to that of DOXP.281,288  Over the years several analogues of 3.238 and 3.239 
have been synthesized.289,290  A few examples of these and their relevant IC50 values against E. coli 
DXR are presented in Figure 3.24.  
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Figure 3.24:  The structures of fosmidomycin (3.238), FR900098 (3.239) and analogues, with IC50 values of 
E .coli DXR.
289,290
 
 
Another approach to DXR inhibition focuses on the inhibition of NADPH binding site.  While all the 
compounds tested showed DXR inhibition (Figure 3.25),291 however the danger of using NADPH 
analogues is that they may bind and inhibit other unrelated biosynthetic pathways.  
 
3.238 R1=H 0.034 μM  
3.239 R1=Me 0.032 μM  
R1=H 0.313 μM   
R1=Me 0.050 μM   R
1=H R2=OMe R3=H 0.156 μM  
R1=H R2=Cl  R3=Cl 0.059 μM  
R1=Me R2=H  R3=H 0.311 μM  
R1=Me R2=Me R3=H 0.396 μM  
R1=Me R2=OMe R3=H 0.459 μM  
R1=Me R2=Cl  R3=H 0.099 μM  
R1=Me R2=Cl  R3=Cl 0.119 μM  
 
R1=Ph  >30 μM 
R1=(3-NO2)Ph >30 μM  
R1=(4-NO2)Ph    34 μM  
R1=2-thienyl    42 μM  
R1=3-thienyl >30 μM  
R1=Ph  5.4 μM  
R1=(4-CN)Ph 5.5 μM  
R1=(3,4-Cl2)Ph 16  μM  
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Figure 3.25:   Structures of adenosine type DXR inhibitors and there % inhibition value.  All inhibition studies 
were tested at a concentration of 30 μM.
291
 
 
3.6.4. Results of DXR inhibition studies 
 
The compounds 3.209-3.212 were tested for their ability to inhibit both PfDXR and EcDXR derived 
from P. falciparum and E. coli repectively.  The enzymatic activity was monitored via the reduction of 
NADPH, which is essential for the function of the reaction.  From Figure 3.26 it is clear that 
compounds 3.209-3.211 jointly show a trend in which there is a reduction in activity in PfDXR and 
EcDXR of >40% and >60% respectively.  Interestingly, our most active antiplasmodial podocarpane, 
3.212, showed very little inhibition of DXR.       
 
  
Figure 3.26: Relative percentage PfDXR inhibition (shown in green) and EcDXR inhibition (shown in purple) 
for compounds 3.238, 3.209-3.212.  All compounds tested at 250 μM.
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3.7. Conclusion 
 
We successfully managed to synthesis compounds 3.203-3.207 and 3.209-3.212 using CeCl3 
mediated Grignard alkylation.  By introducing a halogen atom to the phenyl ring of the 
podocarpanes we generally improved the antiplasmodial activity by 3-5 times.  None of our 
synthesized diterpenes (3.203-3.207 and 3.209-3.212) exhibited any erythrocyte shape change.  We 
attempted to improve the activity through the conversion of the tertiary alcohols of 3.203-3.207 and 
3.209-3.212 to isonitriles, however this reaction resulted in the dehydration products (e.g. 3.217).   
We subsequently tested the most active compounds 3.209-3.212 for the ability to inhibit DXR thus 
attempting to identify the podocarpanes antiplasmodial mode of action.  To best of our knowledge 
this is the first recorded use of diterpene inspired molecules in the inhibition of DXR.  We were 
unable to determine whether these compounds bind to the DOXP receptor or the NADPH receptor.   
Gelb292 has provided evidence to suggest that micromolar anti-plasmodial activity may be indicative 
of multi-target binding in Plasmodium and it is probable that 3.203-3.207 and 3.209-3.212 act at 
more than one, as yet unidentified, target in P. falciparum.  The ability of 3.203-3.207 and 3.209-
3.212 to inhibit the sequestration of haem will be evaluated in Chapter 4.     
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4.1. Background     
4.1.1. Quinolines and the inhibition of haem detoxicification in P. 
falciparum  
 
Chloroquine has been the primary treatment for malaria over the past seven decades.  Its mode of 
action has been studied in great detail and the consensus of the mode of action of chloroquine is the 
inhibition of the polymerization of haem thus poisoning the parasite as described in Chapter 2.   
As such chloroquine is often used as a positive control in assays designed to evaluate potential 
inhibitors of haem polymerisation.   
Several variants of haem will be discussed in this Chapter and to avoid confusion it is important to 
clearly present their structures upfront (Figure 4.1).  The term haem applies to free haem or 
protophorphyrin IX [Fe(III)PPIX] in which there is no ligand bound to the iron atom at the centre of 
the porphyrin ring.  Two commercial haem compounds are available viz. haematin [H2O-Fe(III)PPIX]  
or [HO-Fe(III)PPIX] (pH-dependent) and haemin [Cl-Fe(III)PPIX] in which water and chloro ligands are 
bound to the central iron atom of haem respectively.  Plasmodium falciparum is able to facilitate the 
dimerization of haem to form a haem dimer and then undergo further polymerization, often also 
referred to as sequestration, to form a crystalline substance known as hemozoin.  β-Haematin is a 
synthetic analogue of hemozoin that has been shown by three different research groups to be 
identical in all respects to hemozoin.96,293-295   
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Figure 4.1: The five relevant forms of haem: Free hame, Haematin [HO-Fe(III)PPIX], haemin[Cl-Fe(III)PPIX] 
the haem dimer and hemozoin/ β-haematin 
 
Chloroquine interacts with free haem through vertical π-stacking with the aromatic quinoline ring 
orientating itself above the haem porphyrin ring (Figure 4.2).296  In the haem dimer the amine side 
chain of chloroquine orientates itself at 45o to the planes of the porphyrin rings and occupies the 
space immediately adjacent to the haem dimer (Figure 4.2).  The combination of this orientation of 
the amine side chain coupled with the π-stacking of the quinoline ring across the monomeric and 
dimeric porphyrin faces prevents hemozoin crystal growth both vertically and laterally.   
 
 
 
 
 
Haemin Haematin 
Hemozoin/ β-haematin 
 Free Haem (haem) 
Haem dimer 
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Figure 4.2:   A graphical display of chloroquine (shown inset) binding to free haem (left) and the 
haem dimer (right).  Oxygen atoms, red; carbon atoms, grey; nitrogen atoms, blue; chlorine 
atoms, green; hydrogen atoms, white and iron atoms, orange. Chloroquine was optimized 
using the B3YLP correcting functional and 6-31G(d) basis set. Docking simulation calculated in 
AutoDock
297
 and results visualized in DSVisualizer.
21
 
 
There are two primary theories for the mode of action of quinoline antimalarial drugs: complexation 
with haem dimer thus minimizing access to crystal cell units (Figure 4.2)94,298 and inhibition of 
hemozoin formation through attachment of the drug to the growing crystal (Figure 4.3).299-301  Both 
theories involve the non-covalent binding of quinolines to the haem, haem dimer or the developing 
hemozoin crystal.  Buller et al.296  propose a quinoline binding site at the end face of the fastest 
growing crystal face (the [001] crystal face)302 of β-haematin (the synthetic equivalent of hemozoin).  
The [001] face contains the exposed carboxylic acids of haem as well as aromatic surfaces which 
encourage further propagation of the β-haematin crystal.  In their model the quinoline ring fits 
snugly within the cleft of the corrugated surface (Figure 4.2).  The loosely bound quinoline results in 
no further crystallization of haem onto the crystal face.  The addition of chlorine to the quinoline 
ring e.g. in chloroquine, helps anchor the inhibitor within the crevice of hemozoin.302 
NCl
HN
N
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 Figure 4.3:   β-Haematin viewed along the a-axis, bold arrows indicate the exposed corrugated face,
 296,302
 
with crevices where chloroquine is proposed to fit snugly (bold arrows).  The cif file (CCDC 
162267)
303
 was visualized in Mercury 2.4.5.
304
  Note how the β-haematin crystal lattice is 
comprised of haem dimers.     
 
4.1.2. A review of assays to determine inhibition of haem polymerization 
 
The earliest description of an assay designed to detect inhibitors of haem polymerization was 
presented by Slater and Cerami in a letter to Nature in 1992.305  In their assay red blood cell-derived 
trophozoite extracts were centrifuged, affording a pellet capable of facilitating the formation of 
hemozoin from free haem.  Radiolabelled 14C haem was added to the pellet and incubated for 12 hrs 
and subsequent purification of the product mixture yielded 14C containing hemozoin.  The addition 
of chloroquine to the trophozoite pellet and 14C-labelled haem mixture resulted in no radiation being 
emitted from the purified hemozoin in other words this hemozoin had formed prior to incubation 
with 14C-labelled haem and no 14C-labelled hemozoin formed from the addition of 14C-labelled haem.   
Dorn et al. extended the study of trophozoite extracts and hemozoin formation by concluding that 
haem sequestration into hemozoin is protein independent.  Their argument is based on the 
observation that hemozoin is still synthesized after heating the trophozoite extract (Note: heating 
denatures most proteins).  From this observation they suggested that the polymerization of haem is 
a chemical process.306  Sullivan et al. subsequently further explored the interaction of chloroquine 
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with haem and hemozoin.  They incubated a mixture of haem and purified hemozoin in sub 
inhibitory concentrations of 3H-labelled chloroquine overnight at 37 °C.   After incubation they 
discovered tritium in both free haem and hemozoin and concluded that chloroquine binds initially to 
haem and is then incorporated into the hemozoin crystal.  Sullivan et al., also proposed that 
chloroquine essentially “end caps” the nascent crystal of hemozoin thereby preventing elongation of 
the crystal lattice.299  They went on to demonstrate that the addition of histidine-rich proteins 
(HRPs), which are found in the parasites food vacuole, appear to initiate hemozoin formation.307 
Dorn and co-workers308 later elaborated and improved on their original assay with the addition of 
acetonitrile trophozoite extracts.  They suggested, as lipids dominated the acetonitrile extract, that 
the sequestration of haem into hemozoin may be lipid catalyzed.  While these methods have the 
potential to identify haem polymerization inhibitors, the use of radiolabelled compounds is 
expensive, reliant on access to specialized equipment and facilities and necessitates the final 
disposal of radioactive waste.  Slater and Cerami also showed that there was a decline in activity of 
the trophozoite pellet over time,305 thus fresh trophozoites need to be continuously available in 
order to conduct this assay.  A limitation of Sullivan’s method is clearly the availability of suitably 
radiolabelled inhibitors. Despite the challenges of a radiolabelled based assay a high throughput 
screen was reported using 14C-labelled haematin.309    
Basilico and co-workers310 exploited the solubility differences between haematin [H2O-Fe(III)PPIX] 
and β-haematin in creating a method to determine the haem polymerization inhibitory activity 
(HPIA) of potential antimalarial drugs.  An acidic solution of haematin (final pH of 2.7) was incubated 
for 24 hours at 37 °C, to ensure complete polymerization.  The solid matter was collected via 
centrifugation and resuspended in DMSO to remove any soluble unreacted haematin before being 
centrifuged once again.  The pelleted portion, containing pure β-haematin, was finally analyzed via 
FTIR.  The lack of precipitated material after incubation with a suspected inhibitor indicated 
inhibition of β-haematin.  The advantage of the HPIA assay is that it is inexpensive and suitable for 
high throughput screening of both water soluble and water-insoluble compounds (solvents used to 
solubilise test compounds do not interfere with the assay).  The disadvantage of this assay is that it is 
time consuming, requiring a 24 hour incubation period and two centrifugation steps.  The assay was 
found to be flawed when it was later discovered that, several salts including chlorides and 
phosphates gave a false positive result.  This is of concern because many aminoquinoline drugs are 
formulated as salts, e.g. chloroquine phosphate and primaquine diphosphate.  The limitations of 
HBIA led to the development of the β-haematin inhibitory activity (BHIA) assay.311  By replacing 
haematin [H2O-Fe(III)PPIX] with haemin [Cl-Fe(III)PPIX] as the porphyrin source and replacing the 
NaOH solution with DMSO to dissolve the porphyrin, adding of the test solution followed by 
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acidification, no salt induced false positive results were observed.311  Baelman et al. used a slightly 
modified BHIA assay, in an attempt to identify bioactive natural products from Bolivia, by reducing 
the number of centrifuge steps and monitoring β-haematin formation with UV/vis spectroscopy as 
opposed to FTIR.312  Unfortunately, the use of FTIR as a detection method for β-haematin requires 
the β-haematin samples to be solvent and water free which necessitates a lengthy drying period in 
addition to the 12-48 hour incubation period.                        
Egan and co workers developed two methods for determining a compound’s ability to interfere with 
the formation of hemozoin, namely the Pyridine hemichrome inhibition of β-haematin (Phi-β)313 and  
β-haematin inhibition assays (which we have abbreviated to EBHIA – Egan’s β-haematin inhibitory 
assay).314  In both methods the β-haematin crystals are grown in an acetate buffer (pH 5.00) in the 
presence of potential inhibitors, thus providing a means to assay the inhibitors ability to hinder the 
biocrystallization of haem under similar pH conditions to those found in the plasmodial food 
vacuole. We used both Phi-β and EBHIA to study the inhibition of haem polymerization, in the 
presence of both naturally occurring (2.4, 2.9, 2.15, 2.19, 2.34 and 2.35) and synthetic (3.215) 
compounds, because of the accessibility of these methods with regards to availability of reagents, 
analytical techniques, cost and incubation times.  While others have reported alternative methods 
for determining the presence of β-haematin, including fluorometry315 and HPLC,316 spectroscopy still 
remains the most convenient and widely used analytical technique.   
The discovery that β-haematin (the synthetic equivalent of hemozoin) may be synthesized in a 
laboratory has initiated a debate as to whether the polymerization in vivo is a spontaneous chemical 
or biological facilitated process, as many of these in vitro methods are conducted in 
supraphysiological conditions, such as high temperature (60 °C) in the EBHIA and Phi-β or lengthy 
incubation times (18-24 hrs) in both the HPIA and the BHIA assays.  However, the consensus view is 
that the sequestration of haem into hemozoin in vivo occurs by a multifarious mechanism, where 
lipids may play a major role in mediating the polymerization of haem to hemozoin.83,317  A summary 
of known mechanisms of haem polymerisation and valid criticisms of each mechanism is presented 
in Table 4.1.   
Haem polymerization still attracts the interest of a number of research groups and Stiebler et al.317 
recently proposed the following mechanism for the polymerisation of haem to hemozoin within the 
food vacuole of Plasmodium (Figure 4.4):  Firstly protein (e.g. α-glucosidase) initiates the nucleation 
of haemozoin via the formulation of the intial seeds of haemozoin.  Secondly, the haemozoin crystal 
elongates at the lipid-water interface mediated by membrane lipids.  Thirdly, the nascent hemozoin 
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crystal is released from the lipid membrane where it may continue to slowly elongate via 
autocatalysis.            
Table 4.1: A summary of the mechanisms proposed for the sequestration of haem into hemozoin by the 
Plasmodium parasite.  
      
Mechanism Proof for mechanism theories Criticisms 
   
Spontaneous - Synthesis of β-haematin occurs 
despite the removal of all 
biological 
components.
310,311,313,314
 
- Rates of β-haematin formation do 
not mirror those observed for 
hemozoin formation in the 
parasite.
83
  
Lipids - The addition of lipids into in vitro 
β-haematin inhibition assays 
minimises the discrepancy 
between experimental and 
physiological conditions.
301,318,319
  
- The calculated stoichiometric ratio 
of lipids required to sequester the 
amount of haem contained with 
the parasite is inconsistent with 
the actual quantities of lipids 
contained with the FV.
83
  
Autocatalytic - The addition of hemozoin or β-
haematin, increases the 
formation of hemozoin.
306
 
- The formation of the original 
hemozoin nucleation site is 
unknown. 
Proteins:   
HRP II and III - The rate of β-haematin synthesis 
in vitro is accelerated in the 
presence of HRP.
299
 
- Removal of the genes which code 
for HRP II and III in P. falciparum 
still result in the formation of 
hemozoin.
87
   
- HRP genes are not found in other 
species of Plasmodium however, 
hemozoin is produced in all of 
them.
320
  
 
Heme-detoxicfication 
protein (HDP) 
- HDP actively converts haem to β-
haematin in vitro.
321
   
- HDP is localized in the FV of the 
parasite.
321
 
- Heating of the trophozoite extracts 
still results in the formation of 
hemozoin.
306
  
α-Glucosidase - Removal of the α-glucosidase or 
pharmacological inhibition of this 
enzyme reduces the formation of 
hemozoin.
322
  
- Only discovered in Rhodnius 
prolixus (a haemoglobin 
/haemolyph feeding insect), which 
also sequesters haem into 
hemozoin.
322
  
Abbreviations:  FV – Food Vacuole 
HRP – Histidine Rich Proteins  
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Figure 4.4: The proposed mechanism of haem polymerization in the Plasmodium parasite.
317
  
 
In more recent years the reports of new β-haematin inhibition assays have decreased in the 
literature although several modifications to existing methods have been recorded, most notably the 
introduction of lipids as initiators of haem sequestration into β-haematin.  The addition of lipids 
(such as MOG, polysorbate 20, lectin, MSG or MPG) to the assay has many advantages.  Lipids 
appear to stabilize haem stock solutions,318 and reduce incubation time319 and temperatures,318,319 
the latter being of particular importance should the potential inhibitor be thermally unstable.  The 
incorporation of lipids into β-haematin inhibition assays, and subsequent reduction in the incubation 
temperatures and duration of the assay has the advantage of making the assay a closer match to 
physiological conditions.  While our study was in progress the use of lipids in β-haematin inhibition 
assays was not well-established and to the best of our knowledge has still not become standard 
practise.   
4.1.3. Egan’s β-haematin inhibition assay (EBHIA) and Phi-β assay 
 
Egan reported that without scrupulous experimental accuracy the variables of the EBHIA assay may 
alter the outcome, (e.g. pH, temperature, acetate concentration and stirring rate).301  The EBHIA 
method is discussed in Chapter 6, however the reaction condition we used will be discussed here.  
Whilst testing marine natural products we were limited by the quantity of material and therefore, all 
natural products were tested at three equivalents relative to haem.  Synthetic material, however, 
Nucleation Elongation 
Crystal 
release from 
interface 
Crystal 
extended by 
autocatalysis 
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was abundant and we tested these compounds at ten equivalents (the highest practical 
concentration is 20 equivalents).173  Unfortunately, due to limitation of the quantities of the marine 
isonitrile inhibitors in hand, we had to scale down Egan’s method to one fifth of the reported 
quantities (reported mass of required haemin was 75 mg).301  Due to the capricious nature of this 
assay, we deemed it necessary to therefore scale down all reaction apparatus accordingly and all 
subsequent reactions were conducted in a 20 mL cylindrical glass vial (20mm in diameter and 64 mm 
in height).  The rate of stirring can alter the results and thus all reactions were stirred at consistent 
rate by a stirrer bar (2mm in diameter and 5mm in length).  The 100 mL of 12.8 M stock acetate 
buffer was made up to a final pH of 5.00 ± 0.005 and incubated at 60 °C.  The acetate buffer was 
supersaturated at ambient temperatures and it was critical to the success of the assay that the 
NaOAc remained dissolved.  When transferring the warmed acetate buffer to the reaction vessels a 
new pipette tip was used every time.  NaOAc microcrystals contaminating the pipette tips resulted in 
rapid crystallization of NaOAc out of the buffer solution thus altering the pH and acetate 
concentration of the buffered solution.   It must be noted that all potential inhibitors were added in 
methanol after neutralization of 0.1M NaOH with 1 M HCl in strict accordance with the method 
reported in literature.313  The assay reaction mixture was sealed to avoid evaporation and heated in 
a water bath at 60 ± 0.5 °C surrounded by aluminium foil to remove any interference by light.         
 
4.1.3.1. UV/vis spectroscopy (Phi-β assay) 
 
This Phi-β assay is based on pyridine’s ability to form a monomeric low spin complex with only 
unreacted haematin and not with β-haematin.  The presence of this complex can be measured by 
UV/vis spectroscopy.  In an aqueous medium haematin exhibits a broad and relatively weak Soret 
band (389 nm), which is typical of the aggregated state of porphyrins, possibly from dimerization.323  
Aqueous solutions of haematin also exhibit a very weak Q-band (450-700 nm) and a prominent 
charge-transfer (CT) band (625 nm)313 in the UV/vis spectrum.  With the addition of pyridine, the 
Soret band of haematin experiences a red-shift of 15 nm as well as an increase in intensity and 
sharpening with a maximum peak emerging at 405 nm.  In the longer wavelength region, the Q-band 
becomes more prominent at 527 nm indicating the formation of low spin Fe(III)-protoporphyrin IX-
pyridine complex.  These changes are indicative of the displacement of the axial water from the 
central Fe(III) atom of haematin with two pyridine ligands coordinating in its place (Figure 4.5).324  
Under aqueous neutral conditions the axial ligand in haem is thought to be H2O rather than 
–OH.  
Water is a weak field ligand and will readily be replaced by the strong-field ligand pyridine.313  
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β-Haematin consists of dimers in which one of the acid side-chains of one porphyrin is coordinated 
to the Fe(III) centre of the other porphyrin in the dimer (see Section 4.1.3.2).325  However, it was 
shown by Hempelmann et al.326 that at high concentrations of imidazole (similar coordination 
properties to that of pyridine) and subsequent strongly basic conditions, β-haematin may be broken 
down to form a haem-imidazole complex.  It is thus essential that this interaction of pyridine and 
haematin takes place in a medium buffered to a pH of 7.5.  In strongly basic conditions pyridine also 
promotes the formation of the µ-oxo dimer of Fe(III)-protoporphyrin IX instead of coordinating itself 
to Fe(III) of haematin.327  These changes in the UV/vis spectra of haematin in the presence of 
pyridine are the basis for a potentially good assay for the following three reasons.  Firstly the 
sharpening and increase in intensity of the Soret band increases the sensitivity of the assay.  
Secondly, the red shift experienced in the UV/Vis spectra on the addition of pyridine will allow a 
higher degree of accuracy as there is no overlap of the spectra of free haematin and pyridine 
coordinated haem.  And finally, pyridine is thought to remove any other molecules that may have 
coordinated to the iron(III) centre.313   
 
Figure 4.5: The image of two pyridine molecules chelating to the iron core of haem. 
 
From the intense Soret band in the UV/vis spectra (Figure 4.6, purple) below, it can be seen how 
chloroquine inhibits the formation of β-haematin i.e. pyridine has a high concentration of free haem 
to coordinate to.  The control spectrum in the Phi-β assay is acquired in the absence of any 
chloroquine type compounds, i.e. a negative control. However, a small peak at 405 nm is still 
observed indicating that not all haematin was polymerized to β-haematin.  Interestingly, on the 
addition of pyridine to the chloroquine containing solution of haematin the resultant solution turned 
an orange-pink colour reflecting the red-shift.   This colour change was almost instantaneous 
indicating that the complexation of pyridine to haematin is a very rapid reaction.  
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Figure 4.6:   The UV/vis spectra (350-700 nm) of Phi-β assay solutions containing chloroquine (purple) and 
no inhibitor (red).  The Soret and Q-bands are indicated.     
 
This methodology has been validated in that there is a good correlation with results obtained in the 
BHIA and the HPIA assays.313  The advantages of the Phi-β method is that it is fast, cheap and 
requires easy detection methods, even visual confirmation would tentatively suffice.  The appeal of 
this assay for the identification of potential natural product β-haematin inhibitors, is the sensitivity 
of the assay (only 0.17 μmol of material is required) and that it is suitable for use in the field.  
Disadvantages of this assay are firstly that poorly water soluble compounds appear to prevent 
solubilisation of haematin producing a false negative result.  However, poorly water soluble 
compounds may never reach bioactive concentrations in vivo, and thus may not be considered as 
viable antimalarial drugs in the long term.  Secondly, the use of strongly coloured samples may 
interfere with the absorbance spectra recorded in this assay and a change in the Soret band 
absorbance does not necessarily always provide definitive proof of β-haematin inhibition.  Other 
scenarios may also be envisioned, such as haematin degradation in the presence of the test 
compound, and slow crystallization of the test compound-haematin complex resulting in a product 
that does not readily react with pyridine.  Alternatively, the drug may replace pyridine or 
preferentially bind to free haem, but still allow polymerization to occur.  For these reasons, the 
results from the Phi-β assay cannot be accepted unilaterally and further validation of the inhibition 
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of β-haematin formation must be provided by other complementary analytical techniques e.g. FTIR, 
XRD and SEM. 
4.1.3.2. FTIR spectroscopy 
 
The coordination of the carboxylate group to the iron (III) centre in hemozoin is readily identifiable 
using FTIR viz two peaks (ca. 1663 and 1210 cm-1) in the IR spectrum of hemozoin corresponding to 
the respective C=O (blue in Figure 4.7) and C-O (red in Figure 4.7) stretching frequencies of the 
carboxylate group bound to iron.328 These two peaks are absent in the IR spectra of haematin and 
only present when the dimer is formed, in which water/hydroxyl bound to the iron in haematin is 
displaced by the carboxylate bonds.  The haem dimer subsequently congregates through hydrogen 
bonding to form hemozoin crystals (Figure 4.1).   
 
N N
N
OO
N
O OH
3+Fe
NN
N
O O
N
OHO
Fe3+
 
 
Figure 4.7:   The chemical structure of the haem dimer, the red bond indicates the C-O bond responsible for 
the IR peak at 1210 cm
-1
 while the blue bond is indicative of the C=O responsible for the IR 
peak at 1663 cm
-1
 in FTIR spectra.   
 
A comparison of the FTIR spectra of the precipitate chloroquine-added sample obtained from EBHIA 
assay and a precipitate obtained without chloroquine (negative control) are presented in Figure 4.8.  
The two strong peaks at 1210 and 1663 cm-1 in the spectrum of the negative control indicates the 
successful sequestration of haem to β-haematin.  The absences of these two distinct stretching 
frequencies in the purple FTIR spectrum (Figure 4.8) show the lack of the formation of the Fe-O bond 
i.e. the haem dimer, indicating inhibition.    
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Figure 4.8: The FTIR spectra (1100-1800 cm
-1
) of the precipitates obtained in EBHIA, containing 
chloroquine (purple) and no chloroquine (red).  The IR peaks of interest (1663 and 1210 cm
-1
) 
are indicated by a dotted line.   
 
The advantages of FTIR are that it is fast and requires minimum amounts of material.  Due to the 
intensity and location of the monitored IR peaks the sample does not need to be pure and a mixture 
of haematin and β-haematin would still yield useful results, which has been proved from previous 
reports where this technique has been used successfully.305,306,314,329  The disadvantages of this 
methodology predominately stem from the use of compounds containing carboxylic acid moieties, 
which may bind to the central iron atom and produce a false negative result.   The other limitation of 
this analytic technique for monitoring β-haematin polymerization inhibition is that it will only be 
representative of the inhibition of free haem rather than further polymerization of the haem dimer, 
where iron-carboxylic acid bond may have already been established.  Results arising from this 
analytical technique, therefore, also require further validation with supplementary techniques e.g. 
X-ray powder diffraction and SEM. 
4.1.3.3. X-ray powder diffraction 
 
As can be seen from the X-ray diffraction pattern, the diffraction angles of our synthesized 
β-haematin corresponded to those in the X-ray powder diffraction pattern reported by Pagola et 
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al.303 for pure β-haematin (Figure 4.9) indicating a similar powder diffraction pattern.  The peaks for 
our synthesized β-haematin are much broader and can be attributed to the source of the X-rays.  
Pagola et al. used a synchrotron which is greatly superior to a conventional source of X-rays such as 
the one used in our experiments.  Secondly the β-haematin crystals formed in an acetate solution 
are of a smaller size and are of poorer crystallinity thus broadening the peaks.313  What must be 
noted is that the intensity of the peaks is related to structure and orientation, not concentration.  
Also what is unique to all crystalline compounds is the position of the Bragg reflections, i.e. the 2θ 
values corresponding to each peak.330   Although the peaks may be broader the general diffraction 
patterns are essentially the same which provides a crystalline compound with a definitive X-ray 
powder diffraction fingerprint.   
 
          
Figure 4.9: The X-ray powder diffraction pattern (2θ: 5°-30°) of β-haematin obtained with synchrotron 
radiation using X-rays of wavelength 1.16192Å (above).
303
  Reproduced from the cif file 
(162267)
303
 in Mercury.
304
  The X-ray powder diffraction pattern (2θ: 5°-30°) we obtain from 
EBHIA in the absence of an inhibitor (below). X-ray powder diffraction patterns were recorded 
on a Bruker D8, Discover equipped with a proportional counter, using Cu-Kα radiation                
(λ = 1.5405 Å, nickel filter). 
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In X-ray powder diffraction it is important to note that amorphous solids do not have crystalline 
surfaces with which to reflect X-rays and therefore no diffraction pattern is detected.   Amorphous 
haematin is a product of the EBHIA assay when polymerization is inhibited whereas β-haematin, the 
product when there is polymerization, is crystalline.  This difference in the solid states of these two 
compounds can be exploited to determine if haem polymerization inhibition has occurred.  The X-ray 
powder diffraction patterns of Figure 4.10 shows chloroquine’s ability to inhibit hemozoin 
formation.   
 
Figure 4.10: The X-ray powder diffraction patterns (2θ: 5°-30°) of the precipitates of the EBHIA containing; 
chloroquine (red) and control (orange). X-ray powder diffraction patterns were recorded on a 
Bruker D8, Discover equipped with a proportional counter, using Cu-Kα radiation (λ = 1.5405 Å, 
nickel filter). 
 
Due to the micro-crystalline nature of synthetic β-haematin produced in the EBHIA, a relatively large 
amount of sample is required in order to obtain enough precipitate to afford X-ray powder 
diffraction peaks of sufficient intensity.  The minimum with which we managed to achieve 
reasonable X-ray powder diffraction patterns was 5 mg of β-haematin/haematin containing 
precipitate.  It must be noted that the same amount of EBHIA precipitate was used for each X-ray 
powder diffraction analysis and therefore the lack of peaks in the diffraction pattern was a true 
indication of an inhibitor’s ability to hinder haem sequestration as opposed to a limitation in the 
sensitivity of the detector in the X-ray diffractometer.  The EBHIA requires the addition of a 
minimum of three equivalents, relative to haem, of potential inhibitor which requires significant 
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amounts of test compounds.   Although, this technique is not quantifiable it is the most conclusive 
for determining if β-haematin has formed. 
      
4.1.3.4. Scanning electron microscopy (SEM) 
 
Figures 4.11A-C are SEM micrographs, with increasing magnification, showing the external 
morphology of commercially available haematin.  In these images large angular amorphous 
structures can be seen.  On increased magnification the surfaces of haematin appear smooth and 
unobstructed (Figure 4.11C).   Large smooth amorphous particles can again be seen in Figure 4.11 D 
and G, which is to be expected as these scanning electron micrographs were obtained from 
haematin collected at the beginning of the EBHIA.   On allowing the EBHIA to proceed in the absence 
of a polymerization inhibitor e.g. chloroquine for 15 min the external appearance of haematin is 
altered with the addition of small but distinguishable lath-like331 microcystals of β-haematin (150-
350 nm in length)301 on the surface of haematin (Figure 4.11 E and H).  After the 30 minute interval 
(not shown) there is a significant increase in the β-haematin with the majority of the orginal 
haematin covered with microcrystals of β-haematin.  After 60 minutes the total surface appears 
covered with β-haematin with no evidence of the original amorphous haematin (Figure 4.11 F and I).  
Egan has shown that de novo β-haematin microcrystals formed in an acetate solution are smaller 
and less ordered than naturally formed hemozoin, β-haematin formed through seeding by pre-
existing β-haematin or crystals grown in a non-aqueous medium.332-334  The SEM micrographs of the 
precipitate obtain after the addition of chloroquine (Figure 4.11J and K) shows large smooth 
amorphous particles of haematin comparable to 4.11A-C.  SEM provides impressive visualization of 
the formation of β-haematin from haematin in the absence of inhibitor e.g. chloroquine.      
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Figure 4.11: The SEM micrographs of A-C:  Commercial haematin at 29, 206 and 2600x magnification 
respectively; D:  The growth of β-haematin at t = 0 min; E: t = 15 min; F: t = 60 min; G-I:  surface 
images at t = 0, 15 and 60 min; respectively.  J and K: SEM micrographs of the precipitates from 
the EBHIA containing chloroquine at 463x and 3000x magnification respectively. 
All images taken using a Tescan Vega scanning electron microscope at 20 kV and a working 
distance of 20mm.  Scale at the bottom of the image. 
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4.2. Research aims 
 
As discussed in Chapter 2 several mono, di, tri and tetracyclic marine isonitriles and isothiocyanates 
have exhibited potent antiplasmodial activity.  In this Chapter, the ability of a representative group 
of this class of marine compounds as well as the synthetic isonitrile (3.215) to inhibit the 
polymerization of haem will be evaluated.  The interference of haem detoxicification remains a 
viable drug target as sequestration of haem to hemozoin is a chemically fixed process, i.e. not 
subject to mutation.335  In this Chapter, the antiplasmodial mode of action of 2.4, 2.9, 2.15, 2.19, 
2.34, 2.35 and 3.215 will be evaluated to determine whether this antiplasmodial activity is based in 
2.4, 2.9, 2.15, 2.19, 2.34 and 2.35’s ability to inhibit the detoxicification of haem.  The ability to 
disrupt haem polymerization was determined with Egan’s β-haematin inhibition assay (EBHIA), and 
β-haematin formation was monitored by XRD, SEM, UV/vis and FTIR spectroscopy.323  A putative 
computer generated model of marine isonitriles ability to bind to haem was reported a decade 
ago.196 However, with the availability of more advanced computational methods we chose to revisit 
this haem-isonitrile interaction, focusing particularly on the charges associated with the isonitriles 
functionality.  We hoped to discover a haem/haem dimer binding motif in the hope that future β-
hematin inhibitors could be identified from the way these inhibitors dock to haem receptors in 
modelling studies.     
 
4.3. In vitro evaluation of haem polymerization inhibition by 
marine and synthetic isonitriles and isothiocyanate (2.4, 2.9, 
2.15, 2.19, 2.34, 2.35 and 3.215) 
 
The marine isonitriles (2.4, 2.9, 2.15, 2.19 and 2.35) and the isothiocynate (2.34) were kindly 
provided by Professor Wright, College of Pharmacy, University of Hawaii at Hilo, Hawaii, USA, so that 
we could explore their ability to inhibit haem polymerization in vitro.  The results of our investigation 
using the practical procedure outlined in Chapter 6 are presented here.   
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4.3.1. UV/vis spectroscopy (Phi-β assay)  
 
Only the synthetic isonitrile 3.215 was tested for β-haematin inhibition using the Phi-β assay.313  
Given the small quantity of (2.4, 2.9, 2.15, 2.19, 2.34 and 2.35) in hand and since Wright et al.196  had 
already proposed mode of action of 2.4, 2.9, 2.15, 2.19, 2.34 and 2.35, may be the interference with 
haem polymerization, it was not deemed necessary to screen these compounds in the Phi-β assay.  
The Soret-band evident in the pyridine containing solution of 3.215, indicated the presence of free 
haem and that possibly some inhibition of β-haematin formation had occurred (Figure 4.12).  While 
the peak intensity for the solution containing 3.215 (10 equiv.) was not as intense as the one 
obtained for chloroquine, the continued assessment of 3.215 as a β-haematin inhibitor was merited.         
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Figure 4.12: The UV/vis spectra (350-700 nm) of Phi-β assay solutions containing chloroquine (purple), 
3.215 (blue) and no inhibitor (red). 
 
4.3.2. FTIR spectroscopy 
 
Egan and co-workers301 developed an FTIR method for approximately quantifying the amount 
β-haematin formed in EBHIA assay.  By measuring the change in absorbance (         ) of the 
peak at 1210 cm-1 relative to the shoulder peak at 1229 cm-1 the intensity of which remains constant 
(Figure 4.13, Left) for various molar ratios of haematin mixed with β-haematin they were able to 
show that a liner relationship exists (Figure 4.13, Right).  The difference in these two absorbances 
(ΔA) could be easily determined and thus a percentage value calculated for the β-haematin present 
in each precipitate resulting from the EBHIA assay carried out with chloroquine, no inhibitor 
(control) and isonitriles 2.4, 2.9, 2.15, 2.19, 2.34, 2.35  and 3.215 (Table 4.2).     
The precipitates (1.0 ±0.2 mg) resulting from each of the EBHIA assays performed with 2.4, 2.9, 2.15, 
2.19, 2.34, 2.35, 3.215 and chloroquine were analyzed using FTIR and the presence of the two IR 
peaks (1210 and 1663 cm-1) monitored.  All marine metabolites 2.4, 2.9, 2.15, 2.19, 2.34 and 2.35 
were added at three equivalents, while 3.215 was added at ten equivalents relative to haem.   
Interestingly, the compounds which exhibited good (i.e. < 50% calculated formation of β-haematin) 
inhibition of β-haematin formation were 2.9, 2.15 and 2.19.  These compounds all contained a tri- or 
-0.1 
0 
0.1 
0.2 
0.3 
0.4 
0.5 
0.6 
0.7 
0.8 
0.9 
350 400 450 500 550 600 650 700 
A
b
so
rb
an
ce
 
Wavelength [nm] 
3.215 
Control 
Chloroquine 
Chapter Four:  In vitro and in silico studies of β-haematin inhibition 
 
 
106 
tetracyclic scaffold with isonitrile functionalities attached.  Compound 2.9 showed total inhibition of 
haem polymerisation at 3 equivalents, whereas compounds 2.15 and 2.19 all showed good potential 
to inhibit β-haematin formation at the same equivalency and may show greater inhibition at higher 
concentrations.  Interestingly, compound 2.9  also exhibited the greatest antiplasmodial activity (4 
nM), although 2.19 and 2.15  are not as active, with IC50 values of 47 and 84 nM they managed to 
limit the amount of β-haematin formed in the assay (14 and 26% respectively).  The results, obtained 
for 3.215 appear to correlate to those obtained in the Phi-β assay, i.e. only partial inhibition of haem 
polymerization.   
 
Figure 4.13:   A section of the IR absorbance spectrum (1150-1250 cm
-1
) of the precipitate obtained in the 
EBHIA assay (left).  The arrow indicates the shoulder peak at 1229 cm
-1
.  A reproduced plot of 
ΔA vs. percentage of β-haematin (right).
301
  
 
 
 
 
 
 
 
 
0.05 
0.1 
0.15 
0.2 
0.25 
0.3 
1150 1200 1250 
A
b
so
rb
an
ce
 
Wave number [cm-1] 
0 
0.05 
0.1 
0.15 
0.2 
0.25 
0 20 40 60 80 100 
Δ
A
 
% β-haematin 
Chapter Four:  In vitro and in silico studies of β-haematin inhibition 
 
 
107 
Table 4.2:   A comparison of the conversion of haemin to β-haematin in the presence of 2.4, 2.9, 2.15, 
2.19, 2.34, 2.35 and 3.215.  All conversions calculated from the change in the FTIR absorbance 
spectra of the precipitates obtained from EBHIA assay. (ND = not determined) 
 
Compound 
% β-haematin 
contained in the 
precipitate. 
Antiplasmodial 
Activity 
Control 97 - 
Chloroquine 4 70 nM 
Commercial 
Haematin 
2 - 
2.4 76 71 nM 
2.9 0 4 nM 
2.15 26 84 nM 
2.19 14 47 nM 
2.34 71 5.7 μM 
2.35 62 ND 
3.215 52 
 
3.1 μM 
 
4.3.3. X-ray powder diffraction 
 
The X-ray powder diffraction patterns (Figure 4.14) shows the ability of 2.9 to completely inhibit β-
haematin formation as no reflections were detected.  X-ray powder diffraction peaks were present 
in all other compounds tested (2.4, 2.15, 2.19, 2.34, 2.35 and 3.215), indicating the presence of β-
haematin.  These data supported the results obtained from the other analytical techniques discussed 
above. 
                                         
Figure 4.14: The representative X-ray powder diffraction patterns (2θ: 5°-30°) of the precipitates of the 
EBHIA incubated in the presence of: 2.35 (light blue), 2.9 (dark blue), 3.215 (green) and 2.15 
(pink).  X-ray powder diffraction patterns were recorded on a Bruker D8, Discover equipped 
with a proportional counter, using Cu-Kα radiation (λ = 1.5405 Å, nickel filter). 
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4.3.4. Scanning electron microscopy  
 
The scanning electron micrographs (Figure 4.15A and 4.15B) were obtained from the precipitate 
formed during the addition of chloroquine and a control experiment i.e. when no inhibitor was 
added in the EBHIA assay and β-haematin was free to form, respectively. Figure 4.15A shows large 
smooth amorphous particles of haematin, comparable to Figure 4.11A-C, whereas Figure 4.15B 
illustrates the presence of β-haematin as layers of fine microcrystals.  Figures 4.15C-F are 
representative SEM images of the precipitates from the EBHIA assays when 2.9, 2.15, 2.34, and 2.35, 
respectively had been added.  Figure 4.14C shows complete inhibition of haem polymerization 
(Figure 4.15E) partial inhibition (Figure 4.14F) and no inhibition (Figure 4.15C and D).  The SEM 
micrographs support the results obtained from both FTIR and XRD analyses of the EBHIA assay 
precipitates. 
 
Figure 4.15:  The representative SEM micrographs of the precipitates from the EBHIA carried out with; A:  
chloroquine, B: no β-haematin polymerisation inhibitor, C: 2.9, D: 2.15, E: 2.34 or F: 2.35, at 
various magnifications. Images taken using a Tescan Vega scanning electron microscope at 20 
kV and a working distance of 20mm.  Scale given at the bottom of the image. 
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4.4. In silico studies of marine and synthetic isonitrile/haem and 
isonitrile/haem dimer interaction  
4.4.1. Background into molecular modelling and optimization of docking 
studies 
 
In the case of modelling very large molecular systems two modelling approaches are used, molecular 
mechanics (MM) and molecular dynamics (MD).  Both of these use Newtonian motion equations to 
monitor the trajectory of a system’s components.  The major difference between these two methods 
is that MD caries out energy evolutions at a finite temperature while MM does not.  The accuracy of 
the energy calculations performed by these two computational methodologies is determined by the 
way in which the inter atomic forces are defined.  In this study the inter atomic forces were first 
determined by means of a force field approach, allowing for both the equilibrium thermodynamic 
and dynamic properties of the system to be calculated. 
The force field models are limited because they often fail to take electronic polarization effects into 
account and can only manage chemical reactivity through specialized techniques e.g. an empirical 
valence bond approach.336,337  For this reason ab initio methods are becoming the preferred method 
for exploring chemical reactivity.  The ability of this method to simulate bonding breaking and 
formation affords invaluable information.  Basic ab initio calculations are based on the assumption 
that there exist a finite number of nuclei and electrons for a given system, and that the Born-
Oppenheimer approximation (BOA) may therefore be applied to the system.  The BOA treats the 
nuclei as stationary due to their lack of momentum relative to the electrons; thus allowing for the 
Schrödinger equation to be solved for only the electron wavefunctions.338  The total energy of the 
system is expressed as the sum of the electron and nuclear energies, where the nuclear term is given 
an approximate value.336,339   
A modern method incorporating ab initio calculations is the Kohn-Sham formulation of density 
functional theory (DFT).340  This has become the preferred method amongst molecular modellers 
and as such was used here for the optimization calculation for all receptors (haem and haem dimer) 
and ligands (2.4, 2.9, 2.15, 2.19, 2.34, 2.35 and 3.215) in this study.  In DFT the atomic forces acting 
on a system are expressed as a functional of the electronic density where the electron density is 
described as a series of single electron orbitals.336,338  These approximations treat the electrons’ 
motion as independent of one another, and suggests a greater interaction between electrons than 
would normally be experienced in a true multi-electron system.  This leads to an over estimation of 
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the inter-electron repulsion term, resulting in an inflated total energy.  To correct this an electron 
correlation term is introduced, the most popular being Møller-Plesset (MP2), Becke-Lang-Yee-Parr 
(B3LYP) and Perdew-Burke-Ernzerhof (PBE) gradient correcting functionals.  The MP2 is a pure 
Hocktree-Fock method, whilst the PBE is a pure DFT and the B3LYP is a hybrid of the two.341-344  Thus 
for all minimization calculations the B3LYP correcting functional was used here.   Currently the 
preferred DFT formulation is 6-31G(d) basis set which describes the core electronic states by means 
of six Gaussian functions and then describes the valence states with two vector sets containing three 
and one vectors respectively.   
 
4.4.2. Electronic configuration of haem 
 
Haem can exist in four different electronic states: singlet, triplet, quintet and septet.345 In order to 
ascertain which state to use in our studies, the haem model was minimized in the singlet, triplet and 
quintet states and the one possessing the lowest energy was used for subsequent analyses.  We 
chose not to minimise the septet as this electronic state has been shown to be much higher in 
energy than the other three states.345  The free haem model was therefore successfully minimized in 
both the singlet and triplet electronic states with electronic energies of -8.13507×106 kJ.mol-1 and 
-8.13524×106 kJ.mol-1 respectively. Hence, the triplet state is 0.0017×106 kJ.mol-1 lower in energy 
than the singlet. The quintet state repeatedly failed to achieve electronic self-consistency and it was 
thus deemed necessary to use a pseudopotential to describe the iron atom’s core electrons and then 
use the standard DFT method to account for the valence electrons. The LANL2DZ346 double zeta 
pseudopotential was used and the minimized quintet structure was found to have an electronic 
energy of -5.14×106 kJ.mol-1, which correlates to an energy 3.00×106 kJ.mol-1 kJ higher than the 
triplet model.  From this optimization study we decided that the triplet haem model would be used 
for all subsequent modelling of haem-ligand interactions. 
 
4.4.3. Charge state of the isonitrile functionality 
 
One of the most arduous tasks facing molecular modellers is the quantification of charge on each 
atom in a given system.  Simply put, the nucleus may be treated as a point charge, whereas the 
electrons are treated as a distribution of charge.  This distribution is more concentrated around the 
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individual nuclei or where two atoms are in a close proximity to one another i.e. are bonded.338  Thus 
atomic charge is unique to the environment in which it is situated.   
The use of empirical charges in docking calculations is limited due to their inability to accurately 
describe the charge of uncommon functional groups, such as isonitriles i.e. R-N+≡C-.  These charges 
are defined from structural libraries or an empirical methods’ databases e.g. AutoDock’s modified 
AMBER forcefield.297  AutoDock uses methods such as Gasteiger-Marsilli347 algorithms to describe 
the charges on ligands, often inaccurately as we have found in unusual moieties e.g. isonitriles.  Due 
to accessibility and ability to afford reliable simulations in a plethora of binding situations, AutoDock 
has become the most cited docking methodology.348  While the use of Gasteiger-Marsilli charge 
calculation is sufficient for a large system such as proteins where high accuracy is often not 
affordable.  In the case of haem-ligand interactions we needed a definitive charge calculation in 
order to determine if the interaction between the negative carbon of the isonitrile and the iron core 
is electrostatic as originally proposed by Wright et al.196   We therefore looked at three other charge 
theories in order to obtain an accurate docking study.  Charges pertaining to the isonitrile 
functionalities are provided in Table 4.3, using different atomic charge theories including Mulliken,349 
Merz-Singh-Kollman (MK)350 and Natural Bonding Orbitals (NBO).351  
Gasteiger and Marsilli pioneered the concept of equalization of electronegativity.  Their algorithm is 
based on the concept of highly electronegative atoms drawing electrons away from less 
electronegative ones.  This was appealing to us as it was founded on empirical data, performed rapid 
calculations and may be transferred over a range of different molecules.  Unfortunately, this 
theory’s major fault is dealing with formal charge were it often fails.352   Mulliken Population Analysis 
is a charge partition scheme where the electrons are equally distributed over the basis set (the 
functions linearly combined, which make up a set of molecular orbitals).338  Fitting the charges to 
electrostatic potentials (ESP), such as MK charge theory, relies on the computation of the ab initio 
quantum mechanic at sampling points around the molecule.  This may become complicated if the 
molecule is large and may result in hours of computer time.  ESP charges are also dependent upon 
the conformation of the molecule, due to changes in the electron environment also altering charges 
and changes in the conformation which will alter the distribution of sampling points.    ESP tends to 
assign different charges to chemically equivalent moieties, e.g. the protons of a methyl 
functionality.352  However, this has been addressed by the Restrained Electrostatic Potential (RESP) 
method,302,353 which divides the sum of the charge across chemically equivalent atoms.  In NBO 
charge calculation the nearest Lewis structure to the desired molecule is determined.  This 
calculation generates orbitals which are localized electron pair orbitals for bonding pairs and lone 
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pairs i.e. NBOs. The hybridization of the atoms and the weight of each atom in each localized 
electron pair bond is calculated in this idealized Lewis structure. 354              
  
Table 4.3:   The Gasteiger-Marsilli, Mulliken, Merz-Singh-Kollman and NBO charges calculated for the 
nitrogen and carbon atoms in the isonitrile functionality of the marine isonitriles 2.4, 2.9, 2.15, 
2.19, and 2.35.   
 
Compound Gasteiger-Marsilli Mulliken Merz-Singh-
Kollman 
NBO 
 N C N C N C N C 
2.4 -0.434 0.188 -0.188 -0.094 0.718 -0.565 -0.544 0.269 
2.9 (i) -0.430 0.188 -0.192 -0.110 0.574 -0.520 -0.549 0.275 
2.9 (ii) -0.430 0.188 -0.189 -0.096 0.737 -0.566 -0.555 0.274 
2.15 -0.430 0.188 -0.192 -0.113 0.522 -0.512 -0.548 0.272 
2.19 -0.430 0.188 -0.191 -0.112 0.540 -0.512 -0.548 0.273 
2.35 -0.430 0.188 -0.200 -0.102 0.533 -0.516 -0.551 0.274 
 
It is clear from the Table 4.3, that the charges for the Gasteiger-Marsilli algorithm do not adequately 
describe the isonitrile functionality.  The terminal carbon has not been allocated enough electron 
density and appears as a positively charged atom.  Conversely, the nitrogen of the isonitrile appears 
far more negative than expected.  This is again true with NBO theory resulting in an isonitrile 
containing a negative nitrogen and a positive carbon. Mulliken charge theory reduces the positive 
and negative charge on the carbon and nitrogen respectively, leaving the MK theory in our opinion 
affording the most accurate description of charge distribution in the isonitrile functionality.   
Charges are essential to accurately solve the electrostatic term (ΔGelec) in the AutoDock energy 
equation (Equation 4.1). 
 
               
   
   
  
   
   
                      
   
   
  
   
   
                  
    
         
           Equation 4.1 
   
The charges on all the atoms were consequently changed from the Gasteiger-Marsilli to the MK 
charges in our docking studies.  The charge corrected isonitriles 2.4, 2.9, 2.15, 2.19, 2.34, 2.35 and 
3.215 were subsequently docked against free haem and the haem dimer to determine what role the 
electrostatic charge has in their binding to haem and the haem dimer.  Despite our initial concerns 
about the influence which incorrect charges (especially on the isonitrile moiety) may have on either 
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the haem or the haem dimer docking studies, there appeared to be no apparent difference in the 
docking models obtained when each of the four modified per atom charges for all the atoms were 
changed in the respective input files from Gasteiger-Marsilli to Mulliken, MK or NBO charges 
respectively.  From the docking models below in Figure 4.16 it is clear that the interaction between 
the marine isonitriles and the iron centres in free haem and the haem dimer are not electrostatic but 
rather reflect ring stacking which occurs between the terpene scaffold and the porphyrin ring with 
the isonitrile functionalities directed away from the haem ring.    
     
 
 
Figure 4.16:  Docking images of 2.9 and haem dimer with different atomic charges  A: Gasteiger-Marsilli; B: 
Mulliken; C: Merz-Singh-Kollman and D: NBO charges.  All ligands docked in AutoDock
297
 and 
visualized in DSVisualizer.
21
 
 
4.4.4. Docking of marine and synthetic isonitriles to haem and haem 
dimer 
 
Despite there being no apparent difference related to the charge set used to produce the final 
AutoDock model, we opted to use MK charges throughout our study because this charge theory 
most accurately represents the isonitrile functionality.  A representative selection of the docking of 
compounds 2.4, 2.9, 2.15, 2.19, 2.34, 2.35 and 3.215 to haem and haem dimer is shown in Figure 
4.17.  All the compounds docked align their carbon scaffold along the porphyrin rings of both the 
haem and haem dimer receptors.  In all cases the functional groups (i.e. isonitriles and 
isothiocyanates) are directed away from the iron centre of haem and the haem dimer.  None of the 
ligands orientated themselves in such a way that a feasible distance existed between the anionic 
A B 
C D 
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functionalities and the iron core for the formation of a formal bond as originally proposed by Wright 
et al.196   
 
Figure 4.17: A: 2.35 Docked against haem; B: 2.4 docked against haem dimer; C: 3.215 docked against free 
haem. All ligands docked in AutoDock
297
 and visualized in DSVisualizer.
21
  All ligands charges 
changed using MK charge theory.  
 
4.4.5. Attempted validation of the AutoDock approach 
4.4.5.1. Comparison with the halofantrine haem complex 
 
In order to validate our AutoDock docking model, the crystal structure of a known haem binder 
halofantrine355 (4.1) was compared to that of the proposed docking conformation of 4.1 to triplet 
haem.  The structural conformation of 4.1 was optimized and the MK charges of halofantrine 
calculated using Gaussian03 at the B3LYP density function and the 6-13G basis set.  The S-halfantrine 
enantiomer  was used in our docking studies as it was found to be the more active enantiomer 
against P. falciparum.356  The optimized structure of 4.1 was imported into AutoDock where the 
PDBQT (Protein Database with Charge and Torsion) file was generated.  This PDBQT file, containing 
all the Gasteiger-Marsilli per atom charges for halofantrine, were changed to those per atom charges 
calculated using MK theory contained in the DFT log file.  The charge corrected halofantrine was 
subsequently docked against free haem (Figure 4.18, Right).             
The X-ray crystal structure was obtained from CSD (CSD 659633) of a crystal structure described by 
de Villiers et al. of halofantrine bound through the C-1’ oxygen atom to the iron atom in haem.355  
The bond length of the iron-oxygen bond calculated from the crystal structure was described as 
1.838 Å (Figure 4.18, Left).  The image of 4.1 obtained from AutoDock indicates a distance of 2.105 Å 
between the oxygen of the alcohol on C-1’ in halofantrine and the iron core of haem, which suggests 
that a formal bond between the OH in 4.1 may be possible as observed in the crystal structure.  It 
A B C 
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must be noted that the X-ray crystal structure is a solid state structure whereas the docking studies 
are performed in vacuo.     
Cl
Cl
F
F
F
(S) N
OH
4.1
1'
 
  
Figure 4.18:   The crystal structure of halofantrine (4.1) bound to haem (CSD 659633)
355
 visualized in DS 
Visualizer
304
 (left).  The image of 4.1 docked to haem using AutoDock,
297
 also visualized in DS 
Visualizer
304
 (right).  
 
4.4.5.2. MALDI-TOF mass analysis of a haem-isonitrile complex 
 
The precipitate obtained in the EBHIA (see Section 4.3) after the addition of 2.9, was subjected to 
MALDI TOF mass analysis (Figure 4.19).  The soft ionization provided by the laser should result in Fe-
isonitrile bond remaining intact, should it exist.  From the mass spectrum (Figure 4.19), there is no 
mass corresponding to m/z 941.008 (the mass of a haem-2.9 complex) or m/z 1555.752 (the mass of 
a haem dimer-2.9 complex, not shown in Figure 4.19), thus suggesting no isonitrile-haem complexes 
had formed.  These data reinforced the idea that the interaction between marine isonitriles and free 
haem or the haem dimer is not an ionic one but suggests the ring stacking implied by the AutoDock 
studies. 
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Figure 4.19: The deconvoluted MALDI-TOF mass spectra of the precipitate obtained in the β-haematin 
inhibition assay containing 2.9.  FP represents free haem while HD represent the haem dimer.  
The matrix used was α-cyano-4-hydroxycinnamic acid as the MALDI matrix, using a 354 nm 
Nd:YAG laser.  The masses of the free haem (m/z = 616.751) and the haem dimer (m/z = 
1231.495) are indicated. 
 
4.5. In silico and in vitro studies of podocarpane-haem interaction 
4.5.1. Docking of podocarpanes to haem and haem dimer 
 
Now that a representative ligand-haem docking model had been established for known and newly 
discovered β-haematin inhibitors, it was hoped that this model may be extended to other ligands in 
order to identify potential inhibitors of haem polymerization in silico.  We therefore docked our 
previously synthesized podocarpanes (3.203-3.212) against the haem and haem dimer, using the 
AutoDock method, to gauge their theoretical ability to inhibit the sequestering of haem in the 
malaria parasite (Figure 4.20).  All the docking models of 3.203-3.212 show a similar docking 
conformation to those obtained for 2.4, 2.9, 2.15, 2.19, 2.34, 2.35 and 3.215, with the diterpene ring 
scaffold stacking above the porphyrin ring of haem.  Interestingly, the most active phenyl containing 
compounds 3.204 and 3.209-3.212, aligned themselves with the phenyl ring more centred above the 
iron core.  A notable difference found in the docking of podocarpanes to haem and the haem dimer 
when compared to the docking studies of the marine and synthetic isonitriles was the ability of the 
hydroxyl functionalities of 3.203-3.212 to form hydrogen bonds with the flexible carboxylic acid side 
chains of the receptor.   
FP 
HD 
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Figure 4.20: A: 3.207 Docked against the haem dimer; B: 3.206 docked against free haem and C: 3.211 
docked against the haem dimer. All ligands docked in AutoDock
297
 and visualized in 
DSVisualizer.  All ligands charges changed using MK charge theory.  Broken green lines 
indicative of hydrogen bonding. 
.   
       
4.5.2. In vitro evaluation of haem polymerization inhibition by 
podocarpanes 3.203-3.207 and 3.209-3.212 
 
Since the docking studies of podocarpanes and haem suggested a docking model similar to that 
obtained for the marine isonitriles, we once again used Egan’s β-haematin inhibition assay to 
determine the podocarpanes’ (all tested at 10 equiv. relative to haem because of the large quantities 
of synthetic compounds in hand) ability to inhibit haem polymerization.  While none showed any 
promise as potential β-haematin inhibitor, 3.212 (the most active antiplasmodial podocarpane) will 
be used here as a representative compound to support this conclusion.  The Phi-β assay indicated 
very little inhibition, with only a weak Sorret-band appearing at 405 nm (Figure 4.21A).  The 
preliminary UV/vis data was corroborated by an the FTIR analysis of precipitate of EBHIA containing 
3.212, which indicated a 89% conversion of haemin to β-haematin.  The SEM micrograph showed the 
presence of microcrystals in all the precipitates of EBHIA containing 3.203-3.207 and 3.209-3.212 
(e.g. Figure 4.21B).  Finally the lack of β-haematin inhibition exhibited by 3.203-3.207 and 3.209-
3.212 was confirmed by the identification of β-haematin peaks in the X-ray powder diffraction 
pattern of all precipitates isolated from EBHIA which contained podocarpanes.              
A B C 
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Figure 4.21: UV/vis spectra (375-500 nm) of Phi-β assay solutions containing chloroquine (purple), 3.212 
(blue) and no inhibitor (red) (Left).  The SEM micrographs of the precipitates from the EBHIA 
contain 3.212 (Right). Images taken using a Tescan Vega scanning electron microscope at 20 kV 
and a working distance of 20mm.  Scale given at the bottom of the image. 
 
4.6. Conclusion 
 
We have unequivocally shown the ability of 2.9 to completely inhibit haem polymerization at 3 
equivalents relative to haem, which suggests that the primary antiplasmodial mode of action of 2.9 
may be the inhibition of the formation of hemozoin within the parasite as originally proposed by 
Wright et al.196  Compounds 2.19 and 2.15 also exhibited promise in their ability to inhibit β-
haematin formation and may show greater inhibition of β-haematin sequestration at higher 
concentrations.   
We have addressed the limitations of certain charge theories in describing unusual functionalities 
and have used this newly acquired knowledge to determine a more accurate docking study for 
marine isonitriles with free haem and the haem dimer.  These docking studies have shown that the 
interaction between the isonitriles and haem porphyrin is possibly a result of ring-stacking rather 
than ionic interaction between the Fe(III) core and the carbon of the isonitrile as previously 
proposed by Wright et al.196  The β-haematin inhibition assays would suggest that a tri- or tetracyclic 
ring scaffold increases the ability of a compound to inhibit haem polymerization.   While we have 
shown that the isonitrile functionality is not relevant for ionic bonding to the iron of haem, the 
isonitrile group may still play a significant role in antiplasmodial activity, which can clearly be seen in 
the decrease in antiplasmodial activity (from the nanomolar to the millimolar range) with the 
addition of an isothiocyanate moiety i.e. 2.34.  The exact function of the isonitrile moiety in 
determining the parent compound’s bioactivity is unknown but it may be essential for facilitating 
entry into the cell across membranes or through ion channels.  The molecular models of marine 
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isonitriles docked with haem dimers suggest that the isonitrile moieties are directed outwards, thus 
possibly repelling other haem or haem dimer units from adding to the growing crystal lattice of β-
haematin.  The lack of the inhibition of β-haematin shown by the tricyclic podocarpanes, suggests 
that a tricyclic scaffold alone may not be enough to inhibit haem polymerization.    
A summary of the in vitro antiplasmodial activities of all compounds 2.4, 2.9, 2.15, 2.19, 2.34, 2.35, 
3.188, 3.203-3.207, 3.209-3.212 and 3.215 may be seen in Table 4.4.  
Table 4.4:    A summary of the results obtained from the EBHIA and DXR inhibition assay. 
 
Compound HA
a UV/
vis
b 
FTIR
c 
XRD
d 
SEM
e 
PfDXR
f 
Conclusion 
2.4  ND    ND Not a β-haematin inhibitor 
2.9  ND    ND β-haematin inhibitor 
2.15  ND    ND β-haematin inhibitor 
2.19  ND    ND β-haematin inhibitor 
2.34  ND    ND Not a β-haematin inhibitor 
2.35  ND    ND Not a β-haematin inhibitor 
3.188      ND Not a β-haematin inhibitor 
3.203      ND Some β-haematin inhibition, but not sufficient at 
10 equiv. 
3.204      ND Not a β-haematin inhibitor 
3.205      ND Not a β-haematin inhibitor 
3.206      ND Not a β-haematin inhibitor 
3.207      ND Not a β-haematin inhibitor 
3.209       Possible mode of action, PfDXR inhibition 
3.210       Possible mode of action, PfDXR inhibition 
3.211       Possible mode of action, PfDXR inhibition 
3.212       Neither a β-haematin nor PfDXR inhibitor 
3.215      ND Causes haemolysis not a good drug candidate 
 
a
  HA (Haemolytic Activity): A positive results was determined by haemolytic activity being > 60% at 50 μL 
b
  A positive results was determined by a difference in absorbance from the baseline to the crest at 405 nm      
> 0.4 
c
  A positive results was determined by conversion of haematin to β-haematin < 50% 
d
  A positive results was determined by no detection of peaks corresponding to β-haematin 
e
  A positive results was determined by a visual inspection concluding that the majority of the precipitate was 
not microcrystals  
f
  A positive results was determined by < 40% conversion of NADPH to NADP
+
 at 250 μM 
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5.1. Background 
 
The original discovery of the penicillin class of antibiotics, (e.g. 5.1 and 5.2) revolutionised the war 
on bacterial infection.357  Penicillin targets the bacterial cell wall, which is important for maintaining 
the shape of the bacterial cell and providing protection against osmotic lysis.  Penicillin covalently 
binds and inhibits penicillin binding proteins (PBPs).  These bacterial proteins (PBP 1-4) are essential 
for construction, maintenance and regulation of the cell wall and its functions.358-360  However, the 
discovery of penicillin over 80 years ago appeared to initially lull the medical fraternity into a false 
sense of security, possibly slowing the further development of antibiotics.  For example, in a 1966 
issue of Time magazine an article appeared stating “...experts agree that by year 2000, viral, and 
bacterial diseases will have been eliminated.”361  Ironically, by 1941 strains of Staphylococcus aureus 
had already appeared that could degrade penicillin by means of the enzyme β-lactase (Scheme 5.1).  
Today in excess of 95% of all strains of S. aureus worldwide are resistant to penicillin.  While the 
development of the semi-synthetic antibiotic methicillin (5.3) initially filled the void left by penicillin 
resistance up until the 1980s, the emergence of methicillin resistant S. aureus (MRSA) ultimately 
negated the efficacy of this drug.362   The addition of a bulky substituent to the basic penicillin 
scaffold, e.g. 2,6 dimethylphenyl in methicillin, resulted in the bacterial β-lactase being unable to 
facilitate methicillin’s conversion to the inactive penicilloic acid (5.4).363 However, the mecA gene 
encodes for a 76 kDa protein called PBP2a, which exhibits a low affinity for methicillin and therefore 
enables MRSA bacteria processing this protein to resume cell wall maintenance in the presence of 
methicillin.364              
 
 
Scheme 5.1: The enzyme facilitated breakdown of penicillin compounds to penicilloic acids.   
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Resistance to antibiotics may occur in several ways.  Firstly, the antibiotic may be pumped out of the 
bacterial cell via over expressed membrane proteins,365  which are increasingly able to recognise a 
wider spectrum of antibiotics.  Secondly by metabolising and/or altering an antibiotic through 
specially mutated enzymes366 such as methicillin-hydrolyzing β-lactase and thirdly downregulating, 
modifying or deleting proteins targeted by antibiotics.367  The latter is the major form of resistance 
to penicillin antibiotics.   
Methicillin resistant S. aureus (MRSA) is responsible for severe post-operation infection in hospitals 
around the world, i.e. hospital associated (HA-MRSA), and has led to entire hospital wings being 
closed.368  In one study it was reported that the percentage of MRSA related hospital deaths was as 
high as 39% and several years ago the associated costs of the prolonged treatment of MRSA infected 
patients in the USA alone was a staggering $ 14.5 billion (Figure 5.1).369  Asymptomatic hosts act as a 
reservoir for the human to human spread of S. aureus.  For example the predominate mode of 
infection is skin-to-skin contact of a colonised source or contact with colonised fomites (any 
inanimate object on which bacteria may grow).370  To initiate infection S. aureus forms colonies on 
host tissue via a series of surface proteins, referred to as MSCRAMM (microbial surface components 
recognising adhesive matrix molecules),371 with each MSCRAMM is unique to each strain of S. 
aureus.  Once adhered to the surface tissue the colony of S. aureus begins to produce a biofilm in 
order to evade the host immune response and keep out antibiotics, thus ensuring successful initial 
colonization and infection.372  While infections can be prevented via physical barriers, i.e. epithelial 
and endothelial tissue; in burn and post-operation patients this first line physical barrier is severely 
compromised often leading to successful invasion of S. aureus.  S. aureus has several mechanisms, 
which it uses to evade the host’s immune system and facilitate infection.  Firstly, S. aureus may also 
secrete a special type of MSCRAMM, known as the fibronectin-binding protein, which creates a 
fibronectin bridge between bacterial and endothelial/epithelial β1 intergrins resulting in absorption 
of S. aureus into the host’s tissue.  The refuge afforded by fibronectin bridges provides protection 
against phagocytic cells such as neutrophils, monocytes and macrophages.373-375  Secondly, S. aureus 
may secrete Protein A, a protein which binds to the universal Fc region of host’s immunoglobins and 
thus inhibits opsonisation and phagocytosis.376  Thirdly, S. aureus may secrete a substance called 
CHIPS (chemotaxis inhibitory proteins of S. aureus), which hinders the recruitment of neutrophils.  
Fourthly, the secretion of leukocidins by S. aureus can result in disruption of leukocytes membranes, 
thus severely impairing their function.377  Finally, S. aureus may secrete a series of enzymes including 
lactamases, proteases, lipases, nucleases, hyaluronate lyase, phospholipase C and 
metalloproteinases, which aid in further infection and tissue damage.378  The successful infection of 
the host’s skin by S. aureus results in a number of unpleasant afflictions including: skin abscess, 
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cellulitis, bullous impetigo, folliculitis, furunculosis and necrotizing fasciitis.379  Exfoliating toxins 
produced by the bacterium can also result in erythema, skin exfoliation and Ritter’s Disease.380  
Should S. aureus penetrate the skin-barrier, via the mechanism discussed vide supra, endocarditis, 
septic arthritis (the purulent invasion of the joints), osteomyelitis, sepsis and toxic shock syndrome 
induced by the superantigens secreted by S. aureus, may result.381,382      
In the last two decades the infection of MRSA has no longer been confined to hospital environments.  
Non-hospital contained MRSA infections were first described in the town of Kimberly in Western 
Australia in the 1990s and have subsequently spread worldwide.383,384   What is of particular concern, 
are individuals infected by community associated MRSA (CA-MRSA), whom have had no contact with 
a health-care setting prior to infection.  The appearance of CA-MRSA suggests a new S. aureus 
virulence.385   Genetic analysis of CA-MRSA clones have shown that these carry SCCmec allotypes IV 
and V and also the lukSF-PV genes, which encode for the leukotoxin, Panton-Valentine leukocidin 
(PVL).385,386  This toxin has been hypothesized to play a role in the pathogenesis of CA-MRSA, due to 
90 percent of all CA-MRSA cases presenting severe skin and soft tissue infections.385,387  Fortunately 
while the newest CA-MRSA clones, are resistant to β-lactam antibiotics, they are still susceptible to 
other non-penicillin based antibiotics, such as tetracyclines and quinolones.388  Conversely, HA-MRSA 
clones are multidrug resistant, thus increasing the urgency for the discovery and development of 
new MRSA bioactive compounds and the ongoing identification of novel MRSA specific targets.           
        
 
Figure 5.1:  Increase of MRSA infections (bar) and related cost (line) in the United States from 1998-2005
369
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Professor Raymond Andersen and co-workers at the University of British Columbia (UBC) recently 
identified the inhibition of pyruvate kinase (PK) in MRSA as a viable drug target given the significant 
structural differences between S. aureus PK and mammalian PKs.389-391  Pyruvate kinase plays a key 
role in regulating carbohydrate metabolism and catalyzes the final step in glycolysis, where it 
irreversibly transfers the phosphoryl moiety from phosphoenolpyruvate (PEP) to ADP forming ATP 
and pyruvate, which then feeds into a number of other biosynthetic pathways.392  The bacterial PK 
enzyme is highly conserved and exists as homo-tetramers of identical subunits, each monomer 
consisting of three or four domains (designated N-terminal and A-C domains).  The active site of this 
protein lies at the interface between the A and B domains while the allosteric effector site lies in the 
C domain (Figure 5.2).393   
 
Figure 5.2: A:  The binding of 5.7 to the small interface of the bacterial PK.   
B:  An enlargement of 5.7 binding to the receptor site.   
C:  The anti-parallel interaction of helix 357-370 with 5.7.   
D and E:  The binding pocket of human PK consists of much tighter dimeric packing around the 
‘small’ interface, which drastically alters the nature of the pocket, and also the closer 
interaction of a helix 340-350 above the interface, thereby limiting access to the pocket. 
Reproduced from Andersen and co-workers.
393
     
 
A total of 968 crude extracts of marine benthic invertebrates, collected from Papua New Guinea, 
Indonesia, Dominica, Brazil, British Columbia, South Africa and Norway were screened in a 
programme designed to find potential inhibitors of MRSA PK.  Despite the comprehensive nature of 
this screening programme, only one extract from the South African sponge (Figure 5.3) Topsentia 
A 
B C 
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pachastrelloides (Topsent, 1892) collected off the Aliwal Shoals in Kwa-Zulu Natal, showed promising 
activity.  Bioactivity-guided fractionation of this extract resulted in the isolation of a series of 
bisindole alkaloids, spongotine A (5.5), bromotopsentin (5.6), cis-3,4-dihydrohamacanthin (5.7) and 
bromodeoxytopsentin (5.8).393             
 
Figure 5.3:  Surface photograph of SAF94-035 (Topsentia pachastrelloides) taken immediately after 
collection.  
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Two of these marine bisindoles alkaloids (5.7 and 5.8) showed a 166-600 fold preference for the S. 
aureus PK over human PKs (Figure 5.4).  In the X-ray crystal structure of cis-3,4-dihydrohamacanthin 
(5.7) complexed with PK, the bisindole is bound to a remote site on the protein (Figure 5.2).  
Andersen and co-workers hypothesized that this remote binding may prevent the enzyme from 
folding correctly, thus retarding the phosphoryl transfer of the active site.393 The two most active 
compounds 5.7 and 5.8 exhibited an activity against MRSA of 6 and 60 nM respectively.393     
 
 
 
 
 
    Figure 5.4:  MRSA inhibition assay results of compound 5.5-5.8 (Left).  Selective inhibition of compounds 
5.7 and 5.8 between bacterial and human PK’s (Right) 
 
Strangman et al.394 at UBC synthesized 5.7 and compared the antibacterial activity of several 
synthetic precursors  (5.9-5.12) and structural analogues (5.13-5.19) of this compound (Table 5.1).     
Table 5.1:  A comparison of 5.7, 5.9-5.19 ability to inhibit MRSA pyruvate kinase
394
 
  
Compound MRSA PK inhibition
* 
5.7 98% 
5.9 35% 
5.10 22% 
5.11 4% 
5.12 35% 
5.13 43% 
5.14 No Activity 
5.15 38% 
5.16 23% 
5.17 No Activity 
5.18 86% 
5.19 24% 
*
  All inhibition levels reported at 10 μM 
 
A B C D
0
20
40
60
80
100
Bis-indole alkaloids
M
R
S
A
 P
K
in
hi
bi
tio
n 
(%
)
C D
0
20
40
60
80
100 MRSA PK
Human M1
Human M2
Human R
Human L
Bis-indole alkaloids
P
K
 in
hi
bi
tio
n 
(%
)
          5.7                      5.8 5.5         5.6         5.7        5.8 
Chapter Five:  Marine Bisindole Alkaloids 
 
 
127 
N
H
Br
5.9
N
H
NH
Br
Br
N
HN
O
5.13
NO2
N
H
Br
NH2
5.10
N
H
Br
Cl
5.11
O
O
HN
Br H
N
O
O NH
BrO
5.12
N
H
NHNH
HN
O
5.14
N
H
NH
Br
NH
HN
O
N
H
NHNH
HN
O
5.15 5.16
N
H
NHNH
HN
O
5.17
N
H
NH
Cl
NH
HN
O
N
H
NH
F
F
NH
HN
O
5.18 5.19
Br
Br
Cl
5'
5''
6''
6'
 
 
 
 
 
 
 
Chapter Five:  Marine Bisindole Alkaloids 
 
 
128 
Strangman et al.394 were able to draw four major conclusions from the results present in Table 5.1.  
Firstly, the full structure of 5.7 is required for inhibition activity of MRSA PK, since none of the 
intermediates (5.9-5.13) showed promising activity including the pyrazine containing 5.13.  Secondly, 
the removal of the bromine substituent greatly decreases the bioactivity.  The complete removal of 
the bromines (5.14) shows no activity while, the mono-substituent decreases the activity of 5.7 by 
approximately half.  The 6’,6’’-dimethyl substituted analogue (5.16) was tested as the methyl moiety 
fills similar chemical space to that of bromine, however this compound failed to achieve equal 
bioactivity.  Thirdly, the position of the bromine on the indole ring is important for bioactivity.  
Substituting bromine atoms on the 5’ and 5’’ positions on the ring (5.17), afforded no inhibition.  
Finally, as the electronegativity of the 6-substituent (5.18 and 5.19) decreases the bioactivity 
increases.   
Stangman et al., supported by their SAR study and by the X-ray structure (Figure 5.2) highlighted the 
importance of the two bromine atoms at C-6’ and C-6’’ in the binding of MRSA PK.  A halogen bond 
occurs when a halogen is shared between a donor (5.7) and an acceptor (e.g. an amino acid 
contained in the active site).395  In halogen bonding both the donor and especially the acceptor tends 
to be electronegative or electron-withdrawing, resulting in unusually short atomic distances i.e. less 
than the sum of van de Waal's radii of the atoms involved.395  In the past many biologically significant 
examples of halogen-bonded complexes have been described,396-398 demonstrating the potential for 
using such interaction in drug design.  Surprisingly the mono-brominated 5.8 was significantly active 
against MRSA PK and it occurred to us that preparing the dibromobisindole imidazole (5.20, 
isobromotopsentin) and analogues of 5.20 might result in a more active compound.  The research 
presented in this Chapter records our attempts to find a new and more efficient method for 
preparing 5.20 and related analogues for future SAR studies.   
5.2. Research aims. 
 
Our approach to the SAR studies of 5.20 was to firstly prepare a series of simple diphenylimidazole 
(5.21-5.26) analogues of 5.20.  Although these are all known compounds399  we envisaged that 
microwave assisted selenium dioxide (SeO2) oxidation might prove to be a more efficient method of 
preparing the prerequisite synthetic phenyl glyoxal precursors (5.27-5.32) required for the synthesis 
of these compounds.  Once the microwave assisted organic (MAO) synthetic methodology had been 
established on simple model compounds we planned to extend this method for the preparation of 
indole glyoxals which surprisingly, have not previously been used to synthesize bisindole imidazoles.  
Initial preparation of deoxytopsentin (5.33) was to be followed by the attempted synthesis of bis-
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5-bromoindole imidazole (5.34) and our target molecule isobromotopsentin (5.20).  Our goal 
throughout this work was to find a simple, fast and high yielding route to bioactive imidazole 
alkaloids.         
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5.3. Naturally occurring topsentin alkaloids from marine sponges. 
    
In order to contextualize the synthetic work presented in this Chapter an intial overview of the 
naturally occurring marine sponge secondary metabolites from the topsentin class of alkaloids is 
presented here.  We summarized some aspects of Yang’s comprehensive 2004 review400 of these 
compounds and elaborated on further progress made in the discovery and synthesis of bisindole 
topsentin type alkaloids up until June, 2011.   
5.3.1. Structure and isolation. 
 
N
H
NH
O
NH
N
R1
R2
R1=H;  R2=OH  topsentin (#)
R1=Br; R2=OH  bromotopsentin (#)
R1=H;  R2=H    deoxytopsentin (#)
R1=Br; R2=H    bromodeoxytopsentin (#)
R1=H;  R2=Br   isobromodeoxytopsentin (#)
R1=Br;  R2=Br  isobromotopsentin (#)
6''
6'
 
Topsentin alkaloids contain a 2-acylimidazole moiety inserted between two indole rings, mostly 
brominated or hydroxylated at the C-6’ and C-6’’ positions.  This class of bisindole alkaloids was first 
5.6 R1 = Br;  R
2 = OH  bromotopsentin   
5.8 R1 = Br;  R
2
  = H bromodeoxytopsentin  
5.20 R1 = Br;  R
2
  = Br isobromotopsentin   
5.33 R1= H;  R2  = H deoxytopsentin   
5.35 R1 = OH;  R
2
  = Br isotopsentin   
5.36 R1 = H;  R
2
  = OH topsentin   
5.37 R1 = OH;  R
2
  =OH hydroxytopsentin   
5.38 R1 = H;  R
2
  = Br isobromodeoxytopsentin 
  
 
 
 
5.21 R = H  
5.22 R = OMe 
5.23 R = NO2  
5.24 R = Cl  
5.25 R = Br  
5.26 R = F  
5.27 R = H  
5.28 R = OMe 
5.29 R = NO2  
5.30 R = Cl  
5.31 R = Br  
5.32 R = F  
5.20 R1 = Br R2 = H 
5.33 R1 = H R2 = H 
5.34 R1 = H R2 = Br 
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isolated from sponges in 1987 and the geographic location and taxonomy of sponges producing 
topsentin like compounds is summarized in Table 5.2. 
Since Yang and co-workers’400 comprehensive review seven known and one new (5.20) topsentin-like 
alkaloid have been isolated from marine sponges.  In 2005, Bao et al.401  isolated the bisindole 
alkaloids 5.6, 5.8, 5.20, 5.33, 5.35-5.38 from a sponge Spongosorites sp. collected off the coast of 
Jeju Island, Korea.  Again off the coast of Jeju island, compounds 5.8, 5.33 and 5.38 were isolated 
this time from the sponge Discodermia calyx.402  More recently in 2010, our laboratory isolated 
compounds 5.6 and 5.8 from the South African sponge Topsentia pachastrelloides.393  Bao et al.403  
later isolated a series of tryptophan modified monoindoles (5.39-5.45) from the sponge 
Spongosorites sp. These compounds are believed to be putative precursors in the biogenesis of the 
topsentin and hamacanthins classes of marine alkaloids where the imidazole ring is formed through 
the nucleophillic attack by the amino group of one monoindole precursor (either 5.42 or 5.43) on 
the adjacent carbonyl group of another monoindole (5.42 or 5.43)(Scheme 5.2).  The mechanism for 
the removal of the ketone functionality of the imidazolone ring (5.46) is unknown and is assumed to 
be facilitated by an, as yet, unidentified enzyme, resulting in the topsentin scaffold.      
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5.40 R = H    
5.41 R = OH
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Scheme 5.2:   The proposed biogenesis of the topsentin scaffold reproduced from Boa et al.
403
 
 
Table 5.2:   Geographical location and taxonomy of sponges producing the topsentin class of alkaloids 
1987-2011 
 
Year Organism Location Compounds 
1987
404
 Topsentia genitrix Banyuls, France 5.6; 5.33; 5.36 
1988
405
 Spongosorites Chub Cay and Goulding's Cay, Bahamas 5.6; 5.8, 5.35-5.37 
1989
406
 Hexadella sp. Jervis Inlet, British Columbia 5.33 
1991
407
 Spongosorites ruetzleri Bahamas 5.6; 5.36 
1995
408
 Spongosorites sp. Southern Australia 5.6; 5.8; 5.33; 5.36 
1999
409
 Spongosorites genitrix Jaeju
*
 Island, Korea 5.6; 5.8; 5.3; 5.38 
2000
410
 Rhaphisia lacazei Ustica, Italy 5.6; 5.8; 5.33; 5.36 
2005
401
 Spongosorites sp. Jeju Island, Korea 
5.6; 5.8; 5.20; 5.33; 
5.35-5.38 
2007
402
 Discodermia calyx Jeju Island, Korea 5.8; 5.33; 5.38 
2010
393
 
Topsentia 
pachastrelloides 
Umkomaas, South Africa 5.6;  5.8 
   *Note:  The spelling of the name Jeju Island is not consistent in the literature.  
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5.3.2. Past syntheses of topsentins 
 
In 1987, Braekman and co-workers411 published the first total synthesis of deoxytopsentin (5.33).  
Their synthetic procedure (Scheme 5.3) involved the conversion of indole acyl bromide (5.47), to the 
quaternary dimethyl hydrazine ion (5.48).  The hydrazine ion product was refluxed in alcohol to 
afford the indoylglyoxaldimine (5.49) and dimethylamine.  Dehydrative condensation of the 
intermediate 5.49 afforded the natural product 5.33.  While this approach appears relatively simple, 
the multiple steps are low yielding (8.2%).    
i.
N
H
O
N
H
O
Br
ii.
N
H
O
N NH2
iii.
N
H
O
NH
N
H
N
H
N
NH
O
5.47 5.485.105 5.49
5.33
 
Scheme 5.3:   Braekman and co-workers’ synthesis of deoxytopsentin (5.33). 
411
  Reagents and conditions:   i)   
 CuBr2, CHCl3/EtOAc, 37%; ii)  1,1-dimethylhydrazine, EtOH, -15 °C, 82%; iii) n-propanol, reflux,  
 27% 
 
Horne and co-workers412 (Scheme 5.4) synthesized deoxytopsentin (5.33), firstly through the 
conversion of the 3-indole-α-oxoacetyl chloride (5.50)  to indole acylcyanide (5.51).   Subsequent 
hydrogenation of the acyl cyanide in the presence of a Pd/C catalyst afforded oxotryptamine (5.52).  
Oxidative dimerization of 5.52 in NH4OH afforded the marine natural product 5.33, in a total yield of 
36.2%.       
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Scheme 5.4:   Horne and co-workers’ synthesis of deoxytopsentin (5.33).
412
  Reagents and conditions:   
i) (COCl)2, ether; ii)  CuCN; iii)  H2, Pd/C, AcOH, 90%; iv)  NH4OH, 100 °C, 80% 
 
Arcab and co-workers413 applied a completely different approach to the synthesis of 5.6, 5.33, 5.36 
and 5.38 (Scheme 5.5),  in which they coupled sulphonamide protected indole-3-carboxaldehydes 
(5.53-5.55) with either a 2-(trimethylsilyl)ethoxymethyl (SEM) or a benzyloxymethyl (BOM) 
protected 2-lithioimidazole (5.56 and 5.57 respectively), to yield the corresponding alcohols 
(5.58-5.61).  Alcohols 5.58-5.61 were subsequently oxidized with MnO2 to yield keto iodides (5.62-
5.65).  Compounds 5.64-5.67 were coupled with variably substituted indole-stannanes (5.66 and 
5.67) to afford the variably protected bisindoles products (5.86-5.71).  Final cleavage of the N-S 
sulphonamide bond was achieved by saponification under standard conditions.  The hydroxyl 
protecting groups; methoxymethyl ether (OMOM) and SEM or benzyl (OBn) and BOM were 
simultaneously removed either by acidification or hydrogenolysis respectively to afford the natural 
products 5.6, 5.38, 5.36 and 5.33.  Yields for this synthesis range from 27-60%.  Despite the difficulty 
of working with lithium and tin compounds in synthesis this synthetic approach is target orientated 
and minimizes the production of side products.  Arcab and co-workers subsequently also synthesized 
isotopsentin (5.35) using this synthetic method.414      
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Scheme 5.5:   Arcab and co-workers’ synthesis of 5.6, 5.33, 5.36 and 5.38.
413
  Reagents and conditions: i) THF, 
-78 °C, 63-84%; ii) MnO2, CH2Cl2, RT, 5 hrs, 95%; iii)  PdCl2(PPh)2, CuI, DMF, 120 °C, 2 hrs, 
76-81%; iv) 10% KOH, EtOH-THF, reflux, 2 hrs, 86-97%; va)  5M HCl, EtOH, reflux, 3 hrs, 68%      
(R
2
 = SEM) or vb) EtOH, HCO2NH4, 10% Pd/C, reflux, 4 hrs, 88-96% (R
2
 = BOM)  
 
Kawasaki et al.415 synthesized topsentin (5.36) through coupling tert-butyldimethylsilyl (TBS) 
protected indole-3-boronic acid (5.72) and a SEM protected 4,5-iodoimidazole 5.73 (Scheme 5.6).  
Protected O-methoxytopsentin (5.74) was subsequently synthesized through the reaction of the 
indole imidazole (5.75) and the tertiary amine (5.76).  Subsequent deprotection of the N- and O-
methoxy moieties with 20% HCl and boron tribromide respectively afforded in 5.36 in a 36.3% 
overall yield.    
 
5.68 R1 = OMOM R2 = SEM R3 = Br   
5.69 R1 = H R2 = BOM R3 = H    
5.70 R1 = OBn R2 = BOM R3 = H    
5.71 R1 = H R2 = SEM R3 = Br   
5.53 R1 = OMOM 
5.54  R1 = OBn      
5.55  R1 = H      
 
5.58 R1 = OMOM  R2 = SEM  
5.59 R1 = H   R2 = SEM  
5.60 R1 = OBn  R2 = BOM  
5.61 R1 = H  R2 = BOM
   
 
5.56 R2 = SEM   
5.57 R2 = BOM
  
 
5.62 R1 = OMOM  R2 = SEM  
5.63 R1 = H   R2 = SEM  
5.64 R1 = OBn  R2 = BOM  
5.65 R1 = H   R2 = BOM
   
 
5.66 R3 = H  
5.67  R3 = Br     5.6 R
1 = OH R3 = Br     
5.33 R1 = H R3 = H    
5.36 R1 = OH R3 = H    
5.38 R1 = H R3 = Br    
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Scheme 5.6:   Kawasaki et al.’s synthesis of topsentin (5.5).
416
  Reagents and conditions:  i)  Pd(Ph3)4, NaCO3,  
  75%; ii)  EtMgBr, H2O, 84%; iii)  n-BuLi, 73%; iv)  20% HCl, 66%; v)  BBr3, 69% 
 
In a more recent synthesis, Denis and co-workers417 used α-ketothioimidate salts (5.77 and 5.78) and 
the indolic 1,2-diammonium salt (5.79) in the synthesis of brominated sponge alkaloids (Scheme 
5.7).  The β-amino indolic N-hydroxylamine (5.80) was reduced to 5.79, in three steps.  The first step 
was the cleavage of the N-O bond with the aid of titanium trichloride in dilute acid, to afford the 
diprotected diamine (5.81).  Selective removal of the benzyl group in 5.81, with Pearlman’s catalyst 
[Pd(OH)2] afforded the monoprotected diamine (5.82).  Denis and co-workers also reported that 5.80 
may be directly converted to 5.79 via catalytic hydrogenation with Pd(OH)2 in a solution of MeOH-
AcOH (96:4) by simply extending the reaction time.  The final step involved acidic removal the 
carbamate protecting group to yield the 1,2 diamine salt 5.79. 
A series of S-methylthioimidate salts  were synthesized concurrently with 5.79 with the intention of 
coupling them with 5.79.  Two 3-indole-α-oxoacetyl chlorides (5.50 and 5.11) were prepared from 
the corresponding indole (5.83) and 6-bromoindole (5.84) respectively with oxalyl chloride in ether.  
Compounds 5.50 and 5.11 were treated with tributyl tin hydride, and elemental sulfur  in a mixture 
of piperidine and pyridine to afford 3-indolyl-α-ketothioamides (5.85 and 5.86).  Finally, 5.85 and 
5.86 were converted to S-methylthioimidate salts 5.77 and 5.78 by refluxing in excess methyl 
iodide.418    
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The S-methylthioimidate salts (5.77 and 5.78) were coupled with the 1,2 diamine salt (5.79) in MeOH 
and triethylamine, to afford spongotine A (5.5) and spongotine C (5.87) respectively.  The oxidation 
of the imidazoline ring in 5.5 and 5.90, in the presence of 2-iodoxybenzoic acid (IBX), yielded 
bromodeoxytopsentin (5.8) and isobromotopsentin (5.20) respectively.  While this synthesis is 
lengthy it is highly selective and provides a useful route to many of the topsentin and spongotine 
classes of compounds and their respective analogues.  The overall yields of 5.8 and 5.20 were ca. 
17%.            
 
Scheme 5.7:   Denis and co-workers’ synthesis of the natural products 5.5, 5.8, 5.20 and 5.87.
418
  Reagents 
and conditions:  i)  TiCl3, HCl aq., MeOH-H2O, RT, 15 min, 89%; ii)  H2, Pd(OH)2, MeOH-AcOH, RT, 
16 hrs, 93%; iii) HCl, MeOH, RT, 1 hr, 100%; iv)  (COCl)2, Et2O, 0 °C, 4 hrs, 82-92%; v)  n-Bu3SnH, 
AcOEt, 0 °C, 30 min, RT, 16 hrs, S8, piperidine, pyridine, 80 °C, 5 hrs, 31%; vi) MeI, refluxing, 5 
hrs, 100%; vii)  Et3N, MeOH, RT, 48 hrs, 65-74%; viii)  IBX, DMSO, RT, 15 hrs     
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5.4. A new approach to the synthesis of deoxytopsentin (5.33), 
isobromotopsentin (5.20) and 5-bromoindole imidazole (5.34) 
 
As reviewed in the previous section, several members of the topsentin class of marine secondary 
metabolites have been successfully synthesized in relatively low yields five times in the past.  Our 
proposed synthesis (Scheme 5.8) uses microwave assisted irradiation (MWI) for the high yielding 
preparation of the N-Boc protected indole glyoxal (5.88) from the N-Boc protected indole methyl 
ketone (5.89). Conversion of 5.88 into an imine intermediate in the presence of ammonium acetate 
would facilitate the formation of the imidazole ring (5.90).  We also envisaged that thermal cleavage 
of the N-Boc carbamate bond under argon and in the absence of solvent with MWI would provide 
the target compounds in high yield.419,420 
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Scheme 5.8:   Proposed route of synthesis of the marine metabolite 5.33.  Reagents and conditions:          
i)  Boc2O, MeCN, DMAP, 30 min; ii)  SeO2, H2O, 1,4-dioxane, MWI; iii)  NH4OAc, EtOH, RT; 6 hrs; 
iv)  MWI, 185 °C, Ar  
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5.4.1. Microwave assisted synthesis of aryl glyoxals 
 
Glyoxals are well-established precursor for the synthesis of imidazole rings.421-423  In 1932, Riley and 
co-workers,424 first used selenium dioxide as an oxidising agent for the preparation of glyoxals from 
methyl ketones.  This classical method for the preparation of phenyl glyoxal and substituted aryl 
glyoxals, via selenium dioxide oxidation under reflux (several hours to two days) in a variety of 
solvents e.g. acetone, ethanol, acetic acid or aqueous 1,4-dioxane has changed little in nearly 80 
years and is still the method of choice to prepare these compounds.  Successful closed-vessel 
microwave-accelerated selenium dioxide oxidations to afford 1,2-dicarbonyl compounds, e.g. 1,2-
naphthoquinones,425  3-camphorquinone426  and 6-formylpterin427 have recently appeared in the 
chemistry literature.  
Microwave assisted organic (MAO) synthesis has been in use since the mid-1980s,428,429 and has 
become increasingly popular over the last two decades due to its ability to shorten reaction times 
and increase the range of possible reaction conditions.430  Prior to MAO synthesis, the general heat 
transfer media for organic synthetic reactions have been oil/water/sand baths or heating mantles 
which are often slow and may lead to heating fluctuations which can result in the decomposition of 
organic compounds.  With the microwave heating of organic reactions, radiation is directly and 
evenly applied to the reaction vessel causing rapid and uniform heating throughout the vessel and 
its contents,430  thus minimizing decomposition and the formation of by-products.  The use of MWI in 
the preparation of aryl glyoxals has appeared twice in the chemical literature, once non-reproducibly 
using a commercial household microwave oven,431 and secondly in an inaccessible Russian journal.432 
 
5.4.1.1. Optimization of the microwave assisted synthesis of phenyl glyoxal (5.27) 
 
The chosen method to monitor the percentage conversion of acetophenone (5.91) to 5.27 was gas 
chromatography (GC).  Since both 5.91 and phenyl glyoxal monohydrate (5.92) are commercially 
available it was decided to standardize the GC separation conditions using these two compounds.  A 
number of GC stationary phases were tried, finally a J & W Scientific DB 225 capillary column (ID 
250 µm, length 30 m), produced the most acceptable separation.  The toxicity of selenium 
compounds is well documented.433,434  In order to minimize exposure to SeO2, the minimum 
quantities necessary to oxidize 5.92 to 5.27 were determined (Table 5.3).  Quantative oxidation of 
5.91 was achieved with 2.7 equivalents of SeO2 and this equivalency of selenium dioxide was used 
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for all subsequent microwave assisted oxidations.  Interestingly, 2.7 equivalents of SeO2 is often used 
in the standard reflux preparation of aryl glyoxals.435 
Table 5.3:  Optimization of the number of selenium dioxide equivalents for the conversion of 5.91 into 5.27a 
 
SeO2 (equiv) % Conversion into 5.27
b 
1.0 75 
1.5 87 
2.0 92 
2.5 99 
2.7 100 
 
a   
The reactions were conducted under the same microwave conditions, i.e. with a hold time of 15 min at a set 
temperature of 100 °C.  Hold time is the time the microwave remains at the set temperature. In all cases the 
set temperature was reached within 1 min and the reaction was forced-air cooled to 50 °C over a period of 5 
min and then allowed to cool to room temperature (ca. 20 min).  
b   
The % conversion was calculated from quantitative GC analysis. 
            
Having established the optimal equivalency of selenium dioxide for the microwave assisted synthesis 
of 5.27 at 100 °C we turned our attention to establishing the minimum temperature which could be 
used for this reaction in aqueous 1,4-dioxane (the most common solvent used for selenium dioxide 
oxidations of methyl ketones).  While, MWI allows solvents to be heated approximately 15 °C above 
their boiling points,430 Table 5.4 reveals that a temperature of 100 °C (1,4-dioxane b.p. 101 °C)436 
proved most suitable for quantative oxidation of 5.91 to 5.27.   
Table 5.4:   Optimization of the reaction temperature for the conversion of 5.91 to 5.27a 
 
Temperature [
o
C] % Conversion into 5.27
b 
70 30 
80 49 
90 88 
100 100 
  
a 
The reactions were conducted under the same microwave conditions, with a hold time of 15 min and 2.7 
equivalents of SeO2. 
b 
The % conversion was calculated from quantitative GC analysis. 
 
These optimized microwave reaction conditions were subsequently applied to the selenium dioxide 
oxidation of 5.91 and three para-substituted aryl methyl ketones 5.93-5.95.  The progress of each 
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reaction was monitored at hold times of 3, 6, 9, 12, 15, 18 and 21 minutes by GC-analysis (Figure 
5.5). Each reaction was performed in triplicate to confirm the reproducibility of the microwave 
method. Interestingly, the quantitative oxidation of an activated aryl methyl ketone, e.g. 5.93 was 
achieved in <3 minutes, while quantitative oxidation of a deactivated aryl methyl ketone, e.g. 5.94 
took six times longer under the same microwave conditions.   This suggests that the activating or 
deactivating characteristics of the para substituent makes the acetyl group more or less susceptible 
to oxidation respectively.    
O
R
O
R
H
O
O
R
OH
OH
 
 
     
 
 
Scheme 5.9:   The MAO synthesis of aryl glyoxals from methyl ketones.  Reagents and conditions: SeO2, H2O,  
 1,4-dioxane, MWI, 25 min, 100 ˚C, 100%  
 
 
Figure 5.5:   Conversion of compounds 5.91 (empty diamonds ◊); 5.93 (filled squares ); 5.94 (empty 
squares ) and 5.95 (filled circles ) to the corresponding aryl glyoxals 5.27, 5.28, 5.29 and 
5.30 respectively.   
5.92 R = H  
5.98 R = OMe 
5.99 R = NO2  
5.100 R = Cl  
5.101 R = Br  
5.102 R = F  
5.27 R = H  
5.28 R = OMe  
5.29 R = NO2  
5.30 R = Cl  
5.31 R = Br  
5.32 R = F  
5.91 R = H  
5.93 R = OMe  
5.94 R = NO2  
5.95 R = Cl  
5.96 R = Br  
5.97 R = F  
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5.4.1.2. Standardization of the GC method for quantification of glyoxal formation 
 
The chromatographs below show the retention times of the starting material 5.91 and 5.27 (17.2 
and 18.2 min respectively, Figure 5.6).  As expected the ratio of 5.91 : 5.27 changes with an increase 
in reaction time i.e. the peak corresponding to 5.91 decreasing while the peak corresponding to 5.27 
increases. 
 
 
Figure 5.6:    GC chromatograph of MW reaction involving acetophenone (5.91) at 3 min (top left), 6 min 
(top right), 9 min (bottom left) and 18 min (bottom right).  The peak at 17.2 minutes 
corresponds to acetophenone while the peak at 18.2 minutes corresponds to phenyl glyoxal 
(5.27).  
 
The detector used to produce the chromatographs shown in Figure 5.6 was a Flame Ionisation 
Detector (FID), which detects oxidised carbon ions.437   The functionality of organic species, 
particularly carbonyls and alcohols, may result in a reduction of the FID generated peak intensity.438  
Since we were using this method to detect the formation of carbonyl containing compounds, the GC-
analysis technique needed to be standardized and Equation 5.1 was derived in an attempt to 
standardize the GC data.    
O
5.91
O
H
O
5.27
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             Equation 5.1 
Where                       and                        and    
 
 
   and    
 
 
 
When an equal concentration of acetophenone (5.91) and phenyl glyoxal monohydrate (5.92) is 
injected into the gas chromatograph, fb may be calculated by    
 
 
.  Several GC chromatographs at 
various concentrations of 5.91 and 5.92 were recorded and the integrals of their respective peaks 
calculated, subsequently resulting in a calculated (Equation 5.1) average discrepancy of -7.5% in the 
intensity of the glyoxal peak, confirming what was reported in the literature.438  Note the 
discrepancy is not consistent and increases at lower concentrations of glyoxal.  The % conversion 
data reported in Figure 5.5 and elsewhere were corrected accordingly upwards to account for this 
error in the detector. 
 
5.4.1.3. The glyoxal/glyoxal monohydrate equilibrium   
 
Originally we attempted to isolate the glyoxal using Mikol et al.’s439  vacuum distillation method.  
Glyoxal 5.27 distilled at 63-65 oC under 20 mmHg of pressure as a pure yellow oil.  However, on 
contact with atmospheric moisture, white crystals of the glyoxal monohydrate 5.92 were 
immediately formed.   The water sensitivity of glyoxals is clear from closer inspection of their 
structure.  Additional polarization of the electrophillic aldehyde by the adjacent C-1’ ketone 
functionality would result in a relatively more polarized C-2’, susceptible to nucleophillic attack by 
water (Scheme 5.10).  Monohydrates are more stable than their corresponding glyoxals and we 
therefore decided to convert all the glyoxals (5.27-5.32) to the more stable monohydrate form 
through refluxing in water (2 hrs) and recrystallizing the glyoxal monohydrates (5.92 and 5.98-5.102) 
from the aqueous solution.         
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Scheme 5.10:   Equilibrium of the nucleophillic attack of water in glyoxals 
 
Interestingly, from our inspection of the chemistry literature most authors do not differentiate 
between the monohydrate or glyoxal forms, rather assuming that the monohydrate will partially 
revert back to the glyoxal in anhydrous non-polar conditions to form an equilibrium mixture 
(Scheme 5.10).  For the synthesis of the imidazole the glyoxal is essential and so the equilibrium 
between 5.27 and 5.100 in solution was investigated using 1H NMR spectroscopy.  A comparative 
analysis in three different solvents (CDCl3, DMSO-D6 and CD3OD) determined that the equilibrium 
occurred in CDCl3 and DMSO-D6.  An unexpected hemiacetal formed in CD3OD and this will be 
discussed later.          
To the best of our knowledge, details of the kinetics of the interconversion of 5.92 and 5.27 in 
solution have not been reported before.   The kinetics of the equilibrium between 5.92 and 5.27 in a 
CDCl3 solution of 5.92 was explored in a 
1H NMR stack-plot  which illustrated clearly the decay of the 
oxymethine proton resonance (δH 5.69) and the appearance and increase in intensity of the 
aldehyde proton signal (δH 9.71) with time (Figure 5.7). 
 
 
Figure 5.7:   A stack plot of the downfield region (δH 9.40-9.90) of the 
1
H NMR spectra (CDCl3, 600 MHz) of 
5.92 over time.  Z-axis 10 s apart.   
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The conversion of 5.92 into 5.27 (Figure 5.7) in chloroform follows first-order kinetics with a rate 
constant of 2.0191 x 10-5 s-1 (± 0.0073 x 10-5 s-1) and an R2 value of 0.999 for a linear plot of ln[A] vs. 
time.  Figure 5.8 further suggests that equilibrium concentrations of 5.92 and 5.27 are rapidly 
reached in the chloroform solution. 
 
Figure 5.8:   Kinetic data for the conversion of 5.92 (solid line) into 5.91 (broken line) in CDCl3 at 22 ˚C. 
 
Interestingly, the 1H NMR spectra of phenylglyoxal in deuterated methanol, showed the absence of 
the aldehyde resonance. However, there was the appearance of a new proton signal at δH 5.69 ppm.   
This new signal, representing the oxymethine proton of a putative hemiacetal, suggests, that the 
hemiacetal (5.103) is formed in a methanol solution, by nucleophillic attack by methanol on the 
glyoxal aldehyde carbonyl.  The presence of the hemiacetal was confirmed by HREI-TOF mass 
analysis (calculated for C9H10O3 166.0624. Found 166.0614, Δamu 0.001.)  
Since there was no detection of an aldehyde signal, it was initially assumed there may have been 
deuterium exchange between the CD3OD and the aldehyde proton.  However, when calculating the 
kinetics of the formation of hemiacetal from the monohydrate, the sum of the concentration of 
these two species equal that of the total concentration (Figure 5.10).  The sum of the concentrations 
of 5.92 and 5.104 was monitored with the addition of 1,3,5-trimethoxybenzene (10.7 mM) (TMB), as 
an internal NMR calibrant to calculate the relative concentrations and to ensure no deviations in the 
peak intensities.  This showed that the aldehyde was not present or deuterated, but rather only 
exists as an intermediate, undetectable by NMR under the current conditions (Scheme 5.11).   
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Scheme 5.11:   The equilibrium in which the hemiacetal (5.103) forms via a glyoxal intermediate in a methanol  
 solution. 
 
 
 
 
 
Figure 5.9:   A stack plot of the region δH 5.40-6.00 of the 
1
H NMR spectra (CD3OD, 600 MHz) obtained for 
5.92 over time.  Z-axis 10 min apart.   
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Figure 5.10: Kinetic data for the conversion of 5.92 (solid line) into 5.104 (dotted line) in CD3OD at 22 ˚C. 
 
Interestingly, the 1H NMR signal of the oxymethine proton (H-2’, δH 5.69) of 5.92 appears as a triplet 
with a COSY correlation to a broad singlet (OH, δH 4.16) in a CDCl3 solution (Figure 5.11A).  
Opportunities for hydrogen bonding between the hydroxyl moieties of the germinal diol and the 
ketone functionality probably impede proton exchange in this compound.  As expected, on the 
addition of D2O to the CDCl3 solution of 5.92, the triplet collapses to a singlet and the broad singlet 
(δH 4.16) disappears (Figure 5.11B).      
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Figure 5.11:   The COSY spectra (F1 and F2 = δH 3.55-6.50)  of 5.92.  A:  CDCl3, 600 MHz  (Left)  B:  CDCl3 + D2O 
(20 μL), 600MHz (Right).  The key correlation resulting in the splitting patterns are shown in the 
accompanying figures.    
 
A chloroform solution containing an equilibrium mixture of glyoxal and monohydrate yielded only a 
single peak when injected onto the DB-225 GC column.  A similar result was obtained when the 
equilibrium mixture was injected onto a DB-1 column. Several repeated injections on both columns 
with different temperature gradients and carrier gas flow rates failed to separate the two expected 
peaks.  We therefore proposed that the solution equilibrium between glyoxal and monohydrate 
could possibly be shifted completely in favour of the glyoxal by dehydration of the monohydrate 
during volatilization in the GC inlet (240 °C).  Although the molecular ions for either 5.92 or 5.27 
were absent from GC-HREIMS analysis of the single peak resulting from injection of 5.92 onto the GC 
column, thermogravimetric mass analysis (TGA) of crystalline 5.92 provided evidence for the facile 
loss of water.  The mass spectrometer attached to the TGA was selectively focussed to record the 
change in intensity of the m/z = 18 ion peak with increasing temperature.  Therefore, an increase in 
the intensity of this peak suggested the loss of a water molecule during thermal decomposition.   
Figure 5.12 indicates a 11.8% reduction in mass, while concurrently the m/z peak intensity increases 
at this temperature range (ca. 90 °C), equivalent to the loss of a small molecule with m/z 18. 
ppm
4.04.55.05.56.06.5 ppm
3.6
3.8
4.0
4.2
4.4
4.6
4.8
5.0
5.2
5.4
5.6
5.8
6.0
6.2
6.4
ppm
4.04.55.05.56.06.5 ppm
3.6
3.8
4.0
4.2
4.4
4.6
4.8
5.0
5.2
5.4
5.6
5.8
6.0
6.2
6.4
H-2’ 
OH 
H-2’ 
H-2’ H-2’ 
Chapter Five:  Marine Bisindole Alkaloids 
 
 
148 
At higher temperature a sudden loss in mass was observed corresponding to the volatilisation of the 
glyoxal.  A total loss of mass after 135 °C, indicated that no residue was formed from thermal 
decomposition. 
 
Figure 5.12:  The TGA-MS spectra of 5.92.  Green line indicates the % mass loss with increase in 
temperature.  The blue line represents the change in intensity of the m/z = 18 peak with an 
increase in temperature. 
 
The difficulties associated with attempting to isolate the glyoxal 5.27 from the equilibrium mixture 
with the 5.92 required us to perturb the equilibrium in favour of the monohydrate by refluxing the 
glyoxal equilibrium mixtures from the selenium dioxide oxidation of 5.91 and 5.93-5.97 in water and 
crystallizing out the monohydrates (5.92 and 5.98-5.102) directly from the aqueous solution.  The IR, 
1H, 13C NMR data and melting points of 5.92 and 5.98-5.102 were consistent with published 
values.421,440   
Closed-vessel microwave irradiation greatly accelerates the selenium dioxide mediated oxidation of 
aryl methyl ketones (5.91 and 5.93-5.97) to the corresponding aryl glyoxal monohydrates (5.92 and 
5.98-5.102) in yields comparable with those obtained by traditional reflux methods (Table 5.5) of the 
reaction mixtures for extended periods on a heated oil bath. 
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Table 5.5:   Comparative table of two heating methods for the formation of aryl glyoxal monohydrates 
5.92 and 5.98-5.102. 
 
 
Isolated Yield 
Compound Classical Heating
a
 
[%] 
MWI
b
 
[%] 
5.92 82 84 
5.98 82 84 
5.99 62 62 
5.100 82 81 
5.101 86 89 
5.102 86 87 
 a
 Refluxed for 12hrs.   
 b
 MWI for 3-20 minutes.   
 
5.4.2. Indole glyoxal synthesis 
 
Our approach to the synthesis of the natural product 5.33 required the initial preparation of a 
suitable glyoxal precursor.  Our obvious starting material for a microwave assisted selenium dioxide 
was 3-acetylindole (5.105, Scheme 5.8).  However, on inspection of the 1H and 13C NMR spectra of 
the oxidised product, there was no evidence of the aldehyde resonance although the methyl signal 
(δH 2.55) had completely disappeared in the 
1H NMR spectrum while a new quaternary carbon had 
appeared in the 13C NMR spectrum (δC 166.0).  The HMBC correlations from H-2 (δH 8.52) to C-3, 
C-3a, C-4, C-7a and C-1’ (Figure 5.13) confirmed that the indole ring and the ketone functionality 
were still intact while the chemical shift of the quaternary carbon (δC 166.0) was suggestive of a 
carboxylic acid carbonyl moiety. The HREIMS fragmentation pattern (Figure 5.14) was consistent 
with the EIMS data reported by Bergmann et al.,441 for indole-3-glyoxylic acid (5.106) (HREI-TOF: 
calculated for C10H7O3N 189.04259. Found 189.04205, Δamu 0.0005.)  Faced with an over oxidation 
of 3-acetylindole to 5.106 we reflected on our previous preparation of 5.27-5.32 which had shown 
that the activity of the aromatic ring has a significant effect on the rate of microwave assisted 
selenium dioxide oxidation reactions.  We therefore decided to reduce the influence of the indole 
nitrogen atom on the activity of the indole ring through conversion of 5.105 to an N-Boc carbamate 
ester (5.89, Scheme 5.12).   
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Figure 5.13:   A region of the HMBC spectrum (CD3OD, 600 MHz, delay for evolution of long range coupling 
[d6] = 60 msec; F1 = δC = 97 – 183; F2 = δH 7.20 – 8.60) obtained for 5.106.  Multiple bond 
correlations from H-2 illustrated in accompanying figure.   
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Figure 5.14:   The EI fragmentation pattern of 5.106.  The m/z range = 95-200.   
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O
O
5.105 5.89  
Scheme 5.12:  The N-Boc protection of 5.105.  Reagents and conditions:  Boc2O, DMAP, MeCN, 0 
o
C, 2hrs, 
100% 
 
Initial evidence for the successful preparation of 5.89 was provided from the 1H NMR spectrum of 
this compound in which a nine proton singlet (δH 1.67, t-butyl) was clearly evident.  The compound 
was isolated from the reaction mixture as white needles (mp 140-142 oC lit.442 143-144 oC) in 
quantitative yield. 
Microwave assisted selenium dioxide oxidation of 5.89 proceeded smoothly to give an equilibrium 
mixture of the indole glyoxal (5.88) and the monohydrate (5.107) (Scheme 5.13).  The 1H NMR 
spectrum of the oxidation reaction mixture of 5.89 showed two new singlets (δH 9.53 and 5.79) 
corresponding to the aldehyde proton of the glyoxal and the oxymethine proton of the monohydrate 
respectively.  C18 reversed phase HPLC analysis of the crude mixture gave three peaks.  One peak (tR 
= 5.8 min) corresponded to unreacted 5.89, while the remaining two peaks (tR = 2.6 min with a 
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shoulder at tR = 3.2 min) were inseparable and their relative intensities changed with each injection 
onto the column, thus suggesting an equilibrium mixture of 5.88 and 5.107.  Refluxing the mixture in 
water and subsequent cooling did not result in the crystallization of 5.107 as we observed 
previously.  The solubility of 5.88 in dichloromethane enabled the initial separation of the organic 
products from the excess water soluble SeO2 through liquid-liquid partitioning.  Removal of the DCM 
under reduced pressure followed by semi preparative reversed phase HPLC (C18, 3:2 MeCN:H2O) 
gave an inseparable mixture of 5.88 and 5.107.  The HSQC and HMBC spectrum of the mixture of 
5.88 and 5.107 showed sufficient signal dispersion to individually assign the NMR chemical shift data 
of both compounds.   
 
5.4.3. The formation of the imidazole ring from aryl glyoxal precursors 
 
Khalili et al.399 described the formation of imidazoles via dehydrative self-condensation of two aryl 
glyoxals in the presence of ammonium acetate (Scheme 5.13), in which the aldehyde functionality of 
5.27 is converted into a primary aldimine (5.108).  Nucleophillic attack of 5.108 at the ketone 
carbonyl of another imine followed by intramolecular cyclization of the resulting adduct (5.109) 
affords the keto imidazole 5.110.        
H
O
O
NH4OAc
O
HN
O
NH
OH
N
O
HN
N
N
H
O
5.27 5.108 5.109
5.110   
Scheme 5.13: The proposed mechanism for the formation of an imidazole ring via the in situ dehydrative self-
condensation of phenyl glyoxal (5.27) in the presence of NH4OAc.  Adapted from Khalili et al.
399
 
Chapter Five:  Marine Bisindole Alkaloids 
 
 
153 
Khalili et al.399 have proposed that the methine ring proton in 5.110 may rearrange to form two 
possible tautomers (5.21a and 5.21b Scheme 5.14).  Khalili et al.399 have shown that the yields of 
each of these two tautomers is solvent-dependent with ethanol affording the highest overall yield of 
imidazoles with the greatest tautomeric regioselectivity for compounds 5.22, 5.24 and 5.26 
(Table 5.6).        
N
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Scheme 5.14:  The 1,5 –proton shift resulting in the formation of the two imidazole tautomers a and b.  
Adapted from Khalili and co-workers.
399
   
 
Table 5.6:   The isolated yields and tautomeric ratios (a/b) of compounds 5.22, 5.24 and 5.26 synthesised 
in a variety solvents.  Reproduced from Khalili.
399
 
 
Solvent 
Yield (%) for 5.22, 
5.24 and 5.26 
a/b ratio for 5.22, 
5.24 and 5.26 
H2O 71, 69, 59,  4.80, 3.70, 5.90 
EtOH 83, 71, 87 4.30, 3.90, 6.00 
EtOAc 80, 56, 68 4.16, 1.10, 1.85 
MeCN 62, 48, 63 2.87, 1.00, 6.25 
CHCl3 83, 65, 77 2.93, 1.13, 2.00 
DMSO 84, 67, 65 2.92, 1.94, 6.60 
   
In our synthesis of imidazoles 5.21-5.26 using Khalili et al.’s399 method we obtained a similar mixture 
of tautomers a and b in an ethanol solution.  We subsequently used 1H NMR spectroscopy to 
determine the ratio of tautomers (Table 5.7) through integration of the 1H NMR signals e.g. Figure 
5.15.  Interestingly, Khalili et al.399 never assigned the downfield proton resonances in the 1H NMR 
5.21 R = H  
5.22 R = OMe  
5.23 R = NO2  
5.24 R = Cl  
5.25 R = Br  
5.26 R = F  
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spectrum, of the two isomeric 2-aryloylimidazoles to the protons on either N-1 or N-3, but rather 
arbitrarily chose isomer a as the upfield resonance and isomer b as the downfield resonace.    We 
used molecular modelling to determine the optimized structure of each of the tautomers (5.21a and 
b-5.26a and b) in an attempt to identify the theoretically more likely major isomer.  Both tautomers 
5.21-5.26 were optimized using the B3LYP density function theory at 6-13G basis set.  Using the 
minimized energies, the Boltzmann distribution was calculated from Equation 5.2:   
  
  
  
   
                                Equation 5. 2 
 
From the Boltzmann distributions of the two possible tautomers a putative theoretical tautomeric 
ratio could be calculated (Table 5.7).  
Table 5.7:   A comparison of the experimentally determined ratios of the two tautomers a and b, the 
calculated tautomeric ratios using Gaussian03 and the literature cited values. 
  
Compound Experimental [%]
a
 Theoretical [%]
b
 Khalili et al.
399
 [%] 
 
a b a b a b 
5.21 100 0 78 22 78
c 
22
c 
5.22 75 25 84 16 81 19 
5.23 100 0 98 2 ND ND 
5.24 87 13 93 7 80 20 
5.25 100 0 94 6 84
c 
16
c 
5.26 85 15 90 10 86 14 
a
   Determined via integration of the NH signals δH 13.0-14.0 ppm in the 
1
H NMR spectra 
b
   Determined using Gaussian03
443
 density function at 6-13G basis set and relative energies used to calculate 
Boltzmann distribution 
c
   Khalili’s reported ratios of a and b synthesized in a aqueous solution.    
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Figure 5.15: The representative downfield region (δH 6.0-14.3) of the 
1
H NMR spectrum (DMSO-D6, 600 
MHz) obtained for the tautomeric mixture of 5.22 (shown inset).    
 
 
Figure 5.16:   The representative DFT optimized structures of 5.24a (left) and 5.24b (right).  Visualized in DS 
Visualizer.
21
   
 
From Table 5.7 we can see that tautomer a with the protonated N-3 atom in 5.21-5.26, is more 
energetically favoured.  This may be due to possible steric strain between the imidazole ring and the 
phenyl ring when N-1 is protonated leading to contortion of the molecule (Figure 5.16). 
The seemingly random assignment of the chemical shifts of the tautomeric protons by Khalili et al. 
concerned us and we set about using 2D 15N NMR spectroscopy to conclusively resolve these 
assignments.  In the 15N HMBC spectrum of 5.22 (Figure 5.17A) the methine proton on the imidazole 
ring will only correlate to a 15N atom no more than two bonds away and provided a means of 
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determining the chemical shift of the N adjacent to the C-4 methine proton.  A subsequent 15N HSQC 
spectrum of the mixture of 5.22a and 5.22b (Figure 5.17B) will show which nitrogen of the imidazole 
ring is attached to the proton of the major tautomer.  The spectra below shows the methine proton 
on C-4 in the HMBC is correlating to the same nitrogen of the major tautomer, i.e. N-3 (δN 230).  It 
can therefore be determined that the major tautomer is 5.22a, with the protonated nitrogen 
adjacent to the methine proton.  This validates to the modelling data and fortuitously concurs with 
Khaili et al.’s399 earlier random assignment. Therefore, in conclusion 15N NMR spectroscopy provided 
a method for establishing which nitrogen atom hosted the proton of the major imidazole tautomer 
and conclusively resolved the structures of the major and minor tautomers.   
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Figure 5.17:   A:  The 
15
N HMBC spectrum (DMSO-D6, 600 MHz, delay for evolution of long range coupling 
*d6+ = 60 msec; F1 = δN = 170 – 273; F2 = δH 7.60 – 8.20) obtained for compound 5.22 (left). 
 B:  The 
15
N HSQC spectrum (DMSO-D6, 600 MHz; F1 = δN = 170 – 273); F2 = δH 13.00 – 14.00) 
obtained for compound 5.22 (right).  Key correlations illustrated in accompanying figure.     
 
While the chemical resonances of the tautomeric mixtures of 5.21-5.26 are relatively simply to 
assign we expected far less spectral resolution for the more complicated bisindole compounds (5.20, 
5.33 and 5.34) and felt the use of the EXSY NMR experiment would be an effective tool for full 
individual assignment of the chemical shifts of the inseparable mixture of tautomers and EXSY data 
was subsequently acquired for 5.21-5.26.  Exchange Spectroscopy (EXSY)444 arises from the non-
coherent magnetization transfer between sites with different resonance frequencies.445  These 
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magnetic transfers may occur either by exchange of nuclei in non equivalent environments (e.g. H-
3’’a to H-3’’b in 5.22, Figure 5.18)  or via the exchange of atoms within a molecule (e.g. the 1,3 
proton shift on the imidazole ring in 5.22, Figure 5.18).446  These exchanges are perceived as cross-
peaks in the EXSY spectrum and the exchange process may be clarified by inspection.447  EXSY NMR 
spectroscopy has a number of applications in organic chemistry including but not limited to proton 
exchanges,448-451 chemical equilibria,452 rotamers453 and ring flips.454 The EXSY NMR experiment has 
the same pulse sequence as a phase sensitive NOESY experiment, however if the cross-signals are in 
the same phase as the diagonal this indicates the exchange of protons, rather than cross relaxation 
detected by the NOESY experiment.445 
By evaluating the representative EXSY spectra below of compound 5.22 (Figure 5.18), the 1,3 
hydrogen shift in the imidazole ring resulting in the two tautomers was clearly shown with a cross-
peaks between H-1 and H-3.  The remaining cross-peaks allowed us to assign the chemical shifts of 
known protons of the major tautomer (determined by standard HSQC and HMBC experiments) to 
protons in the same relative position of the corresponding tautomer which were not apparent in the 
2D NMR experiments.  The assignment of the individual chemical shifts of the major and minor 
products of the tautomeric mixture of 5.21-5.26 using EXSY to the best of our knowledge is a first 
(See Chapter 6).  However, the ultimate visual representation of tautomers is X-ray analysis. 
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Figure 5.18:  The representative downfield region (F1 and F2 = δH 5.5 – 14.0) of the EXSY NMR spectrum 
(DMSO-D6, 600 MHz) obtained for 5.22.  The accompanying figure shows the exchange of 
protons in the tautomeric equilibrium.   
 
There are several examples of crystal structures of tautomeric imidazoles in literature, Kubicki455 
showed that the crystals of some imidazole rings contain both tautomers in their unit cell,  and he 
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later described how imidazoles have the ability to form crystal lattices as a result of imidazole-
phenyl-imidazole bonds through π-stacking.456  Mahboobi’s et al.’s457 crystal structure of the natural 
product 5.111 (Figure 5.19, CSD 215662), clearly shows the presence of one tautomer in the solid 
state.  The N-3 atom is required as a hydrogen acceptor from a para substituted hydroxyl group on 
another unit cell, while N-1 acts as a hydrogen donor to the carbonyl of a surrounding molecule.  The 
structure is also supported by phenyl-imidazole ring π-stacking.457  Interestingly, our Boltzmann 
distribution calculations of 5.111, revealed that protonation of the N-3 atom in the imidazole ring 
should be more energetically favoured.   Therefore the crystal lattice of 5.111 apparently locks 
tautomers of this molecule into the energetically more demanding tautomer, but yet a sterically 
favoured conformation for crystal formation.    Inspired by Mahboobi et al.’s ability to isolate a single 
tautomer of an imidazole through crystallization, we attempted to crystallize 5.21-5.26.    
N
N
HO
HO
OH
5.111
1
3
 
 
Figure 5.19:   Mahboobi et al.’s
457
 crystal lattice of 5.111.  Visualized in Mercury 2.4,
304
 the unit cell view 
along the c-axis (left) and b-axis (right).  Red dotted lines represent hydrogen bonding.   
 
Unfortunately, Mahboobi et al. do not describe their method for the crystallization of 5.111.  We 
attempted to crystallize 5.21-5.26 using classical methods at varying temperatures and solvent 
systems, only to obtain microcrystals from an unusual combination of DMSO and methanol.  We 
attempted to enlarge the crystals of 5.21-5.26 to obtain crystals suitable for X-ray analysis and hence 
we reverted to slow diffusion crystallization methodology.  A solution of DMSO was saturated with 
the amorphous powder of the biphenyl imidazoles (5.21-5.26), which was subsequently surrounded 
with methanol and sealed for several weeks allowing the two solvents to slowly mix through 
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evaporation (Figure 5.20). Small needles of 5.21, 5.22 and 5.24-5.26 and a brown solid (5.23) were 
obtained using this method. 
 
 
Figure 5.20:   The diffusion method of crystal growth.  Yellow represents a solution of biphenyl imidazole 
(5.21-5.26) in DMSO and blue represents methanol.   
 
Unfortunately, the crystals of 5.21, 5.22 and 5.24-5.26 were deemed too thin (average thickness was 
17 μm, Figure 5.21) for X-ray diffraction and attempts to increase the thickness of the crystals 
through prolonged crystallization proved fruitless.  
 
Figure 5.21:   Representative SEM micrographs of compounds 5.25 at various magnifications. Images taken 
using a Tescan Vega scanning electron microscope at 20 kV and a working distance of 20 mm.  
Scale given at the bottom of the micrograph.  Average thickness of crystals calculated to be 17 
μm. 
      
5.4.3.1. Improved synthesis of the ascidian natural product 5.140 
 
In 1999, Salva and co-workers458 reported the isolation of 2-(p-hydroxybenzoyl)-5-(p-hydroxyphenyl) 
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imidazole (5.111) from the red ascidian Botryllus leachi (Figure 5.22) collected off the coast of Tarifa 
Island, Spain.  Later Mahboobi et al.457 managed to synthesize and crystallize 5.111 (Scheme 5.15).         
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Figure 5.22:   The underwater photograph of the red ascidian Botryllus leachi (Left)
459
 and isolated 
metabolite 2-(p-hydroxybenzoyl)-5-(p-hydroxyphenyl) imidazole (5.111, Right).
458
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Scheme 5.15:  Mahboobi et al.’s synthesis of the natural products 5.111.
457
  Reagents and conditions:  i)  SeO2,  
MeOH, 60 °C, 5hrs, 67%; ii)  NH4OAc, AcOH;  iii) HBr (48%),  refluxed, 12 hrs; Pd/C (10%), H2, RT, 
12 hr, 75%  
 
The most convenient way to synthesize 5.111 would be via a 4-hydroxyphenyl glyoxal monohydrate 
precursor.  Unfortunately, we were unable to obtain the corresponding glyoxal monohydrate using 
our SeO2 microwave method possibly due to the activation of the aryl ring. Therefore, we pursued a 
similar synthetic route to Mahboobi et al., involving the demethylation of 5.22 as a final step.  
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However, our synthesis of 5.28 was completed in < 3min in quantitative yield and 5.22 was formed 
by stirring 5.28 in NH4OAc for 45 min, while Mahboobi et al. synthesized 5.22 in 5 hrs under reflux, 
followed by two distillation purification steps resulting in a 67% yield.  Several different 
methodologies for the deprotection of the methoxy functionalities on benzene rings have been 
described in literature.  However, these demethylating procedures often require reagents such as 
hydrogen bromide460 and more recently trifluoride-methyl sulphide,461 boron tribromide462 or 
iodotrimethylsilane.463 Demethylation using these procedures afford good yields but require harsh 
conditions.  Recently Zou et al.464 have demonstrated the use of iodocyclohexane as a demethylating 
agent under relatively mild conditions and we found this method suitable for demethylation of 5.22 
(Scheme 5.16).   
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Scheme 5.16:  The demethylation of 5.22.  Reagents and conditions:  Iodocyclohexane, DMF, 12 hrs, refluxing 
under Ar, 93% 
 
Iodocyclohexane is thermally unstable, decomposing into hydrogen iodide which effectively cleaves 
alkyl ethers into alcohols and alkyl iodides.  The acid-catalyzed iodide ion cleavage of ethers 
proceeds regioselectively via an oxonium ion intermediate (5.112) (Scheme 5.17) with the iodide 
anion attacking the less sterically hindered methyl group of 5.112 to form methyl iodide and 5.111.
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Scheme 5.17:   The proposed mechanism for the demethylation of 5.21 in the presence of HI. 
 
Initially, the iodocyclohexane demethylation reaction was refluxed under inert conditions for three 
hours, resulting in a mixture of unreacted starting material, two different monomethylated products 
and fully deprotected biphenyl imidazoles, indicated by the appearance of 8 singlets of various 
intensities in the downfield region, corresponding to 4 pairs of tautomers, in the 1H NMR spectrum.  
Increasing the reaction time to 12 hrs afforded the natural product 5.111 in 93% yield, in a 
tautomeric a:b ratio of 75%:25%, (Boltzmann distribution calculated as a:b 74%:26%).  Deprotection 
of the methyl ether, using Zou et al.’s method resulted in the easy removal of the volatile side 
products, e.g. methyl iodide, under reduced pressure.  The success of the reaction was gauged by 
the absence of the methoxy signals (δH 3.79 and 3.88) in the 
1H NMR spectrum of 5.111, and the 
appearance of a broad signal (δH 3.52) corresponding to the hydroxyl protons.  The 
13C NMR data 
revealed a change in chemical shifts of the para substituted carbons, C-4’ and C-5’’ from δC 55.7 and 
55.9 in the 13C NMR spectrum of 5.22 to δC 158.7 and 163.9 in the 
13C NMR spectrum of 5.111 
respectively.  A full comparison of δH and δC of our synthetic 5.111, Salva et al.’s isolated natural 
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product and Mahboobi et al.’s synthetic product can be found in Table 5.8.  The 13C chemical shifts 
for C-2 and C-5 for both our and Mahboobi’s synthetic 5.111 appear to differ significantly to those 
values reported by Salva for the natural product.  The values assigned to our synthetic 5.111 
correspond to the major tautomer only, with a protonated N-3 imidazole ring (5.111a).  The HMBC 
spectrum of our tautomeric mixture of 5.111, did however show a correlation from a minor singlet 
δH 7.45 to δC 158.3 (H-4b to C-2b) and a minor doublet δH 6.80 to δC 156.1 (H-3’’b to C-5b).  We 
therefore concluded that the natural product Salva isolated was the tautomer 5.111b.  
Table 5.8:   Comparative table of the 
13
C and 
1
H NMR shifts of 5.140, the natural product and a previously 
synthesized product. 
 
 
5.111
a 
Natural Product
b, 458
 
 Mahboobi’s Synthetic 
Product
c, 457
 
13
C [ppm] 
1
H [ppm] 
13
C [ppm] 
1
H [ppm] 
13
C [ppm] 
1
H [ppm] 
1 
      
2 144.2 
 
158.3 
 
145.1 
 
3 
      
4 123.1 7.50 (s) 122.9 7.59 (s) 122.7 7.77 (s) 
5 142.7 
 
155.9 
 
140.9 
 
1' 124.2 
 
119.5 
 
120.5 
 
2' 128.0 7.65 (d) 128.1 7.71 (d) 128.6 7.67 (d) 
3' 116.7 6.85 (d) 117.1 6.89 (d) 116.4 6.97 (d) 
4' 158.7 
 
160.8 
 
159.4 
 
1'' 181.8 
 
178.2 
 
180.8 
 
2'' 129.1 
 
126.8 
 
128.4 
 
3'' 134.5 8.39 (d) 134.8 8.38 (d) 134.6 8.13 (d) 
4'' 116.7 6.90 (d) 117.2 6.84 (d) 116.2 6.90 (d) 
5'' 163.9 
 
167.7 
 
164.5 
 a
  
1
H NMR (600 MHz) and 
13
C NMR (150 MHz) in CD3OD 
b
  
1
H NMR (400 MHz) and 
13
C NMR (100 MHz) in CD3OD
  
c
  
1
H NMR (250 MHz) and 
13
C NMR (62.5 MHz) in CD3OD  
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5.4.4. The formation of the imidazole ring from indole glyoxal precursors 
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N
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Scheme 5.18:   Formation of the imidazole ring from 5.88.  Reagents and conditions: NH4OAc, EtOH, RT, 6 hrs, 
100%  
 
The addition of NH4OAc to an ethanol solution of an equilibrium mixture of 5.88 and 5.107 resulted 
in the solution eventually turning a deep yellow colour.  A yellow solid residue was obtained 
following removal of the solvent under reduced pressure.  The yellow solid was washed with water 
to remove unreacted ammonium acetate and filtered.  The methyl ketone 5.89 does not interfere 
with the formation of the imidazole and therefore the previously discussed HPLC purification of the 
glyoxal, to remove unreacted 5.92 may be omitted thus improving the efficiency of the reaction.  
The mixture of 5.89 and 5.90 was easily separated on a bench top silica column (5:1 hexane and 
EtOAc) with a 96% recovery of 5.90.   
N
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N
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H
N
N
5.90 5.33  
Scheme 5.19:  The thermal deprotection of the indole rings of 5.90.  Reagents and conditions:  MWI, 185 ˚C, 5 
min, 100% 
 
The final step in our synthesis of 5.33 required the quantitative removal of the N-Boc protecting 
group.  The thermal lability of the carbamate has been demonstrated before where Rawal and 
Cava419 reported the cleavage of N-C bond in the carbamate functionality in a number of heterocyclic 
compounds including one containg an indole ring e.g. 5.113 (Scheme 5.20), while more recently 
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Knölker and co-workers thermally deprotected a series of N-boc protected carbazoles  e.g. 5.114 
(Scheme 5.20).420  
N
O
Boc
OEt
O
5.113
N
H
O
OEt
O
i.
 
N
Boc
5.114
ii.
H2N OMe
(CH2)4Me N
H
H2N OMe
(CH2)4Me
 
Scheme 5.20: Rawal and Cava’s
419
 thermal removal of carbamate ester. Reagents and conditions: i) Δ, 
184.5 ˚C, Ar, 30 min, 99% 
 Knölker and co-workers’
420
 thermal removal of carbamate ester. Reagents and conditions: ii)  
Δ, 180 ˚C, Ar, 45 min, 100% 
 
We correctly envisaged that heating 5.90 under an argon atmosphere for 5 minutes in a microwave 
reactor would prove to be a more efficient method for quantative N-Boc deprotection.  This 
deprotection of 5.90 is the first recorded use of microwave irradiation to effect this transformation.  
It was clear that the removal of the carbamate was successful as four new peaks (δH 12.2-11.2) 
appeared in 1H NMR spectrum (Figure 5.23),  corresponding to the pair of secondary amines of 
either tautomer.  From the 1H NMR spectrum it was clear we had prepared a mixture of tautomers 
almost in equal concentrations (a:b 54%:46%).  Two-dimensional 15N NMR was used to determine 
the major tautomer, as described previously.  The methine proton H-4 correlates to the adjacent 
nitrogen (N-3, δN 217) in the 
15N HMBC (Figure 5.24, Left), while  the 15N HSQC reveals that the 
nitrogen at δN 217 correlates to the N-H of the major tautomer (δH 13.37; Figure 5.24, Right), thus 
confirming the major tautomer was protonated at N-3 on the imidazole ring i.e. 5.33a.   
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Figure 5. 23: The downfield region (δH 6.8-13.6) of the 
1
H NMR spectrum (DMSO-D6, 600 MHz) obtained for 
the tautomeric mixture of 5.33 (shown inset).  
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Figure 5.24:   A:  The 
15
N HMBC spectrum (DMSO-D6, 600 MHz, delay for evolution of long range coupling 
*d6+ = 60 msec; F1 = δN = 174 – 227); F2 = δH 6.0 – 10.1) obtained for compound 5.33 (left). 
 B: The 
15
N HSQC spectrum (DMSO-D6, 600 MHz; F1 = δN = 174 – 227); F2 = δH 11.1 – 13.4) 
obtained for compound 5.33 (right).   
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Figure 5.25:   A selected portion of the downfield region (F1 and F2 = δH 9.0 – 11.6) of the EXSY NMR 
spectrum (DMSO-D6, 600 MHz) obtained for 5.33.    
 
The chemical shifts assigned from the 1H and 13C NMR data of 5.33a and 5.33b are compared with 
Rinehart and co-workers405  natural product in addition to  Achab et al.’s413 synthetic 5.33 in Table 
5.9.  Both Rinehart and Achab recorded their NMR data in 1% TFA solution in DMSO-D6 ostensibly to 
reduce tautomerization about the imidazole ring.  We were able to use the EXSY NMR experiment 
(Figure 5.25) to assign 1H and 13C chemical shifts for both tautomers (5.33a and 5.33b) for the first 
time, where no HSQC and or HMBC correlations were detected.    
ppm
9.510.010.511.011.5 ppm
9.5
10.0
10.5
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11.5
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Table 5.9:   Comparative table of 5.33a, 5.33b, Rinehart and co-workers marine natural product isolate and 
Achab et al.’s synthetic product.  Values quoted in ppm and splitting patterns indicated in 
parentheses.   
 
 
5.33a
a 
5.33b
a 
Natural Product
b, 405 
Synthetic Product
c, 413 
 
13
C [ppm] 
1
H 
 [ppm] 
13
C [ppm] 
1
H  
[ppm] 
13
C [ppm] 
1
H  
[ppm] 
13
C [ppm] 
1
H 
 [ppm] 
1 
   
13.12 (s) 
    2 145.2 
 
145.2 
 
143.9 
 
143.5 
 3 
 
13.37 (s) 
      4 125.8 7.63 (s) 114.9 7.69 (s) 119.3 (d) 7.85 (s) 118.8 7.92 (s) 
5 130.4 
 
138.5 
 
133.3 
 
133.1 
 1' 
 
11.45 (s) 
 
11.23 (s) 
 
11.53 (d) 
 
11.56 (s) 
2' 124.0 8.11 (s) 122.8 7.83 (s) 124.2 (d) 8.07 (dd) 123.6 8.08 (d) 
3' 104.7 
 
110.8 
 
105.9 
 
105.5 
 3a' 124.5 
 
124.9 
 
124.6 
 
124.6 
 4' 121.3 8.17 (d) 119.5 7.91 (d) 119.8 (d) 8.05 (dd) 119.6 8.04 (d) 
5' 121.6 7.15 (t) 119.8 7.13 (t) 119.9 (d) 7.18 (m) 120.2 7.23 (t) 
6' 122.7 7.15 (t) 121.9 7.19 (t) 121.9 7.18 (m) 
 
7.18 (t) 
7' 112.1 7.46 (s) 112.0 7.44 (d) 112.1 (d) 7.50 (dd) 112.2 7.52 (d) 
7a' 136.5 
 
136.2 
 
136.5 
 
136.7 
 1'' 
 
12.04 (s) 
 
12.15 (s) 
 
12.33 (d) 
 
12.38 (s) 
2'' 136.6 9.19 (s) 137.0 9.40 (s) 137.5 9.15 (d) 137.8 9.05 (d) 
3'' 113.7 
 
113.9 
 
113.8 
 
113.7 
 3a'' 126.8 
 
126.8 
 
126.6 
 
126.6 
 4'' 121.6 8.41 (d) 121.6 8.41 (d) 121.6 (d) 8.41 (dd) 121.6 8.37 (dd) 
5'' 121.8 7.25 (m) 121.8 7.25 (m) 122.3 (d) 7.29 (m) 122.5 7.32 (m) 
6'' 122.8 7.25 (m) 122.8 7.25 (m) 123.3 (d) 7.29 (m) 122.1 7.32 (m) 
7'' 112.3 7.54 (d) 112.3 7.54 (d) 112.6 (d) 7.59 (dd) 112.7 7.60 (m) 
7a'' 136.2 
 
136.2 
 
136.5 
 
136.7 
 8'' 176.1 
 
176.0 
 
174.9 
 
174.4 
 a  
1
H NMR (600 MHz) and 
13
C NMR (150 MHz) in DMSO-D6 
b
  
1
H NMR (200 MHz) and 
13
C NMR (125 MHz) in DMSO-D6 + 1% TFA
  
c
  
1
H NMR (300 MHz) and 
13
C NMR (125 MHz) in DMSO-D6 + 1% TFA  
 
The use of microwave technology resulted in the rapid production of 5.33 with a total yield of 86%.  
Compared to the other methods this is by far the quickest and the highest yielding.  We extended 
this method in the attempted synthesis of isobromotopsentin (5.20) and its synthetic isomer bis-5-
bromoindole imidazole (5.34).      
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5.4.5. Attempted synthesis of 5.20 and 5.34 
 
With the success of the synthesis of 5.88 we proceeded to attempt to synthesize the 5- and 6- 
bromo substituted indole glyoxal precursors (5.115 and 5.116) required for the synthesis of 5.20 and 
5.34 respectively (Scheme 5.21).  
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Scheme 5.21: The synthetic pathway for the synthesis of 5.115 and 5.116.  Reagents and conditions: i) 
MeMgBr, CeCl3, THF, 0 ˚C, 6 hrs, 100% ii)  MnO2, DCM, RT, 48 hrs, 100%  iii)  Boc2O, DMAP, 
MeCN, 0 
o
C, 2hrs, 100%  iv) SeO2, H2O, 1,4-dioxane, MWI, 30 min, 100 ˚C, 83 -85% 
 
Although, the brominated 3-acetylindoles 5.117 and 5.118 are not commercially available we 
anticipated that they could be synthesized from their respective indole-3-carboxaldehydes 5.119 and 
5.120.  The bromo indole-3-carboxaldehydes (5.119 and 5.120) were accordingly methylated to give 
the racemic secondary alcohols 5.121 and 5.122, by the anhydrous addition of methylmagnesium 
bromide.  The 1H NMR spectra showed that the synthesis of the secondary alcohol had been 
achieved in quantative yield, by the disappearance of the aldehyde peak (δH 10.04 and δH 10.03) and 
the appearance of a quartet (δH 5.13, δH 5.19) and a large doublet (δH 1.60, δH 1.65) corresponding to 
the oxymethine proton and methyl protons respectively in 5.121 and 5.122 (Figure 5.27).  The COSY 
NMR spectra of 5.121 and 5.122 both showed a correlation between H-1’ (δH 5.13, δH 5.19) and H-2’ 
(δH 1.60, δH 1.65) further indicating the successful methylation of 5.119 and 5.120.  Surprisingly, the 
5.119 R1=H R2=Br 
5.120 R1 =Br R2=H
  
 
5.121 R1=H R2=Br 
5.122 R1 =Br R2=H 
5.117 R1=H R2=Br 
5.118 R1 =Br R2=H 
5.132 R1=H R2=Br 
5.133 R1 =Br R2=H 
5.115 R1=H R2=Br 
5.116 R1 =Br R2=H 
5.130 R1=H R2=Br 
5.131 R1 =Br R2=H 
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secondary alcohols 5.121 and 5.122 rapidly degraded under ambient conditions, thus requiring 
oxidation soon after preparation. 
Two oxidation methods were attempted for the preparation of 5.117 and 5.118; the first involving 
tetrapropylammonium perruthenate (TPAP, Scheme 5.22) and the second manganese dioxide 
(MnO2, Scheme 5.24).       
OH
O
OH
HO
O
O
OH
O
1
5
H H
11
13
15
19
20
21
18
14
H
5.123 5.129  
Scheme 5.22: The oxidation of marrubenol (5.123) catalyzed by TPAP. Reagents and conditions:  TPAP, NMO, 
DCM, 4Å molecular sieves, RT, 3hrs 98% 
  
Tetrapropylammonium perruthenate (TPAP) oxidation was first tested on a trial compound viz the 
natural product marrubenol (5.123).  The TPAP salt consists of a tetrapropylammonium cation 
(5.124) and a ruthenium tetroxide anion (5.125) which acts a powerful oxidiser.  The catalytic cycle 
of the ruthenium tetroxide anion is illustrated in Scheme 5.23..  The ruthenium forms an ether 
(5.126) with an alcohol (5.127) with subsequent dehydrative removal of both the alcohol moiety and 
the oxymethine proton.  Anhydrous conditions are necessary for this reaction and the reaction is 
conducted over 4Å molecular sieves.   The ruthenium anion is then replenished through the addition 
of N-methylmorpholine-N-oxide (NMO, 5.128), resulting in the ruthenium tetroxide anion (5.125), 
continuing the catalytic cycle.             
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Scheme 5.23:  The catalytic cycle of the ruthenium tetroxide anion (5.125) in the TPAP reagent with the 
additive NMO (5.128).
465
 
 
The C-19 primary and C-6 secondary alcohols of 5.123 were successfully converted to the aldehyde 
and ketone respectively in a 98% yield, which can be clearly seen by the disappearance of the 
resonance (δC 65 and 69) in the 
13C NMR spectrum of 5.119 and the appearance of two deshielded 
signals (δC 211 and 209) in the 
13C NMR spectrum of 5.129 (Figure 5.26).        
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Figure 5.26:   The 
13
C NMR spectra (CDCl3, 150 MHz) of marrubenol (bottom) and 5.129 (above), the product 
after oxidation with TPAP.  The carbons of interest are labelled in accompanying figures.   
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Scheme 5.24:  The oxidation of 5.121 and 5.122 with manganese dioxide. Reagents and conditions:  MnO2, 
DCM, RT, 48 hrs, 100% 
 
While we established through the oxidation of a trial compound that TPAP would be a suitable 
oxidizing agent for the oxidation of 5.121 and 5.122, one major drawback of TPAP is its exorbitant 
cost and we decided to explore the use of the cheaper alternative, MnO2 for the oxidation 
30405060708090100110120130140150160170180190200210 ppm
C-6 
C-19 
C-9 
C-9 
C-19 
C-6 
OH
O
OH
HO
9
H
6
19
O
O
OH
O H
9
6
19
H
5.121 R1=H R2=Br 
5.122 R1 =Br R2=H
  
 
5.117 R1=H R2=Br 
5.118 R1 =Br R2=H
  
 
CDCl3 
CDCl3 
Chapter Five:  Marine Bisindole Alkaloids 
 
 
174 
(Scheme 5.24).  MnO2 is an effective oxidizing agent under mild conditions and has been widely used 
in our laboratory for oxidising benzylic alcohols.  A comparison of the 1H NMR of 5.121 and 5.117 
shows the methyl doublet (δH 1.60) becomes a singlet with the successful removal of the 
oxymethine proton (δH 5.13) during oxidation (Figure 5.27). 
 
 
Figure 5.27:   The 
1
H NMR spectra (CD3OD, 600MHz) of 5.119 (top), 5.121 (middle) and 5.117 (bottom), the 
product after oxidation with MnO2.  The protons of interest labelled in accompanying figures.  
 
 
The N-Boc protection of 5.117 and 5.118 afforded 5.130 and 5.131 respectively in quantitative yield.  
Interestingly, during the preparation of the equilibrium mixtures of glyoxals (5.115 and 5.116) and 
glyoxal monohydrate (5.132 and 5.133), we did encounter a minor problem in that partial 
deprotection of these compounds occurred resulting in complex mixtures of N-Boc protected and 
deprotected glyoxals (Scheme 5.25).  The reason for the formation of the carbamate was to ensure 
the methyl ketone was not over oxidised to the glyoxylic acid by SeO2.  However, the emergence of 
four new singlets in the downfield region (δH 9.5-13.0) of the 
1H NMR spectrum of the reaction 
mixture of the SeO2 oxidation of 5.130 and 5.131, indicated the formation of two glyoxals, 
corresponding to the N-Boc protected as well as the deprotected glyoxal e.g. 5.115 and 5.134.   The 
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remaining two signals in the downfield region were broad corresponding to the protonated N-1 of 
the indole ring in the deprotected glyoxal (5.134) and deprotected glyoxal monohydrate (5.135).  
The successful oxidation to the glyoxal suggests that the thermal mediated removal of the 
carbamate ester occurs post oxidation.  The mixture of glyoxals (5.115, 5.132, 5.134 and 5.135) was 
taken forward in the synthesis of 5.20 and 5.34.    
N
O
Boc
2'
3a
H
O
N
O
Boc
1'
2
OH
OH
5.115 5.132
N
O
Boc
1'4
5.130
Br
BrBr
N
H
O 2'
3a
H
O
N
H
O
1'
2
OH
OH
5.134 5.135
BrBr
+
 
Scheme 5.25: The microwave assisted selenium oxidation of 5.130.  Reagents and conditions:  SeO2, H2O, 
1,4-dioxane, MWI, 30 min, 100 ˚C, 83-85% 
 
The dehydrative condensation of the 5- or 6- brominated glyoxal mixture afforded an inseparable 
mixture of mono and deprotected topsentin products (Scheme 5.26).  This was confirmed by HRMS 
revealing peaks at m/z = 482.9461 and 582.9989 corresponding to the [M+H]+ pseudo molecular ions 
of compound 5.20 and 5.136 or 5.137.  Interestingly, for both the 5- and 6- brominated imidazoles, 
no diprotected species were detected.  It was at this point that I was required to finish my laboratory 
research and further examination of this synthetic approach to 5.20, 5.138-5.140 continues in our 
laboratory.             
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Scheme 5.26: Formation of the imidazole rings from a mixture of glyoxals (5.115 and 5.134).  Reagents and 
conditions: NH4OAc, EtOH, RT, 6 hrs 
 
5.5. Conclusion 
 
In this Chapter we have reviewed past syntheses of the topsentin class of marine bisindoles.  Our 
microwave based synthetic approach provides a simple, quick and high yielding route to the 
synthesis of the sponge metabolite deoxytopsentin (5.33) and the ascidian metabolite 5.111.  With 
the use of MAO synthesis we have optimized the classic SeO2 oxidation reaction in aryl methyl 
ketones as well as providing an efficient and rapid method for the removal of the Boc protecting 
group.  We have also managed to assign the NMR data for major and minor tautomers of the 
imidazole containing compounds, which many authors have failed to report in the past.   
Further work will be to continue the SAR study of halogenated bisindole compounds with the 
synthesis of 5.138-5.140.  The bisindole alkaloids 5.20, 5.33, 5.34 and 5.138-5.140 will hopefully be 
sent to UBC where they will be tested for their ability to selectively inhibit MRSA PK.                
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6.1. General Procedures 
6.1.1. Analytical 
 
(i) Melting points were determined using a Reichert hot stage microscope and are uncorrected. 
  
(ii) Optical rotations were measured using a Perkin-Elmer 141 polarimeter calibrated at the 
sodium D line (598 nm).   
 
(iii) Infrared spectra were recorded on a Perkin Elmer Spectum 2000 FT-IR and DIGILAB Excalibur 
HE Series FTS 3100 FT-IR spectrometer.    
 
(iv) NMR spectra were acquired on Bruker 400 MHz Avance and 600 MHz Avance II spectrometers 
using standard pulse sequences.  Chemical shifts are reported in ppm, referenced to residual 
solvent resonances (CDCl3 H 7.25, C 77.0; DMSO-D6 H 2.50, C 39.50; CD3OD H 3.31, C 49.00 
ppm), and coupling constants are reported in Hz.  
 
(v) The UV/vis absorbances were measured on a Varian Carrey 1E with sample solutions 
contained in a quartz cuvette. 
 
(vi) HREIMS and HRFABMS data were acquired at the University of Stellenbosch and North West 
University respectively.  MALDI-TOF mass data was acquired with a Bruker AutoFLEX III 
Smartbeam TOF/TOF Mass spectrometer. The instrument was operated in positive ion mode 
using an m/z range of 400 – 3000. The voltage of the ion sources were set at 19 and 16.7 kV 
for ion sources 1 and 2 respectively, while the lens was set at 8.50 kV. The voltages for 
reflectors 1 and 2 were set at 21 and 9.7 kV respectively. The spectra were acquired using α-
cyano-4-hydroxycinnamic acid as the MALDI matrix, using a 354 nm Nd:YAG laser. 
 
(vii) Full intensity data for crystals was collected on a Nonius Kappa CCD diffractometer with the 
crystals cooled in a steady nitrogen stream at -100 oC.  The crystal structures were solved by 
Professor Caira at the University of Cape Town using direct methods and were fully refined by 
the least-squares technique.  All H atoms attached to C were located and inserted in idealized 
positions.  All hydroxyl H atoms were located and inserted with idealized O-H bonding 
distances at their optimised positions consistent with the observed hydrogen bonding 
patterns.   
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(viii) X-ray powder diffraction patterns were recorded on a Bruker D8, Discover equipped with a 
proportional counter, using Cu-Kα radiation (λ = 1.5405 Å, nickel filter). Data were collected in 
the range from 2θ = 5° to 30°, scanning at 1° min-1 with a filter time-constant of 2.5 s per step 
and a slit width of 6.0 mm.  Samples were placed on a silicon wafer slide.   
 
(ix) TGA analysis was done on a TA Q600 heating the sample from room temperature to 200 °C at 
5 °C min−1 under N2 gas. The simultaneous MS analysis of the decomposition gases was done 
using a Pfeifer Thermostar®.   
 
(x) The compounds were prepared for SEM by coating them in gold using a Balzers’ Spluttering 
device.  The compounds were viewed using a Tescan Vega scanning electron microscope at 20 
kV and a working distance of 20mm. 
 
6.1.2. Chromatography 
 
(i) Reactions were monitored by thin layer chromatography (DC-Plastikfolien Kieselgel 60 F254 
plates) and visualized under UV light (254 nm) and developed by spraying with either 10% 
conc. H2SO4 in methanol or iodine adsorbed on silica gel.    Reversed phase thin layer 
chromatography was performed on DC-Ferigplatten RP18 F245 plates.  Plates were viewed 
under UV light (254 nm). 
 
(ii) Kieselgel 60 (230-400 mesh) was used for initial flash chromatographic separations.   
 
(iii) Semi-preparative NP-HPLC was performed using a Whatman’s Magnum 9 Partisil 10 column 
(10 mm i.d., length 50 cm); RP-HPLC was performed using an Onyx Monolithic C18 column 
(10 mm i.d., length 10 cm), with a Waters 410 Differential Refractometer detector or a 
Waters 2414 Refractive Index Detector and an eluent flow rate of 4 mL.min-1 using a Spectra-
Physics Spectra-Series P100 or a Waters 1500-Series isocratic pump.  
 
(iv) Glyoxal and methylketones were separated by an Agilent 6820 GC system using a J & W 
Scientific DB 225 column with an internal diameter of 250 µm and a length of 30 m.  The 
oven was preheated to 50 oC and then heated at a rate of 5 oC.min-1 to a final temperature of  
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220 oC.  The carrier gas was helium administered at a flow rate of 1 ml.min-1.  The 
compounds eluted were detected using FID.     
 
6.1.3. Synthesis 
 
(i) Reactions where exclusion of water was necessary were performed using glassware dried in 
a 150 °C oven overnight or dried at 600 °C with a heatgun and flushed with dry argon to 
remove air and moisture. All reactions were performed under an atmosphere of dry Ar.   
 
(ii) Dry solvents were prepared by standard procedures outlined by Perrin and Amerego.466 
Immediately prior to their use THF was distilled from sodium metal/ benzophenone ketyl 
while Et2O, CH2Cl2 and MeCN were distilled from calcium hydride and all solvents were 
stored over 4 Å molecular sieves under anhydrous argon.  General laboratory solvents were 
distilled before use.   All reactions were magnetically stirred.  All reagents were commercially 
available. 
 
(iii) Microwave reactions were carried out in a CEM Discover single-mode microwave apparatus, 
producing controlled irradiation at 2450 MHz, using standard 10 mL silicon-septum sealed 
glass pressure vials.  The reactions were optimized using the temperature-time mode of 
operation and the temperature was monitored using an IR sensor directed at the outside 
wall of the reaction vial.  Once the reaction was complete the reaction vessel was cooled to 
50 oC by means of propelled airflow.   
 
6.1.4. Molecular Modelling 
 
(i) Where a X-ray crystal structure was unavailable, Accelrys Visualizer21 was used to construct 
the 3-D models of compounds and exported in .mol2 format.  A spin restricted DFT structural 
optimization, using the Gaussian03443 suite of algorithms was performed on each structure.  
The parameters for the DFT runs were the 6-31G(d) basis set while the electronic correlation 
energy was determined using the B3LYP functional.  The calculations were run on a multi-
processor Linux cluster with multi-threading capabilities.  Docking studies will be discussed in 
detail in Section 6.3.3. 
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6.2. Chapter 3 experimental details 
6.2.1. Preparation  of 3.189, 3.190, 3.194 and 3.188 
H
HO
H
CHO
PCC, CH2Cl2
RT, 26 h
3.187 3.189 (E)
3.190 (Z)
19
13
8
18
20
4
10
13
16
15
17
16
 
 
(+)-Manool (3.187, 4.455 g, 15.36 mmol) was dissolved in CH2Cl2 (200 mL), pyridinium 
chlorochromate (PCC) (10.964 g, 50.76 mmol, 3.3 equiv.) was added to solution and stirred (26 h) at 
ambient temperature.  Diethyl ether (200 mL) was added, resulting in the formation of an orange 
precipitate.  The solution was filtered through a Celite 545 plug and the filtrate concentrated under 
reduced pressure, to yield a dark brown oil.  The oil was purified by silica flash chromatography (5 % 
EtOAc, 95 % hexane) to afford and inseparable mixture of (E)-labda-8(17)dien-15-al (3.189) and (Z)-
labda-8(17)dien-15-al (3.190) in a 2:1 ratio (3.897 g, 88% yield) as a yellow oil.  1H and 13C NMR data 
consistent with literature values;467 HRFABMS: calcd for C20H33O1 289.2531. Found 289.2531, Δamu 
0.0000.248 
6.2.2. Intramolecular aldol condensation of 3.189 and 3.190 
 
H
CHO
O
H
O
i) O3, CH2Cl2, -78 
oC
ii) PPh3, CH2Cl2, RT
3.189 (E)
3.190 (Z)
3.194
8
13
16
13
6
1120
19 18
1
3
 
The isomeric mixture of 3.189 and 3.190 (500 mg, 1.75 mmol) was dissolved in CH2Cl2 (25 mL) and 
cooled in a dry ice and acetone slurry to -78 oC.  A steady stream of ozone was bubbled through the 
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solution (20 min) until the solution turned a pale blue colour.  Nitrogen was bubbled through the 
solution to ensure the removal of excess O3.  Triphenylphosphine (3.3 g, 10.5 mmol, 6 equiv.) was 
added to the solution where it was allowed to stir for 4 hours at room temperature.  Hydrogen 
peroxide (10 mL, 30%) was added to the cooled solution (0 oC) and stirring was continued (0.5 h).  
The organic solution was washed with water (3 × 5 mL) and the organic extracts dried with MgSO4 
and concentrated.  The organic fractions were further purified via silica flash chromatography (50% 
EtOAc, 50% hexane) to afford 3.194 (352 mg, 76 %).  
6.2.3.  Cyclization of 3.194 to afford 3.188 
 
15,16,17-Trisnorlabdane-8,13-dione (3.194)467-469: yellow oil; *α+D
20 -28 (c 1.3, CHCl3, lit -11, c 1.05)
468; 
IR (film) νmax 2940, 1709, 1698, 1355, 1164 cm
-1; 1H  NMR (400 MHz, CDCl3) δ 2.56 (ddd, J = 17.4, 8.3, 
5.3, H-12a, 1H), 2.38 (ddd, J= 13.3, 4.8, 2.0, H-7b, 1H), 2.24 (m, H-7a, 1H), 2.17 (m, H-12a, 1H), 2.07 
(s, H-16, 3H), 2.04 (m, H-9, 1H), 2.01 (m, H-6b, 1H), 1.79 (m, H-1b, 1H), 1.76 (ddd, J = 10.7, 5.3, 2.9, H-
11b, 1H), 1.61 (m, H-6a, 1H), 1.59 (m, H-11a, 1H), 1.51 (m, H2-2, 2H), 1.46 (dd, J = 12.9, 2.8, H-5, 1H), 
1.42 (m, H-3b, 1H), 1.21 (m, H-1a and H-3a, 2H), 0.93 (s, H3-18, 3H), 0.82 (s, H3-19, 3H), 0.70 (s, H3-20, 
3H); 13C NMR (CDCl3, 100 MHz) δ 212.3 (q, C-8), 209.2 (q, C-13), 63.1 (CH, C-9), 54.1 (CH, C-5), 42.8 
(CH2, C-12), 42.7 (q, C-10), 42.6 (CH2, C-7), 41.8 (CH2, C-3), 39.1 (CH2, C-1), 33.7 (q, C-4), 33.5 (CH3, C-
18), 29.9 (CH3, C-16), 23.9 (CH2, C-6), 21.7 (CH3, C-19), 19.0 (CH2, C-2), 16.1 (CH2, C-11), 14.5 (CH3, C-
20); HRFABMS: calcd for C17H28O2 265.2168. Found 265.2168, Δamu 0.0000. 
 
O
H
O
H
O
OH
NaH, THF
3.194 3.188
RT, 4 h
20
14
88
16
2
1819
 
 
 The diketone (3.194) (1.12 g, 4.2 mmol) was dissolved in dry THF (5 mL), NaH (0.49 g, 12.7 mmol, 
3 equiv.) added and the solution stirred under argon (4 h).  The reaction mixture was quenched with 
sat. aq. NH4Cl and extracted with Et2O (3 x 10 mL).  The diethyl ether extracts were combined, 
washed with water (2 x 5 mL), sat. brine (1 x 5 mL) and dried over anhydrous MgSO4.  The diethyl 
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ether was removed in vacuo and the resultant yellow oil crystallized from 20% CH2Cl2 80% hexane to 
yield white needles of 3.188 (893 mg, 80%): 
8β-Hydroxy-13-podocarpanone (3.188):  white needles; mp 201-203 oC, lit. 204-205 oC470; *α+D
23 +9.8 
(c 0.4, CHCl3, lit. +11.6, c 2.2, CHCl3)
471; IR (film) νmax 3434 (br.), 3019, 2926, 1215, 756, 668 cm
-1; 1H 
NMR (600 MHz, CDCl3) δ 2.42 (m, H-12a, 1H), 2.35 (d, J = 14.4, H-14β, 1H), 2.26 (m, H-12b, 1H), 2.23 
(d, J = 14.4, H-14α, 1H), 1.92, (m, H2-11, 2H),  1.76 (m, H-1a, 1H), 1.71 (m, H-7β, 1H), 1.60 (m, H-2a, 
1H), 1.56 (m, H2-6, and H-7α, 3H), 1.41 (m, H-2b and H-3β, 2H), 1.40 (m, H-9, 1H), 1.16 (td, J = 13.2, 
4.4, H-3α, 1H), 0.98 (s, H3-17, 3H), 0.94 (m, H-1a and H-5, 2H), 0.88 (s, H3-15, 3H), 0.85 (s, H3-16, 3H); 
13C NMR (150 MHz, CDCl3) δ = 210.7 (q, C-13) 75.5 (q, C-8), 57.3 (CH2, C-14), 56.1 (CH, C-5), 55.3 (CH, 
C-9), 42.2 (CH2, C-7), 42.0 (CH2, C-3), 41.5 (CH2, C-12), 39.8 (CH2, C-1), 37.5 (q, C-10), 33.6 (CH3, C-15), 
33.3 (q, C-4), 21.8 (CH3, C-16), 21.4 (CH2, C-11) , 18.4 (CH2, C-2), 17.9 (CH2, C-6), 15.3 (CH3, C-17) ; 
EIMS m/z (rel. int.) 264 [M+] (32), 250 (19), 249 (100), 179 (27), 123 (25) ; HREIMS (70 eV): calcd for 
C17H28O2 264.2089. Found 264.2083, Δamu 0.0006. 
 
6.2.4. Grignard alkylation of 3.188 
H
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OH
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RMgX, CeCl3
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The following method is representative for the preparation of compounds 3.203-3.207 and 3.209- 
3.212.  A suspension of anhydrous CeCl3 (137 mg, 0.57 mmol, 1.5 equiv.) in dry THF (5 mL) was 
stirred under argon at ambient temperature (2 h), subsequently cooled to 0 oC and an aliquot (1.89 
mL, 0.57 mmol, 1.5 equiv.) of a THF solution of methylmagnesium bromide (3.0 M) added.  The 
suspension was stirred (0 oC, 1.5 h) and a solution of 3.188 (100 mg, 0.38 mmol) in dry THF (2 mL) 
added.  Stirring was continued (0 oC, 1 h) and the reaction mixture gradually allowed to reach room 
temperature (8 h) before quenching with sat. aqueous NH4Cl (5 mL) and extracted with Et2O (3 x 5 
mL).  The combined diethyl ether fractions were washed with water (2 x 5 mL) and sat. brine (1 x 5 
mL).  The organic portion was dried over anhyd. MgSO4, filtered and concentrated under reduced 
pressure to yield a yellow oil.  Further purification of the yellow oil via normal phase semi-
preparative HPLC (20% EtOAc, 80% hexane) afforded a white solid which was recrystallized from 
MeOH to give white prisms of 3.203 (73 mg, 57%): 
 
8β, 13β-Dihydroxy-13α-methylpodocarpane (3.203):  white prisms from MeOH; mp 157-159 oC; 
*α+D
23 −3.2 (c 0.5, CH2Cl2); IR (film) νmax 3311 (br.), 2945, 1462, 1216, 1135, 780 cm
-1; 1H NMR (600 
MHz, CDCl3) δ 1.77 (ddd, J = 13.3, 7.2, 3.1, H-12a, 1H), 1.73 (dt, J = 13.3, 3.3 Hz, H-7β, 1H), 1.71 (m, H-
11a and H-1a, 2H), 1.62 (td, J = 14.0, 2.8, H-14β, 1H), 1.61 (m, H-2a, 1H), 1.51 (m, H2-6, 2H), 1.49 (m, 
H-11b, 1H), 1.39 (m, H-3β, 1H), 1.37 (m, H-2b, 1H), 1.33 (td, J = 14.2, 4.4, H-12b, 1H), 1.30 (m, H-7α, 
1H), 1.28 (m, H-14α, 1H), 1.15 (s, H3-1’, 3H), 1.13 (td, J = 12.9, 4,3, H-3α, 1H), 1.00 (s, H3-17, 3H), 0.85 
(s, H3-15, 3H), 0.84 (s, H3-16, 3H), 0.83 (m, H-5 and H-9, 2H), 0.80 (m, H-1b, 1H); 
13C NMR (150 MHz, 
CDCl3) δ 73.2 (q, C-8), 71.0 (q, C-13), 56.4 (CH, C-5), 56.2 (CH, C-9), 51.1 (CH2, C-14), 42.1 (CH2, C-7), 
42.0 (CH2, C-3), 39.8 (CH2, C-12), 39.5 (CH2, C-1), 37.2 (q, C-10), 33.6 (CH3, C-15), 33.3 (q, C-4), 30.9 
(CH3, C-1’), 21.7 (CH3, C-16),  18.4 (CH2, C-2), 17.7 (CH2, C-6), 16.7 (CH2, C-11), 15.4 (CH3, C-17); EIMS 
m/z (rel. int.) 280 [M+] (13), 262 (82), 244 (38), 179 (75), 126 (54); HREIMS (70 eV): calcd for 
C18H32O2 280.2402. Found 280.2392 Δamu = 0.0010.  
To the suspension of anhydrous CeCl3 an aliquot (5.67 mL, 0.57 mmol, 1.5 equiv.) of a THF solution 
of phenylmagnesium bromide (1.0M) was added.  A yellow oil obtained from the procedure vide 
supra was purified via normal phase semi-preparative HPLC (25% EtOAc, 75% hexane) to afford a 
white solid which was recrystallized from MeOH to give white orthorhombic crystals of 3.204 (38 
mg, 34%). 
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8β, 13β-Dihydroxy-13α-phenylpodocarpane (3.204):  white orthorhombic crystals from MeOH, mp 
161-164 oC; *α+D
23 −14.4 (c 0.6, CH2Cl2); IR (film) νmax 3317 (br.), 2401, 1661, 1216, 757, 668 cm
-1; 
1H NMR (600 MHz, CDCl3) δ 7.46 (d, J = 7.8, H-2’ and H-6’, 2H), 7.33 (t, J = 7.4, H-3’ and H-5’, 2H), 
7.23 (t, J = 7.3, H-4’, 1H), 1.95 (m, H-12a, 1H), 1.86 (m, H-12b, 1H) 1.81 (dd, J = 14.3, 2.7, H-14β, 1H), 
1.76 (m, H-1a, 1H), 1.74 (m, H-7β, 1H), 1.68 (d, J = 14.2, H-14α, 1H), 1.65 (m, H-11b, 1H), 1.64 (m, H-
2a, 1H), 1.55 (m, H2-6, 2H), 1.43 (m, H-2b, 1H), 1.41 (m, H-3β, 1H), 1.36 (td, J = 13.3, 4.6 Hz, H-7α, 
1H), 1.16 (td, J = 13.6, 3.9, H-3α, 1H), 1.06 (s, H3-17, 3H), 1.04 (m, H-9, 1H) 0.90 (dd, J = 11.3, 3.4, H-5, 
1H), 0.88 (m, H-1b, 1H), 0.88 (s, H3-15, 3H), 0.86 (s, H3-16, 3H); 
13C NMR (150 MHz, CDCl3) δ 148.3 (q, 
C-1’), 128.2 (2 x CH, C-3’ and C-5’), 126.7 (CH, C-4’), 124.4 (2 x CH, C-2’ and C-6’), 74.5 (q, C-13), 73.5 
(q, C-8), 56.4 (CH, C-5), 56.2 (CH, C-9), 51.4 (CH2, C-14), 42.2 (CH2, C-3) 42.1 (CH2, C-7), 39.8 (CH2, C-
12), 39.5 (CH2, C-1), 37.3 (q, C-10), 33.6 (CH3, C-15), 33.3 (q, C-4), 21.7 (CH3, C-16), 18.4 (CH2, C-2), 
17.7 (CH2, C-6), 16.9 (CH2, C-11), 15.5 (CH3, C-17); EIMS m/z (rel. int.) 324 [M
+] (50), 306 (24), 179, 
(22), 175 (100), 105 (83); HREIMS (70 eV): calcd for C23H34O2 324.2559. Found 324.2579 Δamu 0.002. 
 
To the suspension of anhydrous CeCl3 an aliquot (2.84 mL, 0.57 mmol, 1.5 equiv.) of a THF solution 
of isopropylmagnesium chloride (2.0M) was added.  A yellow oil obtained from the procedure vide 
supra was purified via normal phase semi-preparative HPLC (33% EtOAc, 67% hexane) to afford 
3.205 as white needles from MeOH (23 mg, 20%). 
 
8β, 13β-Dihydroxy-13α-iso-propylpodocarpane (3.205): white needles from MeOH, mp 132-136 oC; 
*α+D
23 −16.1 (c 0.4, CH2Cl2); IR (film) νmax 3303 (br.), 2946, 1702, 1451, 1190, 757 cm
-1; 1H NMR (600 
MHz, CDCl3) δ 1.76 (m, H-7β, 1H), 1.72 (m, H-12a, 1H), 1.71 (m, H-1a and H-11a, 2H), 1.62 (m, H-2a, 
1H), 1.56 (dd, J = 14.1, 3.0, H-14β, 1H), 1.52 (m, H2-6, H-11b and H-1’, 4H), 1.39 (m, H-2b and H-3β, 
2H), 1.33 (m, H-12b, 1H), 1.30 (td, J = 13.3, 5.1, H-7α, 1H), 1.25 (d, J = 14.1, H-14α, 1H), 1.13 (td, J = 
14.0, 3.8, H-3α, 1H), 1.00 (s, H3-17, 3H), 0.88 (d, J = 7.0, H3-2’ and H3-3’, 6H), 0.87 (s, H3-15, 3H), 0.84 
(m, H-9, 1H), 0.84 (s, H3-16, 3H), 0.82 (m, H-1b, 1H), 0.81 (m, H-5, 1H); 
13C NMR (150 MHz, CDCl3) δ 
75.2 (q, C-13), 73.2 (q, C-8), 56.7 (CH, C-5), 56.6 (CH, C-9), 46.5 (CH2, C-14), 42.6 (CH2, C-3) 42.3 (CH2, 
C-7), 39.7 (CH2, C-1), 37.4 (q, C-10), 38.6 (CH, C-1’), 35.0 (CH2, C-12), 33.7 (CH3, C-15), 33.4 (q, C-4), 
21.8 (CH3, C-16),  18.4 (CH2, C-2), 17.9 (CH2, C-6), 16.9 (CH3, C-3’), 16.8 (CH3, C-2’), 16.5 (CH2, C-11), 
15.6 (CH3, C-17); EIMS m/z (rel. int.) 308 [M
+] (28), 265 (50), 248, (35), 247 (100), 141 (30); HREIMS 
(70 eV): calcd for C20H36O2 308.2715. Found 308.2717 Δamu 0.0002. 
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To the suspension of anhydrous CeCl3 an aliquot (2.84 mL, 0.57 mmol, 1.5 equiv.) of a THF solution 
of isobutylmagnesium bromide (2.0M) was added.  A yellow oil obtained from the procedure vide 
supra was purified via normal phase semi-preparative HPLC (17% EtOAc, 83% hexane) to yield 3.206 
as white needles from MeOH (31 mg, 27%). 
 
8β, 13β-Dihydroxy-13α-iso-butylpodocarpane (3.206):  white needles from MeOH,  mp 138-140 oC; 
*α+D
33 −12.1 (c 0.4, CH2Cl2); IR (film) νmax 3473 (br.), 1640, 1215, 1034, 750, 667 cm
-1;  1H NMR (600 
MHz, CDCl3) δ 1.83 (non, J = 6.5, H-2’, 1H), 1.79 (m, H-12a, 1H), 1.74 (m, H-7β, 1H), 1.71 (m, H-1a and 
H-11a, 2H), 1.66 (dd, J = 14.0, 2.8, H-14β, 1H), 1.61 (m, H-2a, 1H), 1.51 (m, H2-6, 2H), 1.50 (m, H-11b, 
1H), 1.39 (m, H-2b and H-3β, 2H), 1.31 (m, H-12b, 1H), 1.30 (m, H-7α and H-1’, 2H), 1.24 (d, J = 14.0, 
H-14α, 1H), 1.13 (td, J = 13.8, 4.0, H-3α, 1H), 1.01 (s, H3-17, 3H), 0.94 (t, J = 6.2, H3-3’ and H3-4’, 6H), 
0.86 (s, H3-15, 3H), 0.85 (m, H-5 and H-9, 2H), 0.84 (s, H3-16, 3H), 0.81 (m, H-1b, 1H); 
13C NMR (150 
MHz, CDCl3) δ  73.8 (q, C-13), 73.2 (q, C-8), 56.7 (CH, C-9), 56.6 (CH, C-5), 52.9 (CH2, C-1’), 50.0 (CH2, 
C-14), 42.5 (CH2, C-7), 42.3 (CH2, C-3), 39.7 (CH2, C-1), 38.9 (CH2, C-12), 37.4 (q, C-10), 33.7 (CH3, C-
15), 33.5 (q, C-4), 25.2 (CH3, C-3’), 25.1 (CH3, C-4’), 23.5 (CH, C-2’),  21.8 (CH3, C-16),  18.6 (CH2, C-2), 
17.9 (CH2, C-6), 16.5 (CH2, C-11), 15.6 (CH3, C-17); EIMS m/z (rel. int.) 322 [M
+] (8), 304 (42), 289, 
(47), 286 (100), 271 (50); HREIMS (70 eV): calcd for C21H38O2 322.2872. Found 322.2865 Δamu 0.0007 
 
Purification of the product mixture afforded from the preparation of 3.206 via normal phase semi-
preparative HPLC (33% EtOAc, 67% hexane), also yielded 3.207 as white monoclinic crystals from 
MeOH (18 mg, 19%): 
 
8β, 13β-Dihydroxypodocarpane (3.207): white monoclinic crystals  from MeOH, mp 157-160 oC; 
*α+D
33 −16.9 (c 0.5, CH2Cl2); IR (film) νmax 3430 (br.), 3020, 1637, 1214, 754, 670 cm
-1; 1H NMR (600 
MHz, CDCl3) δ 4.07 (br. s, H-13, 1H), 3.09 (br. s, OH), 2.70 (br. s, OH), 1.94 (quin, J = 13.1, 2.6 Hz, H-
12β, 1H), 1.81 (dt, J = 14.3, 2.6, H-14β, 1H), 1.76 (m, H-11a, 1H), 1.74 (m, H-7β, 1H), 1.71 (m, H-1a, 
1H), 1.62 (t, J = 3.45, H-2a, 1H), 1.49 (m, H-6a, 1H), 1.48 (m, H-11b, 1H), 1.46 (m, H-12α, 1H), 1.39 (m, 
H-14α, 1H), 1.38 (m, H-2b and H-3β, 2H), 1.33 (m, H-6b, 1H), 1.31 (m, H-7α, 1H), 1,13 (td, J  = 13.5, 
4.1, H-3α, 1H), 1.00 (s, H3-17, 3H), 0.94 (dd, J = 12.6, 2.8, H-9, 1H), 0.87 (s, H3-15, 3H), 0.83 (m, H-5, 
1H), 0.83 (s, H3-16, 3H), 0.82 (td, J = 13.1, 3.6, H-1b, 1H), 0.81 (m, H-5, 1H); 
13C NMR (150 MHz, CDCl3) 
δ 73.4 (q, C-8), 67.7 (CH, C-13), 56.3 (CH, C-5), 56.5 (CH, C-9), 45.5 (CH2, C-14), 42.2 (CH2, C-3) 42.1 
(CH2, C-7), 39.4 (CH2, C-1), 37.3 (q, C-10), 33.9 (CH2, C-12), 33.5 (CH3, C-15), 33.3 (q, C-4), 21.7 (CH3, C-
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16),  18.4 (CH2, C-2), 17.6 (CH2, C-6), 15.4 (CH3, C-17), 14.9 (CH2, C-11); EIMS m/z (rel. int.) 266 [M
+] 
(49), 251 (41), 233, (75), 180 (17), 179 (100); HREIMS (70 eV): calcd for C20H36O2 266.2246. Found 
266.2239  Δamu 0.0007. 
 
To the suspension of anhydrous CeCl3 an aliquot (5.67 mL, 0.57 mmol, 1.5 equiv.) of a THF solution 
of 4-chlorophenylmagnesium bromide (1.0 M) was added.  A yellow oil obtained from the procedure 
vide supra was purified via normal phase semi-preparative HPLC (20% EtOAc, 80% hexane) to afford 
a white solid which was recrystallized from MeOH to give white orthorhombic crystals of 3.209 (91 
mg, 64%). 
 
8β, 13β-Dihydroxy-13α-4´-chlorophenylpodocarpane (3.209):  white needles from MeOH (64% yield), 
mp 182-184 oC; *α+D
23 −94.7 (c 1.1, CHCl3); IR (film) νmax 3272 (br.), 2945, 1441, 1093, 812, 758 cm
-1; 
1H NMR (600 MHz, CDCl3) δ 7.40 (d, J = 8.6 Hz, H-2’ and H-6’, 2H), 7.28 (d, J = 8.5, H-3’ and H-5’, 2H), 
1.90 (m, H-12a, 1H), 1.89 (m, 11a, 1H), 1.83 (m, H-12b, 1H) 1.76 (m, H-14β, 1H), 1.75 (m, H-1a, 1H), 
1.74 (m, H-7β, 1H), 1.66 (m, H-14α, 1H), 1.65 (m, H-11b, 1H), 1.63 (m, H-2a, 1H), 1.55 (m, H2-6, 2H), 
1.42 (m, H-7α, 1H), 1.41 (m, H-2b and H-3β, 2H), 1.14 (td, J = 13.6, 4.5, H-3α, 1H), 1.04 (s, H3-17, 3H), 
1.04 (m, H-9, 1H) 0.89 (m, H-5, 1H), 0.87 (m, H-1b, 1H), 0.87 (s, H3-15, 3H), 0.85 (s, H3-16, 3H); 
13C 
NMR (150 MHz, CDCl3) δ 147.1 (C, C-1’), 132.6 (C, C-4’), 128.4 (2 x CH, C-3’ and C-5’), 126.3 (2 x CH, C-
2’ and C-6’), 74.2 (C, C-13), 74.1 (C, C-8), 56.6 (CH, C-5), 56.3 (CH, C-9), 51.7 (CH2, C-14), 42.4 (CH2, C-
3) 42.2 (CH2, C-7), 40.1 (CH2, C-12), 39.6 (CH2, C-1), 37.5 (C, C-10), 33.7 (CH3, C-15), 33.5 (C, C-4), 21.9 
(CH3, C-16), 18.6 (CH2, C-2), 17.8 (CH2, C-6), 17.0 (CH2, C-11), 15.7 (CH3, C-17); EIMS m/z (rel. int.) 376 
[M+] (14), 358 (32), 340, (51), 211 (40), 209 (100); HREIMS (70 eV): calcd for C23H33O2Cl 376.2169. 
Found 376.2158  Δamu 0.0011. 
 
To the suspension of anhydrous CeCl3 an aliquot (11.4 mL, 0.57 mmol, 1.5 equiv.) of a THF solution 
of 3-chlorophenylmagnesium bromide (0.5 M) was added.  A yellow oil obtained from the procedure 
vide supra was purified via normal phase semi-preparative HPLC (20% EtOAc, 80% hexane) to afford 
a white solid which was recrystallized from MeOH to give white orthorhombic crystals of 3.209 (77 
mg, 54%). 
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8β, 13β-Dihydroxy-13α-3´-chlorophenylpodocarpane (3.210):  white needles from MeOH (54% yield), 
mp 199-201 oC; *α+D
23 −6.3 (c 0.6, CHCl3); IR (film) νmax 3267 (br.), 2919, 1435, 1204, 772, 692 cm
-1; 
1H NMR (600 MHz, CDCl3) δ 7.48 (t, J = 1.9, H-2’, 1H), 7.34 (dt, J = 7.9, 1.1, H-4’, 1H), 7.24 (t, J = 7.9, 
H-5’, 1H), 7.19 (ddd, J = 8.0, 1.9, 1.0, H-6’, 1H) 1.91 (m, H-12a, 1H), 1.89 (m, H-11a, 1H) 1.81 (m, H-
12b, 1H), 1.77 (m, H-14a, 1H), 1.76 (m, H-1a, 1H), 1.74 (m, H-7a, 1H), 1.66 (m, H-14b, H-11b, 2H), 
1.64 (s, H-2a, 1H), 1.54 (m, H2-6, H-7b 3H), 1.44 (m, H-2b, 1H), 1.41 (m, H-3β, 1H), 1.16 (td, J = 14.4, 
4.5, H-3α, 1H), 1.04 (s, H3-17, 3H), 1.04 (m, H-9, 1H) 0.90 (m, H-5, 1H), 0.87 (m, H-1b, 1H), 0.87 (s, H3-
15, 3H), 0.85 (s, H3-16, 3H); 
13C NMR (150 MHz, CDCl3) δ 150.5 (C, C-1’), 134.1 (C, C-3’), 129.4 (CH, 5’), 
126.7 (CH, 6’), 125.1 (CH, 2’), 122.7 (CH, 4’), 74.0 (C, C-13), 73.9 (C, C-8), 56.3 (CH, C-5), 56.1 (CH, C-
9), 51.4 (CH2, C-14), 42.1 (CH2, C-3) 42.0 (CH2, C-7), 39.8 (CH2, C-12), 39.4 (CH2, C-1), 37.2 (C, C-10), 
33.5 (CH3, C-15), 33.3 (C, C-4), 21.6 (CH3, C-16), 18.3 (CH2, C-2), 17.5 (CH2, C-6), 16.8 (CH2, C-11), 15.5 
(CH3, C-17); EIMS m/z (rel. int.) 376 [M
+] (9), 340 (100), 209, (79), 204 (68), 137 (60); HREIMS (70 eV): 
calcd for C23H33O2Cl 376.2169. Found 376.2148  Δamu 0.0011. 
 
To the suspension of anhydrous CeCl3 an aliquot (2.85 mL, 0.57 mmol, 1.5 equiv.) of a THF solution 
of 4-fluorophenylmagnesium bromide (2.0 M) was added.  A yellow oil obtained from the procedure 
vide supra was purified via normal phase semi-preparative HPLC (20% EtOAc, 80% hexane) to afford 
a white solid which was recrystallized from MeOH to give white orthorhombic crystals of 3.209 (71 
mg, 52%). 
 
8β, 13β-Dihydroxy-13α-4´-fluorophenylpodocarpane (3.211):  white needles from MeOH, (52 % yield) 
mp 176-178 oC; *α+D
23 −105.6 (c 0.9, CHCl3); IR (film) νmax 3267 (br.), 2946, 1509, 1220, 824, 757 cm
-1; 
1H NMR (600 MHz, CDCl3) δ 7.43 (dd,  
 3JH,H = 9.2, 
4JF,H = 5.5, H-2’ and H-6’, 2H), 7.00 (dd,  
3JH,H 
 = 9.2,  
3JF,H = 8.8, H-3’ and H-5’, 2H), 1.94 (m, H-12a, 1H), 1.90 (m, H-11a), 1.84 (m, H-12b, 1H) 1.81 (m, H-
14β, 1H), 1.77 (m, H-1a, 1H), 1.76 (m, H-7β(beta), 1H), 1.66 (m, 11b, 1H), 1.65 (m, H-14α, 1H), 1.64 
(m, H-2a, 1H), 1.55 (m, H2-6, H-3α, 3H), 1.43 (m, H-2b, 1H), 1.41 (m, H-7α, 1H), 1.16 (td, J = 13.6, 4.4 
Hz, H-3β, 1H), 1.05 (s, H3-17, 3H), 1.05 (m, H-9, 1H) 0.91 (m, H-5, 1H), 0.88 (m, H-1b, 1H), 0.88 (s, H3-
15, 3H), 0.85 (s, H3-16, 3H); 
13C NMR (150 MHz, CDCl3) δ 161.6 (C, d, 
1J F,C = 245.4, C-4’), 144.2 (C, d, 
4J 
F,C = 3.3, C-1’), 126.2 (CH, d, 
3J F,C = 7.6, C-2’, C-6’), 114.1 (CH, d, 
2J F,C = 20.8, C-3’, C-5),  74.0 (C, C-13), 
73.8 (C, C-8), 56.4 (CH, C-5), 56.7 (CH, C-9), 51.7 (CH2, C-14), 42.3 (CH2, C-3) 42.1 (CH2, C-7), 40.0 (CH2, 
C-12), 39.5 (CH2, C-1), 37.3 (C, C-10), 33.5 (CH3, C-15), 33.3 (C, C-4), 21.7 (CH3, C-16), 18.4 (CH2, C-2), 
17.6 (CH2, C-6), 16.9 (CH2, C-11), 15.5 (CH3, C-17); EIMS m/z (rel. int.) 360 [M
+] (17), 342 (26), 324, 
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(26), 193 (100), 123 (48); HREIMS (70 eV): calcd for C23H33O2F 360.2462. Found 360.2465  Δamu 
0.0003. 
 
To the suspension of anhydrous CeCl3 an aliquot (11.4 mL, 0.57 mmol, 1.5 equiv.) of a THF solution 
of 4-chloro-2-methylphenylmagnesium bromide (0.5 M) was added.  A yellow oil obtained from the 
procedure vide supra was purified via normal phase semi-preparative HPLC (17% EtOAc, 83% 
hexane) to afford a white solid which was recrystallized from MeOH to give white orthorhombic 
crystals of 3.209 (53 mg, 36%). 
 
8β, 13β-Dihydroxy-13α-4´-chloro-2’-methylphenylpodocarpane (3.212):  white needles from MeOH, 
(36% yield) mp 207-209 oC; *α+D
23 −23.6 (c 0.4, CHCl3); IR (film) νmax 3260 (br.), 2924, 1481, 1201, 862, 
759 cm-1; 1H NMR (600 MHz, CDCl3) δ 7.29 (d, J = 8.3, H-6’, 1H), 7.12 (d, J = 2.2, H-3’, 1H), 7.08 (dd, J = 
8.5, 2.2, H-5’, 1H), 2.57 (s, H-7’, 3H), 2.08 (dt, J = 9.6, 3.1, H-12a, 1H), 2.02 (dd, J = 14.2, 4.0, H-14β, 
1H) 1.90 (m, H-11a and H-12b, 2H), 1.76 (m, H-1a and H-7a, 2H), 1.66 (m, H-11b and H-14α, 2H) 1.65 
(m, H-2a, 1H), 1.55 (m, H-6, 2H), 1.44 (t, J = 3.3, H-2b, 1H), 1.40 (m, H-3α, 1H), 1.15 (td, J = 13.5, 4.6, 
H-3β, 1H), 1.05 (s, H3-17, 3H), 1.00 (m, H-9, 1H) 0.89 (m, H-5, 1H), 0.87 (s, H3-15, 3H), 0.86 (m, H-1b, 
1H), 0.85 (s, H3-16, 3H); 
13C NMR (150 MHz, CDCl3) δ 143.4 (C, C-1’), 138.6 (C, C-2’), 132.5 (CH, C-3’), 
132.4 (C, C-4’), 126.5 (CH, C-6’), 125.4 (CH, C-5’), 75.4 (C, C-13), 73.9 (C, C-8), 56.4 (CH, C-5), 56.3 (CH, 
C-9), 49.0 (CH2, C-14), 42.3 (CH2, C-7), 42.1 (CH2, C-3),  39.5 (CH2, C-1), 38.5 (CH2, C-12), 37.3 (C, C-10), 
33.5 (CH3, C-15), 33.3 (C, C-4), 22.2 (CH3, C-7’), 21.7 (CH3, C-16), 18.4 (CH2, C-2), 17.6 (CH2, C-6), 16.8 
(CH2, C-11), 15.5 (CH3, C-17); EIMS m/z (rel. int.) 390 [M
+] (16), 354 (52), 223, (100), 179 (32), 153 
(46); HREIMS (70 eV): calcd for C24H35O2Cl 390.2326. Found 390.2336 Δamu 0.001. 
 
6.2.5. LAH reduction of 3.188 
 
H
O
OH
H
OH
OH
LAH, THF
3.188 3.207 (R)
3.208 (S)
RT, 4 h
13
9
20
19 18
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LiAlH4 (45.7mg, 1.21 mmol, 3 equiv.) was taken up in anhydrous THF (10 mL).  The ketol 3.188 (106 
mg, 0.40 mmol) was added to the solution and allowed to stir under argon (4 h) at ambient 
temperatures.  The reaction was quenched with a sat. NH4Cl solution, which formed a precipitate on 
addition.  The solution was filtered through a Celite 545 plug and the filtrate was washed with water 
(2 × 5 mL) and sat. Brine (1 x 5 mL).  The organic portion was dried using anhydrous MgSO4 and 
concentrate in vacuo to afford white crystals (101 mg, 91%).  The product of this reaction afforded a 
pair of isomers in a ratio of 2:1 of 3.207 and 3.208, with compound 3.207 being the major product.   
6.2.6. Synthesis of 1-methyl-2,3,4-tetrahydro-naphthalen-1-ol (3.213)   
 
OH
THF, -78 oC
O
MeLi
3.214 3.213
1
7
11
1
5
8
 
 
α-Tetralone (3.214, 500mg, 0.455 mL, 3.4 mmol) was dissolved in anhydrous THF (25 mL) with 
stirring under an argon atmosphere.  The solution was cooled to -78 oC and MeLi (7 mL, 11.2 mmol,  
1.6 M in THF, 3.3 equiv) added.  The reaction was allowed to warm to room temperature, while 
stirring (12 h) and quenched with a sat. NHCO3 solution (25 mL).  The organic fraction was extracted 
with diethyl ether (2 x 25 mL).  The combined organic fraction were washed with water (2 x 25 mL) 
and sat. brine (1 x 25 mL) and dried over MgSO4.  The organic fraction was concentrated under 
reduced pressure to yield a brown oil, which was crystallized from hot hexane to yield 3.213 as off-
white needles (420 mg, 2.59 mmol, 76 % yield) 
1-Methyl-2,3,4-tetrahydro-naphthalen-1-ol (3.213):  off white needles; mp 78-79 oC; IR (solid) νmax 
3441 (br.), 2928, 2352, 1688, 1453 cm-1; 1H NMR (CDCl3, 600 MHz) δ 7.58 (d, J = 7.6, H-9, 1H), 7.20 ( 
br s, H-7 and H-8, 2H), 7.06 (d, J = 7.2, H-6, 1H), 2.79 (t, J = 5.4, H2-4, 2H), 1.95 (t, J = 7.00, H2-2, 2H), 
1.60 (br s, H2-3, 2H), 1.56 (s, H3-11, 3H); 
13C (CDCl3, 150 MHz) δ 142.9 (q, C-10), 136.2 (q, C-5), 128.8 
(CH, C-9), 127.1 (CH, C-8), 126.3 (CH, C-7), 126.3 (CH, C-6), 70.6 (q, C-1), 39.8 (CH2, C-2), 30.7 (CH3, C-
11), 29.9 (CH2, C-4), 20.4 (CH2, C-3); HREIMS (70 eV): calcd for C11H14O 162.1045. Found 162.1048 
Δamu 0.0003. 
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6.2.7. Synthesis of 1-isocyano-1-methyl-2,3,4-tetrahydro-naphthalene 
(3.215) 
OH N
TMSCN, AgOCl4
CH2Cl2, RT, 2 h
3.213 3.215
19 1
6
11
C
12
 
 
The tertiary alcohol 3.213 (128 mg, 0.79 mmol) was dissolved in dry DCM (1 mL) under argon.  
TMSCN (210 µL, 1.58 mmol, 2.0 equiv) was injected into the reaction vessel.  Solid silver perchlorate 
(164 mg, 0.79 mmol, 1 equiv.) was added and allowed to stir at ambient temperatures  (2 h).   The 
reaction was quenched with sat. NaHCO3 solution (1 mL), allowed to stir and vent for 10 minutes to 
remove any unreacted TMSCN.  The insoluble AgOH, AgCl and AgOCl4 was removed by filtering the 
solution through a Celite 545  plug.  The Celite 545  plug was washed with ethyl acetate (100 mL)  
and dried with MgSO4.  The organic fraction was concentrated in vacuo. and purified on a short silica 
column (2:1 hexane:ethyl acetate).  The isonitrile was finally purified with HPLC (12.5% EtOAc, 87.5% 
hexane) to yield 3.215 as a brown oil (91.8 mg, 0.190 mmol, 68 %) 
1-Isocyano-1-methyl-2,3,4-tetrahydro-naphthalene (3.215):  brown oil; IR (film) νmax 2937, 2362, 
2190, 1589, 1015 cm-1; 1H NMR (CDCl3, 600 MHz) δ 7.47 (d, J = 7.6, H-9, 1H), 7.22 (br. s, H-7 and H-8, 
2H), 7.09 (d, J = 7.2, H-6, 1H), 2.82 (t, J = 6.0, H2-4, 2H), 1.90 (t, J = 6.9, H2-2, 2H), 1.72 (s, H3-11, 3H), 
1.57 (br s, H2-3, 2H); 
13C (CDCl3, 150 MHz) δ 167.9 (q, t, 
1JN,C = 4.4 Hz, C-12), 135.8 (q, C-10), 135.7 (q, 
C-5), 129.7 (CH, C-9), 127.8 (CH, C-8), 127.7 (CH, C-7), 126.7 (CH, C-6), 68.0 (q, C-1), 38.7 (CH2, C-2), 
29.2 (CH3, C-11), 28.8 (CH2, C-4), 19.2 (CH2, C-3); HREIMS (70 eV): calcd for C12H13N 171.1044. Found 
171.1048 Δamu 0.0004. 
6.2.8. Attempted conversion of the tertiary alcohol of 3.188 to an 
isonitrile functionality 
O
OH TMSCN, AgOCl4
DCM, RT
O
3.188 3.217  
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The tertiary alcohol 3.188 (100 mg, 0.38 mmol) was dissolved in dry DCM (1 mL) under argon.  
TMSCN (97 µL, 0.76 mmol, 2.0 equiv) was injected into the reaction vessel.  Solid silver perchlorate 
(78 mg, 0.3.8 mmol, 1 equiv.) was added and allowed to stir at ambient temperatures  (2 h).   The 
reaction was quenched with sat. NaHCO3 solution (1 mL), allowed to stir and vent for 10 minutes to 
remove any unreacted TMSCN.  The insoluble AgOH, AgCl and AgOCl4 was removed by filtering the 
solution through a Celite 545  plug.  The Celite 545  plug was washed with ethyl acetate (100 mL)  
and dried with MgSO4.  The organic fraction was concentrated in vacuo. and purified on a short silica 
column (3:1 hexane:ethyl acetate).  The isonitrile was finally purified with HPLC (20% EtOAc, 80% 
hexane) to yield 3.217 as a white crystal (67.4 mg, 0.27 mmol, 72 %).  The spectroscopic and physical 
data of 3.217 was consistent with that published in literature.472,473   
 
6.2.9. Parasite cultivation 
 
The screening of the synthetic compounds was carried out by Dr. R. van Zyl at the University of 
Witwatersrand.  The chloroquine-resistant Gambian FCR-3 strain was cultured in vitro according to 
the method described by Jensen and Trager.474  For experimental purposes the cultures were 
synchronized with 5 % D-sorbitol when the parasites were in the ring.475 Human ethics clearance for 
use of human blood was obtained from the University of the Witwatersrand Human Ethics 
Committee (M090532 ) and the University of the Witwatersrand Biosafely Committee approved the 
use of Plasmodium falciparum for in vitro experimental purposes (number: IOC090503). 
 
6.2.10. Antiplasmodial screening 
 
The antimalarial activity of the various compounds was determined using the tritiated hypoxanthine 
incorporation assay.217  The parasite suspension, consisting of predominately the ring stage, was 
adjusted to a 0.5 % parasitemia and 1 % hematocrit and exposed to the various concentrations of 
compounds for a single cycle of parasite growth. All assays were carried out using untreated 
parasites and uninfected red blood cells as controls. Labelled 3H-hypoxanthine (0.5 μCi/ well) was 
Chapter Six:  Experimental 
 
 
193 
added after 24 h and the cells harvested after a further 24 h incubation period. The concentration 
that inhibited 50 % of parasite growth (IC50 value) was determined from the log sigmoid dose 
response curve generated by the Enzfitter® software. Chloroquine, quinine, primaquine, 
pyrimethamine and cycloproguanil were used as the reference antimalarial agents. All compounds 
were tested in at least three independent experiments and statistical analysis using the student t-
test performed, where a p value of less than 0.05 was regarded as significant. 
 
6.2.11. Haemolytic screening 
 
Freshly obtained human whole blood was washed three times by centrifugation (1500 rpm for 5 
min) in isotonic phosphate buffer saline (pH 7.2) and the buffy coat and plasma discarded. The pellet 
was resuspended in RPMI-1640 culture media, HEPES and glucose supplemented with 10% human 
plasma and NaHCO3 (pH7.4) to a final hematocrit of 1% (v/v).  The compounds (50 and 100µM) were 
incubated with the erythrocytes for 48 h at 37 °C. Thereafter, the suspension was centrifuged at 
1500 rpm for 5 min at room temperature and the absorbance of the supernatant read at 412 nm. 
The observed haemolysis was expressed as a percentage of the positive control, 0.2 % (v/v) Triton X-
100.476  
6.3. Chapter 4 experimental details 
6.3.1. Pyridine hemichrome inhibition of β-haematin assay (Phi-β Assay) 
 
A fresh haematin stock solution (1.680 mM) was prepared by dissolving porcine haemin in a solution 
of sodium hydroxide (0.1 M).  The stock solution (20.2 µL) was pipetted into an 2.0 mL Eppendorf 
tube and incubated in a water bath (3-5 min at 60 °C).  Stock solutions of 3.203-3.207, 3.209-3.212 
and 3.215 in methanol (168.0 mM, 10 equiv. relative to haematin) were prepared.  Aliquots of these 
stock solutions (2.02 μL) were added to the respective Eppendorf tubes after neutralization of the 
haematin stock solution with HCl (2.02 μL, 1.0 M).  Accuracy was important and thus all aliquots 
were added with Eppendorf Auto-pipettes (0.50-10.00 μL and 10.0-100.0 μL volume ranges).  It is 
important to note that on addition of the test solutions to the neutralized haematin stock solution, 
no precipitation was observed.  An aliquot of the control solution, chloroquine diphosphate (2.02 μL 
, 50.3 mM, 3.0 equiv. in 1.0 M HCl), was added to the basic haematin solution.  In order to maintain 
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consistency methanol was added (2.02 µL) to the Eppendorf tubes containing the control and 
chloroquine solutions.  After incubation, an aliquot of the acetate buffer (11.74 µL, the method used 
for preparation of the buffer is given below) was added to each Eppendorf tube and the reaction 
was incubated at 60 oC for 60 min.   The reaction was quenched at room temperature with the 
addition of 5% (v/v) pyridine (900 µL, 200 mM Hepes, pH 8.2) solution followed by the addition of 
5% (v/v) pyridine (1100 µL, 20 mM Hepes. pH 7.5).  The Eppendorf tubes were sonicated in order to 
ensure complete dissolution of haematin and β-haematin, any precipitate was allowed to settle at 
ambient temperature for at least 15 minutes.313  The supernatant was decanted off and transferred 
to a quartz cuvette in order to measure its UV/vis absorbance (350-700 nm).          
 
6.3.1.1. Preparation of the 12.9 M acetate buffer 
 
The preparation of the 12.9 M acetate buffer solution was prepared as follows:  sodium acetate 
trihydrate (126.3 g) was dissolved in glacial acetic acid (94.56 mL).  The solution was warmed slowly 
to 60 oC to ensure complete dissolution of NaOAc.  This solution is required to have a pH of 5.00, 
which is essential for the success of the assay.  The buffer solution temperature was retained (60 oC) 
in order to circumvent the NaOAc crystallizing out as the buffer solution, as the solution is 
supersaturated at ambient temperatures.301  
6.3.2. EBHIA assay 
 
Haematin was formed by dissolving haemin (15 mg) in NaOH (3.0 mL of 0.1 M NaOH).  This solution 
was heated to 60 oC by emerging the reaction vessel in a preheated water-bath where the haematin 
solution was constantly stirred (stirrer bar 2mm in diameter and 5mm in length).  The base was 
neutralised by the addition of 1.0M HCl (0.3 mL).  The acetate buffer (1.74 mL, 12.9 M, pH 5.00, see 
above for preparation) was introduced into the system allow the reaction to proceed.     In order to 
gauge to progression of the reaction after 0, 10, 30 or 60 minutes the reaction was stopped by 
cooling the reaction on ice for 5 minutes.  The solution was filtered on an 8 µm cellulose 
acetate/nitrate Millipore® filter type SC, where it was thoroughly washed with water to remove any 
residual sodium acetate.  The solid was lyophilized for 24 hours.   
The effects of the inhibitors were study by conducting the reaction, with the addition of 10 
equivalents, relative to haem, of compounds 3.203-3.207, 3.209-3.212 and 3.215 and 3 equivalents 
Chapter Six:  Experimental 
 
 
195 
of chloroquine diphosphate, 2.4, 2.9, 2.15, 2.19, 2.34 and 2.35.  The chloroquine was added with the 
1.0M HCl while the other test solutions (2.4, 2.9, 2.15, 2.19, 2.34, 2.35, 3.203-3.207, 3.209-3.212 and 
3.215) were added in a methanol solution (0.3 mL) after neutralization of the haematin solution with 
1.0M HCl (0.3 mL).  Neutralization of the basic solution occurred within 10 min of the addition of the 
haemin and allowed to incubate for 3-5 min followed by the addition of the test compounds and 
finally the pre-incubated buffer solution (as above).  An equivalent of methanol was added to the 
control sample as well as the chloroquine solution in order to maintain consistency throughout the 
experiment.314  The samples were incubated for 60 min where the reaction was stopped by cooling 
the reaction vessel on ice for 5min.  The solution was filtered on an 8 µm cellulose acetate/nitrate 
Millipore® filter type SC, where the precipitate was thoroughly washed with water.  The solid was 
lyopholized (24 h).   While all these experiments are reproducible, the successful formation of 
haematin is dependent upon stirring rate, total volume, vessel dimensions, acetate concentration, 
pH and temperature. 301   All experimental conditions were accordingly rigorously adhered to.  
 
6.3.3. Docking studies 
(i) The receptor model for the free haem (FP) was obtained from the Cambridge Structural 
Database (CSD code 162267)303 and the haem dimer group model (HD) was obtained from 
the Protein Database (PDB code 2q9f)477 respectively. The FP model underwent energy 
optimizations using unrestricted DFT calculations in the singlet and triplet electronic states; 
whilst the quintet electronic state model was optimized using the LANL2DZ346 
pseudopotential to describe the iron atom and then the UB3LYP / 6-31G(d) method for all 
other atoms. A single-point spin unrestricted energy calculation was performed on the HD 
crystal structure in the singlet electronic state.  
(ii) The ligand models of structures 2.4, 2.9, 2.15, 2.19, 2.34, 2.35, 3.203-3.207, 3.209-3.212, 
3.215 and 4.1 were constructed and underwent DFT structural optimization. The minimized 
structures were imported into AutoDockTools, AutoDock atom types were assigned, 
Gasteiger347 charges were added and non-polar hydrogens were merged. Bond torsions were 
assigned and aromatic elements identified. The assigned Gasteiger charges were substituted 
with MK350 atomic charges from the DFT optimization output logs. For all atoms other than 
polar hydrogens and their attached heavy atom, MK350 charges were computed with 
attached hydrogens’ charges merged into the heavy atom. For polar hydrogens, unmerged 
charges were used for both the hydrogen and the heavy atom. 
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(iii) The minimized haem models from Section 4.4 and 4.5 were imported into AutoDockTools, 
AutoDock atom types were assigned, Gasteiger charges were added and non-polar 
hydrogens were merged. All rotational elements on the heam targets, i.e. vinyl and 
carboxylic acid groups, were treated as the flexible residues. The Gasteiger charges were 
substituted for MK atomic charges as previously mentioned. 
(iv) Grid maps for each of the ligands were generated across the active sites, with surrounding 
residues, using a grid box of 503 points (0.325 Å point spacing) referenced to the iron atom.  
The dockings were executed according to a Lamarckian genetic algorithm to create 
populations containing 150 individuals and allowing for a maximum of 2.5 x 106 energy 
evaluations for each of 10 unique docks per ligand. The results were clustered and the 
lowest energy conformer from each cluster printed as part of the docking log file along with 
its associated energies. These conformers were extracted from the log file using custom 
scripting and visualized. 
 
6.4. Chapter 5 experimental details 
6.4.1. Preparation of aryl glyoxal monohydrates (5.92-5.102)    
O
R
O
R
H
O
O
R
OH
OH
SeO2, H2O, 1,4-dioxane
MWI, 3-25 min, 100 oC
100 oC, 2 h
2'1
4
1'
5
2
 
 
     
 
SeO2 (360 mg, 0.3 mmol, 2.7 equiv.) was suspended in a mixture of 1,4-dioxane (1 mL) and H2O (20 
µL) and the methyl ketone, 5.91 and 5.93-5.97 (1.2 mmol) was added just before microwave 
irradiation [ramp time (1 min) to a maximum power of 250 W, hold time (3-18 min) at a set 
temperature of 100  °C].  Following microwave irradiation the reaction solution was rapidly cooled 
to 50 oC (5 min) by means of propelled airflow and finally allowed to cool to room temperature (ca. 
20 min).  The solution was filtered through Celite 545, in order to remove Se, and washed with 
MeOH (10 mL).  The combined organic filtrate was concentrated under reduced pressure and the 
organic residue subsequently stirred in boiling H2O (6 mL) for 2 h and filtered hot to remove any 
5.92 R = H  
5.98 R = OMe 
5.99 R = NO2  
5.100 R = Cl  
5.101 R = Br  
5.102 R = F  
5.27 R = H  
5.28 R = OMe  
5.29 R = NO2  
5.30 R = Cl  
5.31 R = Br  
5.32 R = F  
5.91 R = H  
5.93 R = OMe  
5.94 R = NO2  
5.95 R = Cl  
5.96 R = Br  
5.97 R = F  
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insoluble precipitate.  The aqueous filtrate was cooled on ice to afford crystals of the glyoxal 
monohydrate product which were collected under vacuum filtration, washed with cold H2O and 
dried in a vacuum desiccator to yield the monohydrates 5.92 and 5.98-5.102. 
Phenyl glyoxal monohydrate (5.92) white needles from H2O, (84 % yield) mp 78-80 
oC, lit. 76-78 oC478; 
IR (solid) νmax 3392 (br), 1695, 1595, 1219, 1107, 708 cm
-1; 1H NMR (600 MHz, DMSO- D6) δ 8.06 (d, J 
= 8.8, H-2 and H-6, 2H), 7.63 (t, J = 7.2, H-4, 1H), 7.51 (dd, J = 7.89, 7.82, H-3 and H-5, 2H), 5.69 (t, J = 
7.3, H-2’, 1H) 13C NMR (150 MHz, DMSO-D6) δ 196.3 (q, C-1’), 133.7 (q, C-1), 133.4 (2 x CH, C-3 and C-
5), 129.4 (2 x CH, C-2 and C-6), 128.5 (CH, C-4), 89.2 (CH, C-2’); EIMS m/z (rel. int.) 106 (9), 105, (100), 
78 (5), 77 (77), 51 (27) 
4-Methoxyphenyl glyoxal monohydrate (5.98) white needles from H2O, (84 % yield) mp 92-94 
oC, lit. 
93-95 oC421; IR (solid) νmax 3375 (br.), 1694, 1586, 1219, 1024, 671 cm
-1; 1H NMR (600 MHz, DMSO-D6) 
δ 8.05 (d, J = 9.0, H-2 and H-6, 2H), 7.02 (d, J = 9.0, H-3 and H-5, 2H), 5.96 (t, J = 7.1 H-4, 1H), 3.84 (s, 
H3-7, 3H); 
13C NMR (150 MHz, DMSO-D6) δ 192.0 (q, C-1’), 163.7 (q, C-4), 131.9 (2 x CH, C-2 and C-6), 
126.1 (q, C-1), 113.8 (2 x CH, C-3 and -5), 90.5 (CH, C-2’), 55.5 (CH3, C-7); EIMS m/z (rel. int.) 136 (10), 
135 (100), 92 (14), 77 (24), 64 (7) 
4-Nitrophenyl glyoxal monohydrate (5.99) brown flakes from H2O, (62 % yield) mp 70-72 
oC, lit. 67-72 
oC421; IR (solid) νmax 3345 (br.), 1691, 1533, 1346, 1012, 725 cm
-1; 1H NMR (600 MHz, DMSO- D6) δ 
8.35 (d, J = 8.8, H-2 and H-6, 2H), 8.29 (d, J = 8.8, H-3 and H-5, 2H), 5.91 (s, H-2’, 2H); 13C NMR (150 
MHz, DMSO-D6) δ 195.5 (q, C-1’), 149.9 (q, C-4), 138.8 (q, C-1), 130.8 (2 x CH, C-2 and C-6), 123.5 (2 x 
CH, C-3 and C-5), 89.8 (CH, C-2’); EIMS m/z (rel. int.) 181 (26), 150 (100), 135 (7), 104 (24), 76 (12) 
4-Chlorophenyl glyoxal monohydrate (5.100) white needles from H2O, (81 % yield) mp 40-41 
oC, lit. 
40-41 oC479; IR (solid) νmax 3375 (br.), 1694, 1586, 1219, 1012, 810 cm
-1; 1H NMR (600 MHz, DMSO-D6) 
δ 8.07 (d, J = 8.6, H-2 and H-6, 2H), 7.58 (d, J = 8.3, H-3 and H-5, 2H), 5.63 (s, H-2’, 1H); 13C NMR (150 
MHz, DMSO-D6) δ 195.3 (q, C-1’), 138.2 (q, C-1), 132.3 (2 x CH, C-3 and C-5), 131.4 (2 x CH, C-2 and C-
6), 128.7 (q, C-4), 89.7 (CH, C-2’); EIMS m/z (rel. int.) 170 (2), 141 (31), 139 (100), 111 (47), 75 (21) 
4-Bromophenyl glyoxal monohydrate (5.101) white needles from H2O, (89 % yield) mp 52-54 
oC, lit. 
51-53 oC479; IR (solid) νmax 3374 (br.), 1694, 1583, 1219, 1025, 735 cm
-1; 1H NMR (600 MHz, DMSO-D6) 
δ 7.99 (d, J= 8.8, H-2 and H-6, 2H), 7.73 (d, J = 8.6, H-3 and H-5, 2H), 5.62 (t, J = 6.99, H-2’, 1H); 13C 
NMR (150 MHz, DMSO-D6) δ 195.5 (q, C-1’), 132.7 (q, C-1), 131.6 (2 x CH, C-3 and C-5), 131.4 (2 x CH, 
C-2 and C-6), 127.5 (q, C-4), 89.6 (CH, C-2’); EIMS m/z (rel. int.) 213 (5), 186 (10), 183 (100), 155 (45), 
76 (17); 
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4-Fluorophenyl glyoxal monohydrate (5.102) white needles from H2O, (87% yield) mp 82-84 
oC, lit. 
80-82.4 oC480; IR (solid) νmax 3349 (br.), 1700, 1231, 1062, 804, 686 cm
-1; 1H NMR (600 MHz, 
DMSO-D6) δ 8.16 (td, J = 6.0, 
4JF,H = 3.3, H-2 and H-6, 2H), 7.35 (t, J = 8.8, 
3JF,H = 9.7, H-3 and H-5, 2H), 
5.63 (t, J = 6.38, H-2’, 1H); 13C NMR (150 MHz, DMSO-D6) δ 195.0 (q, C-1’), 165.0 (q, 
1JF,C = 251.4, C-4), 
132.4 (2 x CH, 3JF,C = 9.7, C-2 and C-6), 130.2 (q,
 4JF,C = 2.2, C-1), 116.2 (2 x CH, 
2JF,C = 21.6, C-3 and C-
5), 89.5 (CH, C-2’); EIMS m/z (rel. int.) 124 (7), 123 (100), 96 (5), 95 (57), 75 (14) 
 
6.4.2. Synthesis of indole glyoxals 
6.4.2.1. Preparation of 3-indolylglyoxylic acid (5.106) 
 
SeO2, H2O, 1,4-Dioxane
MWI, 15 min, 100 oCN
H
O
N
H
O
OH
O
2'
2
3a
5.105 5.106
6
 
SeO2 (171 mg, 1.54 mmol, 2.7 equiv) was suspended in a mixture of 1,4-dioxane (1 mL) and H2O (20 
µL) and 3-acetylindole (5.105, 90 mg, 0.57 mmol) was added just before microwave irradiation 
[ramp time (1 min) to a maximum power of 250 W, hold time (15 min) at a set temperature of 100  
°C].  Following microwave irradiation the reaction solution was rapidly cooled to 50 oC (5 min) by 
means of propelled airflow and finally allowed to cool to room temperature (ca. 20 min).  The 
solution was filtered through Celite 545 , in order to remove Se, and washed with CH2Cl2 (10 mL).  
The combined organic filtrate was washed with water (2 x 10 mL) and sat. brine (1 x 10mL), and the 
organic fraction was dried over anhydrous MgSO4, filtered and concentrated under reduced pressure 
to afford a brick red solid (5.106). 
 
3-Indolylglyoxylic acid (5.106)  brick red solid (100% yield); IR (solid) νmax 3209 (br.), 1701, 1599, 
1231, 1063, 804 cm-1; 1H NMR (600 MHz, CD3OD) δ 8.52 (s, H-2, 1H), 8.28 (d, J = 7.51, H-4, 1H), 7.49 
(d, J = 7.89, H-7, 1H), 7,28 (m, H-5 and H-6, 2H); 13C NMR (150 MHz, CD3OD) δ 181.2 (q, C-1’), 166.0 
(q, C-2’), 139.5 (CH, C-2), 138.3 (q, C-3a), 127.5 (q, C-7a), 125.1 (CH, C-5), 124.0 (CH, C-6), 122.9 (CH, 
C-4), 114.4 (q, C-3), 113.2 (CH, C-7); EIMS m/z (rel. int.) 189 [M+H]+ (18), 161 (22), 144 (100), 115 
(26), 102 (5); HREIMS (70 eV): calcd for C10H7NO3 189.0426. Found 189.0421, Δamu 0.0005 
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6.4.2.2. N-Boc protection of 3-acetylindol (5.105) 
 
Boc2O, DMAP
MeCN, 0 oC, 2 hrsN
H
O
N
O
O
O
1'
1''
2'' 3''
3a
6
5.105 5.89  
 
3-Acetylindole (5.105, 2.5 g, 15.7 mmol) was dissolved in dry MeCN (37.5 mL) and cooled on ice.  Di-
tert-butyl dicarbonate (5.14g, 23.6 mmol, 1.5 equiv.) was added followed by 4-
dimethylaminopyridine (191.9 mg, 1.57 mmol, 0.1 equiv.) and allowed to stir under argon for two 
hours.  The solvent and excess reagents were removed under reduced pressure to yield 
spectropically pure white solid of 3-acetylindole-1-carbamate (5.89).  
  
3-Acetylindole-1-carbamate (5.89), white needles from hexane (100 % yield), mp 140-142 oC, lit. 143-
144 oC442; IR (solid) νmax 3274, 1635, 1596, 1509, 1287, 847 cm
-1; 1H NMR (600 MHz, DMSO-D6) δ 8.53 
(s, H-2, 1H), 8.24 (d, J = 8.0, H-4, 1H), 8.09 (d, J =8.1, H-7, 1H), 7.41 (dd, J = 8.7, 7.8, H-6, 1H), 7.35 
(dd, J = 8.7, 7.6, H-5, 1H), 2.55 (s, H3-2’, 3H), 1.67 (s, H3-3’’, 9H); 
13C NMR (150 MHz, DMSO-D6) δ 
193.8 (q, C-1’), 149.1 (q, C-1’’), 135.5 (CH, C-2), 132.3 (q, C-3a), 127.3 (q, C-7a), 125.4 (CH, C-6), 124.3 
(CH, C-5), 122.6 (CH, C-4), 120.6 (q, C-3), 114.9 (CH, C-7), 85.3 (q, C-2’’), 28.1 (CH3, C-3’’), 27.7 (CH3, 
C-2’); HREIMS (70 eV): calcd for C15H18NO3 260.1287. Found 260.1302, Δmmu 0.0015. 
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6.4.2.3. Selenium dioxide oxidation of 3-acetylindole-1-carbamate (5.89) 
 
N
O
O
O
2'
1''
2'' 3''
3a
N
O
O
O
2'
1''
3''
3
H
O
N
O
O
O
1'
2''
2
OH
OHSeO2, H2O, 1,4-Dioxane
MW, 40 min, 100 oC
5.88 5.1075.89
5
7a
6
 
 
SeO2 (171 mg, 1.54 mmol, 2.7 equiv) was suspended in a mixture of 1,4-dioxane (1 mL) and H2O (20 
µL) and the indole methyl ketone, 5.89 (148 mg, 0.57 mmol) was added just before microwave 
irradiation [ramp time (1 min) to a maximum power of 250 W, hold time (40 min) at a set 
temperature of 100  °C].  Following microwave irradiation the reaction solution was rapidly cooled 
to 50 oC (5 min) by means of propelled airflow and finally allowed to cool to room temperature (ca. 
20 min).  The solution was filtered through Celite 545 , in order to remove Se, and washed with 
CH2Cl2 (10 mL).  The combined organic filtrate was washed with water (2 x 10 mL) and sat. brine (1 x 
10mL), and the organic fraction was dried over anhydrous MgSO4, filtered and concentrated under 
reduced pressure to afford a yellow oil containing an inseparable equilibrium mixture of 5.88 and 
5.107 respectively. 
3-Acetylindole-1-carbamate glyoxal (5.88), yellow oil (86 % yield, C18 60% MeCN 40 % H2O; 62 % of 
the equilibrium mixture), IR  (film) νmax  3405, 1741, 1665, 1450, 1236, 745 cm
-1; 1H NMR (600 MHz, 
CDCl3) δ 9.53 (s, H-2’, 1H), 8.89 (s, H-2, 1H), 8.39 (d, J  = 7.6, H-4, 1H), 8.18 (d, J = 7.7, H-7, 1H), 7.43 
(m, H-6, 1H), 7.40 (m, H-5, 1H), 1.71 (s, H3-3’’, 9H); 
13C NMR (150 MHz, CDCl3) δ 190.1 (CH, C-2’), 
182.6 (q, C-1’), 148.6 (q, C-1’’), 136.8 (CH, C-2), 135.2 (q, C-3a), 127.5 (q, C-7a), 125.8 (CH, C-6), 124.7 
(CH, C-5), 122.4 (CH, C-4), 115.1 (CH, C-7), 114.0 (q, C-3), 86.0 (q, C-2’’), 28.0 (CH3, C-3’’); HREIMS: 
calcd for C15H16NO4 274.1079. Found 274.1061, Δmmu 0.0018. 
3-Acetylindole-1-carbamate glyoxal monohydrate (5.107), yellow oil (38 % of the equilibrium 
mixture); 1H NMR (600 MHz, CDCl3) δ 8.83 (s, H-2, 1H), 8.29 (d, J = 7.6, H-4, 1H), 8.14 (d, J = 8.2, H-7, 
1H), 7.36 (m, H-6, 1H), 7.34 (m, H-5, 1H), 5.79 (s, H-2’, 1H), 1.73 (s, H3-3’’, 9H); 
13C NMR (150 MHz, 
CDCl3) δ 188.5 (q, C-1’), 148.6 (q, C-1’’), 136.8 (CH, C-2), 135.4 (q, C-3a), 127.3 (q, C-7a), 126.1 (CH, C-
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6), 124.9 (CH, C-5), 122.2 (CH, C-4), 115.2 (CH, C-7), 115.0 (q, C-3), 87.9 (CH, C-2’), 85.7 (q, C-2’’), 28.0 
(CH3, C-3’’) 
 
6.4.3. Synthesis of bis phenylimidazoles (5.21-5.26) 
 
                                  
N
H
N O
RR
1 3''1''
2
4
1'
4'
R
OH
O
OH
NH4OAc, EtOH
RT, 45 min
3'
6'
6''
 
 
NH4OAc (13.39 mmol, 5 equiv.) was added to an ethanol solution of 5.92, 5.98-5.102 (2.67 mmol in 
17.5 mL).  The mixture was stirred at ambient temperature for 45 min until a precipitate formed.  
The solvent was removed in vacuo and the remaining precipate washed with water (20 mL) and 
filtered to afford tautomeric mixtures of 5.21-5.26.      
2-Benzoyl-5-phenyl-3H-imidazole (5.21a): yellow needles from 5% DMSO / 95 % MeOH (100 % yield) 
mp 203-205 oC; IR (solid) νmax 3267, 1701, 1456, 1271, 866, 687 cm
-1; 1H NMR (600 MHz, DMSO-D6) δ 
13.66 (s, NH-3, 1H), 8.04 (s, H-4, 1H), 7.93 (d, J = 7.4, H-2’ and H-6’, 2H), 7.69 (t, J = 7.3, H-5’’, 1H), 
7.60 (t, J = 7.6, H-3’’ and H-7’’, 2H), 7.56, (m, H-4’’ and H-6’’, 2H), 7.43 (dd, J = 8.3, 7.6, H-3’ and H-5’, 
2H), 7.30 (t, J = 7.15, H-4’, 1H); 13C NMR (150 MHz, DMSO-D6) δ 180.8 (q, C-1’’), 144.7 (q, C-2), 142.9 
(q, C-5), 136.0 (q, C-2’’), 133.6 (q, C-1’), 133.0 (CH, C-5’’), 130.6 (2 x CH, C-4’’ and C-6’’), 128.9 (2 x CH, 
C-3’ and C-5’), 128.3 (2 x CH, C-3’’ and C-7’’), 127.1 (CH, C-4’), 124.9 (2 x CH, C-2’ and C-6’), 118.6 
(CH, C-4); HRESIMS (70 eV): calcd for C16H12N2O 249.1028 Found 249.1036, Δamu 0.0008. 
2-(p-Methoxybenzoyl)-5-(p-methoxyphenyl)-3H-imidazole (5.22a): yellow needles from 5% DMSO / 
95 % MeOH (99 % yield, 74% of tautomeric mixture) mp 219-221 oC; IR (solid) νmax 3264, 1596, 1244, 
1025, 829, 773, 655 cm-1; 1H NMR (600 MHz, DMSO-D6) δ 13.42 (s, NH-3, 1H), 8.69 (d, J = 8.8 , H-3’’ 
and H-7’’, 2H), 7.91 (s, H-4, 1H), 7.85 (d, J = 8.6, H-2’ and H-6’, 2H), 7.13 (d, J = 8.7, H-4’’ and H-6’’, 
2H), 6.99 (d, J = 8.5, H-3’ and H-5’, 2H), 3.88 (s, H3-6’’, 3H), 3.79 (s, H3-5’, 3H); 
13C NMR (150 MHz, 
DMSO-D6) δ 178.9 (q, C-1’’), 163.2 (q, C-5’’), 158.5 (q, C-4’) 144.7 (q, C-2), 142.6 (q, C-5), 133.1 (2 x 
CH, C-3’’ and C-7’’), 128.6 (q, C-2’’), 126.4 (q, C-1’), 126.1 (2 x CH, C-2’ and C-6’), 117.0 (CH, C-4), 
5.21 R = H  
5.22 R = OMe  
5.23 R = NO2  
5.24 R = Cl  
5.25 R = Br  
5.26 R = F  
5.92 R = H  
5.98 R = OMe 
5.99 R = NO2  
5.100 R = Cl  
5.101 R = Br  
5.102 R = F  
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114.0 (2 x CH, C-3’ and C-5’), 113.7 (2 x CH, C-4’’ and C-6’’), 55.5 (CH3, C-8’’), 55.1 (CH3, C-7’); 
HRESIMS: calcd for C18H17N2O3 309.1239. Found 309.1257, Δamu 0.0018. 
2-(p-Methoxybenzoyl)-5-(p-methoxyphenyl)-1H-imidazole (5.22b): yellow needles from 5% DMSO / 
95 % MeOH (99 % yield, 26% of tautomeric mixture); 1H NMR (600 MHz, DMSO-D6) δ 13.54 (s, NH-1, 
1H), 8.56 (d, J = 8.6 , H-3’’ and H-7’’, 2H), 7.89  (d, J = 8.6, H-2’ and H-6’, 2H), 7.64 (s, H-4, 1H), 7.09 
(d, J = 8.6, H-4’’ and H-6’’, 2H), 7.01 (d, J = 8.5, H-3’ and H-5’, 2H), 3.86 (s, H3-8’’, 3H), 3.80 (s, H3-7’, 
3H); 13C NMR (150 MHz, DMSO-D6) δ 179.0 (q, C-1’’), 163.0 (q, C-5’’), 159.3 (q, C-4’) 145.6 (q, C-2), 
135.4 (q, C-5), 132.9 (2 x CH, C-3’’ and C-7’’), 128.9 (q, C-2’’), 127.6 (q, C-4), 127.1 (2 x CH, C-2’ and C-
6’), 121.3 (CH, C-1’), 114.3 (2 x CH, C-3’ and C-5’), 113.5 (2 x CH, C-4’’ and C-6’’), 55.5 (CH3, C-8’’), 
55.2 (CH3, C-7’) 
2-(p-Nitrobenzoyl)-5-(p-nitrophenyl)-3H-imidazole (5.23a): (90 % yield); IR (solid) νmax 3274, 1635, 
1596, 1331, 1289, 848 cm-1; 1H NMR (600 MHz, DMSO-D6) δ 13.94 (s, NH-3, 1H), 8.66 (d, J = 8.4, H-3’’ 
and H-7’’, 2H), 8.35 (d, H-4’’ and H-6’’, 2H), 8.28 (s, H-4, 1H), 8.21 (d, J = 8.6, H-3’ and H-5’, 2H), 8.11 
(d, J = 8.6, H-2’ and H-6’, 2H); 13C NMR (150 MHz, DMSO-D6) δ 179.5 (q, C-1’’), 149.7 (q, C-5’’), 146.1 
(q, C-4’) 144.9 (q, C-2), 141.2 (q, C-5), 141.0 (q, C-2’’), 140.7 (q, C-1’), 131.9 (2 x CH, C-3’’ and C-7’’), 
125.6 (2 x CH, C-2’ and C-6’), 124.1 (2 x CH, C-3’ and C-5’), 123.3 (2 x CH, C-4’’ and C-6’’), 122.1 (CH, 
C-4); HRESIMS: calcd for C17H28O2 264.2089. Found 264.2083, Δamu 0.0006. 
2-(p-Chlorobenzoyl)-5-(p-chlorophenyl)-3H-imidazole (5.24a): yellow needles from 5% DMSO / 95 % 
MeOH (100 % yield, 87% of tautomeric mixture) mp 2.47-249 oC; IR (solid) νmax 3269, 1612, 1444, 
1291, 833, 769; 1H NMR (600 MHz, DMSO-D6) δ 13.72, (s, NH-3, 1H), 8.50 (d, J = 8.4 , H-3’’ and H-7’’, 
2H), 8.14 (s, H-4, 1H), 7.87 (d, J = 8.2, H-2’ and H-6’, 2H), 7.80 (d, J = 8.4, H-4’’ and H-6’’, 2H), 7.60 (d, 
J = 8.3, H-3’ and H-5’, 2H); 13C NMR (150 MHz, DMSO-D6) δ 179.6 (q, C-1’’), 144.5 (q, C-2), 141.8 (q, C-
5), 134.8 (q, C-5’’), 132.8 (q, C-4’), 132.6 (2 x CH, C-3’’ and C-7’’), 131.5 (2 x CH, C-3’ and C-5’), 131.4 
(CH, C-4’’ and C-6’’), 127.4 (q, C-2’’), 126.8 (2 x CH, C-2’ and C-6’), 120.1 (q, C-1’), 119.4 (CH, C-4); 
HREIMS: calcd for C16H11N2OCl2 317.0248. Found 317.0233, Δamu 0.0015.  
2-(p-Chlorobenzoyl)-5-(p-chlorophenyl)-1H-imidazole (5.24b):  yellow needles from 5% DMSO / 95 % 
MeOH (100 % yield, 13% of tautomeric mixture);  1H NMR (600 MHz, DMSO-D6) δ 13.89 (s, NH-1, 
1H), 8.60 (d, J = 8.5 , H-3’’ and H-7’’, 2H), 8.14 (s, H-4, 2H), 7.95 (d, J = 8.3, H-2’ and H-6’, 2H), 7.67 (d, 
J = 8.4, H-4’’ and H-6’’, 2H), 7.49 (d, J = 8.2, H-3’ and -5’, 2H); 13C NMR (150 MHz, DMSO-D6) δ 179.4 
(q, C-1’’), 144.5 (q, C-2), 141.8 (q, C-5), 138.2 (q, C-5’’),134.5 (q, C-2’’), 132.6 (2 x CH, C-3’’ and C-7’’), 
132.5 (CH, C-4’), 131.6 (q, C-1’), 128.6 (2 x CH, C-3’ and C-5’), 128.5 (CH, C-4’’ and C-6’’), 126.5 (2 x 
CH, C-2’ and C-6’), 119.3 (CH, C-4) 
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2-(p-Bromobenzoyl )-4-(p-bromophenyl)-3H-imidazole (5.25a): yellow needles from 5% DMSO / 95 % 
MeOH (63 % yield) mp 202-204 oC; IR (solid) νmax 3264, 1610, 1289, 901, 829, 766 cm
-1; 1H NMR (600 
MHz, DMSO-D6) δ 13.72, (s, NH-3, 1H), 8.50 (d, J = 8.5 , H-3’’ and H-7’’, 2H), 8.15 (s, H-4, 1H), 7.88 (d, 
J = 8.5, H-2’ and H-6’, 2H), 7.81 (d, J = 8.5, H-4’’ and H-6’’, 2H), 7.61 (d, J = 8.7, H-3’ and H-5’, 2H); 13C 
NMR (150 MHz, DMSO-D6) δ 179.9 (q, C-1’’), 144.5 (q, C-2), 141.8 (q, C-5), 134.8 (q, C-5’’), 132.8 (q, 
C-1’), 132.6 (2 x CH, C-3’’ and C-7’’), 131.6 (2 x CH, C-3’ and C-5’), 131.6 (2 x CH, C-4’’ and C-6’’), 127.5 
(q, C-2’’), 126.9 (2 x CH, C-2’ and C-6’), 120.1 (q, C-4’), 119.4 (CH, C-4); HRESIMS: calcd for 
C16H11N2OBr2 404.9238. Found 404.9252, Δmmu 0.0014. 
2-(p-Fluorobenzoyl)-5-(p-fluorophenyl)-3H-imidazole (5.26a): yellow needles from 5% DMSO / 95 % 
MeOH (63 % yield, 85% of tautomeric mixture)  mp 240-242 oC; IR (film) νmax 3273, 1596, 1509, 1289, 
846, 697 cm-1; 1H NMR (600 MHz, DMSO-D6) δ 13.64 (s, NH-3, 1H), 8.71 (t, J = 8.8, 
4JF,H = 6.9, H-3’’ 
and H-7’’, 2H), 8.06 (s, H-4, 1H), 7.96 (t, J = 8.6, 4JF,H = 9.9, H-2’ and H-6’, 2H), 7.41 (d, J = 4.8,
 3JF,H = 
9.8, H-4’’ and H-6’’, 2H), 7.24 (d, J = 5.0, 3JF,H = 9.7, H-3’ and H-5’, 2H); 
13C NMR (150 MHz, DMSO-D6) 
δ 179.0 (q, C-1’’), 165.0 (q, 1JF,C = 253.1, C-5’’), 161.5 (q, 
1JF,C = 243.1, C-4’), 144.5 (q, C-5), 142.0 (q, C-
2), 133.7 (2 x CH, 3JF,C = 9.7, C-3’’ and C-7’’), 132.5 (CH,
 4JF,C = 2.1, C-2’’), 130.2 (CH, 
4JF,C = 2.1, C-1’), 
128.5 (CH, 3JF,C = 8.6, C-4’’ and C-6’’), 126.8 (2 x CH, 
3JF,C = 8.7, C-2’ and C-6’), 118.5 (CH, C-4), 114.8 
(CH, 2JF,C = 21.7, C-4’’ and C-6’’) 114.7 (CH, 
2JF,C = 22.0, C-3’ and C-5’); HREIMS: calcd for C16H11N2OF2 
285.0839. Found 285.0855, Δamu 0.0016. 
2-(p-Fluorobenzoyl)-5-(p-fluorophenyl)-1H-imidazole (5.26b): yellow needles from 5% DMSO / 95 % 
MeOH (63 % yield, 15% of tautomeric mixture); 1H NMR (600 MHz, DMSO-D6) δ 13.81 (s, NH-1, 1H), 
8.57 (m, H-3’’ and H-7’’, 2H), 8.06 (s, H-4, 1H), 7.89 (m, H-2’ and H-6’, 2H), 7.41 (m, H-4’’ and H-6’’, 
2H), 7.24 (m, H-3’ and H-5’, 2H); 13C NMR (150 MHz, DMSO-D6) δ 179.4 (q, C-1’’), 165.0 (q, 
1JF,C = 
249.6, C-5’’), 161.5 (q, 1JF,C = 247.3, C-4’), 146.0 (q, C-5), 142.2 (q, C-2), 133.7 (2 x CH, 
3JF,C = 9.8, C-3’’ 
and C-7’’), 132.4 (CH, 4JF,C = 2.0, C-2’’), 130.2 (CH, 
4JF,C = 2.0, C-1’), 128.1 (2 x CH, 
3JF,C = 8.7, C-2’ and C-
6’), 128.0 (CH, 3JF,C = 8.5, C-4’’ and C-6’’), 117.9 (CH, C-4), 114.6 (CH, 
2JF,C = 21.3, C-4’’) 114.5 (CH, 
2JF,C 
= 22.1, C-3’ and C-5’) 
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6.4.3.1. Synthesis of the ascidian natural product 2-(p-hydroxybenzoyl)-5-(p-
hydroxyphenyl)-3H-imidazole (5.111) 
 
N
H
N O
OMeMeO
I
DMF
N
H
N O
OHHO
5.22 5.111  
A solution of 5.22 (100 mg, 0.325 mmol) and iodocyclohexane (3.25 mmol, 10 equiv.) in DMF (1 mL) 
was refluxed under argon for 12 h.  The reaction was quenched with H2O and the organic fraction 
taken up in EtOAc.  The organic layer was washed with sat. NaHSO3 solution (2x 5 mL) and sat. brine 
(1 x 5mL) and dried with anhydrous MgSO4.  The solvent was removed under reduced pressure to 
yield a yellow solid 5.111 in 93% yield.     
 
2-(p-Hydroxybenzoyl)-5-(p-hydroxyphenyl)-3H-imidazole (5.111a): yellow needles from 5% DMSO / 
95 % MeOH (93 % yield, 74% of tautomeric mixture) mp 293-295 oC, lit. 295-297oC457; IR (film) νmax 
3370, 3254 (br.), 1620, 1290, 871, 711 cm-1; 1H NMR (600 MHz, DMSO-D6) δ 13.42 (s, NH-3, 1H), 8.69 
(d, J = 8.8 , H-3’’ and H-7’’, 2H), 7.91 (s, H-4, 1H), 7.85 (d, J = 8.6, H-2’ and H-6’, 2H), 7.13 (d, J = 8.7, 
H-4’’ and H-6’’, 2H), 6.99 (d, J = 8.5, H-3’ and H-5’, 2H); 13C NMR (150 MHz, DMSO-D6) δ 178.9 (q, C-
1’’), 163.2 (q, C-5’’), 158.5 (q, C-4’) 144.7 (q, C-2), 142.6 (q, C-5), 133.1 (2 x CH, C-3’’ and C-7’’), 128.6 
(q, C-2’’), 126.4 (q, C-1’), 126.1 (2 x CH, C-2’ and C-6’), 117.0 (CH, C-4), 114.0 (2 x CH, C-3’ and C-5’), 
113.7 (CH, C-4’’ and C-6’’), 55.5 (CH3, C-6’’), 55.1 (CH3, C-5’); HRESIMS: calcd for C16H13N2O3 281.0926. 
Found 281.0925, Δamu 0.0001. 
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6.4.4. Synthesis of the sponge natural product deoxytopsentin (5.33) 
6.4.4.1. Synthesis of N-Boc protected deoxytopsentin (5.90) 
 
N
O
O
N
O
O
O
H
N
N
N
O
O
O
2'
1''
3''
3
H
O
N
O
O
O
1'
2''
2
OH
OH
5.885.107
5
7a6
NH4OAc, EtOH
RT, 6 h
5.90
4
3
2 8''
10''
8'
10'
7a
5
4''
1''
 
 
The equilibrium mixture of glyoxal (5.88) and glyoxal monohydrate (5.107) (85 mg, 0.311 mmol) 
were dissolved in EtOH (2 mL) and ammonium acetate (120 mg, 1.56 mmol, 5 equiv.) added.  The 
solution was stirred at room temperature until a yellow precipitate formed (6 h).  The solvent was 
removed under reduced pressure resulting in a yellow solid.  This yellow solid was washed with 
water and filtered under vacuum.  The protected imidazole was purified through a silica flash 
column (80% EtOAc : 20% hexane) to afford 5.90 (78.6 mg, 96%). 
 
(Indol-3-yl)[5-(indol-3-yl)-3H-imidazol-2-yl]-bis(1,1-dimethylethyl) ester (5.90) IR  (solid) νmax 2980, 
1741, 1667, 1370, 1150, 749 cm-1; 1H NMR (600 MHz, CDCl3) δ 13.68 (s, NH-3, 1H), 9.78 (s, H-2’’, 1H), 
8.45 (d, J = 7.1, H-7’, 1H), 8.27 (m, H-4’’, H-7’’, 2H), 8.16 (d, J = 7.7, H-4’, 1H), 8.02 (s, H-2’, 1H), 7.61 
(s, H-4, 1H), 7.42 (m, H-5’’ and H-6’’, 2H), 7.37 (m, H-5’ and H-6’, 2H), 1.72 (s, H3-10’, 9H), 1.71, (s, H3-
11’’, 9H); 13C NMR (150 MHz, CDCl3) δ 177.0 (q, C-8’’), 149.1 (q, C-9’’), 148.6 (q, C-8’), 145.2 (q, C-2), 
137.7 (CH, C-2’’), 135.6 (q, C-7a’), 135.3 (q, C-7a’’), 137.9 (q, C-5), 127.9 (q, C-3a’’), 125.5 (CH, C-6), 
124.6 (q, C-3a’), 124.6 (CH, C-5’’), 124.4 (CH, C-6’), 122.7 (CH, C-5’), 122.5 (CH, C-2’), 122.4 (CH, C-7’), 
120.7 (CH, C-4’), 120.4 (CH, C-7’’), 116.8 (q, C-3’’), 115.8 (CH, C-4), 115.1 (CH, C-4’’), 114.7 (q, C-3’), 
85.5 (q, C-10’’), 85.1 (q, C-9’), 28.2 (CH3, C-11’’), 28.1 (CH3, C-10’);  HREIMS: calcd for C30H31N4O5 
527.2294. Found 527.2304, Δamu 0.0010. 
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6.4.4.2. Deprotection of 5.90 
 
N
H
NH
O
H
N
N
N
O
O
N
O
O
O
H
N
N
5.90
4
3
2 8''
10''
8'
10'
7a
5
4''
1''
MWI
185 oC, 5 min
5.33
8''
5''
1''
5
3
3a'
6'
2'
 
The carbamate protection groups were removed through thermal decomposition.  The dried oil 
(338.6 mg) was placed in a sealed microwave vessel under argon and heated to 185 oC for 5 min.  
The mixture was then dissolved in methanol and filtered through Celite 545.  The methanol was 
removed by evaporation to afford tautomeric mixture (54%:46%) of deoxytopsentin (5.33) as a 
yellow solid (209 mg) in quantative yield.   
3-H-Deoxytopsentin (5.33a), yellow oil (100 % yield, 54 % of tautomeric mixture), IR  (solid) νmax 
2160, 1589, 1414, 1103, 852, 735 cm-1; 1H NMR (600 MHz, DMSO- D6) δ 13.37 (s, NH-3, 1H), 12.04 (s, 
NH-1’’, 1H), 11.45 (s, NH-1’, 1H), 9.19 (s, H-2’’, 1H), 8.41 (d, J = 7.4, H-4’’, 1H), 8.17 (d, J = 7.9, H-4’, 
1H), 8.11 (s, H-2’, 1H), 7.63 (s, H-4, 1H), 7.54 (t, J = 7.1, 8.3, H-7’’, 1H), 7.46 (d, J = 7.5, H-7’, 1H), 7.25 
(m, H-5’’, H-6’’, 1H), 7.15 (t, J = 7.5, 8.0, H-5’, H-6’, 2H); 13C NMR (150 MHz, DMSO-D6) δ 176.1 (q, C-
8’’), 145.2 (q, C-2), 136.6 (CH, C-2’’), 136.5 (q, C-7a’), 136.2 (q, C-7a’’), 130.4 (q, C-5), 126.8 (q, C-3a’’), 
125.8 (CH, C-4), 124.5 (q, C-3a’), 124.0 (CH, C-2’), 122.8 (CH, C-6’’), 122.7 (CH, C-6’), 121.8 (CH, C-5’’), 
121.6 (2xCH, C-5’, C-4’’), 121.3 (CH, C-4’), 113.7 (q, C-3’’), 112.3 (CH, C-7’’), 112.1 (CH, C-7’), 104.7 (q, 
C-3’); 15N NMR (60 MHz, DMSO-D6) δ 215.7 (NH, N-3), 194.0 (NH, N-1’’), 188.1 (NH, N-1’); HREIMS: 
calcd for C20H15N4O 327.1246. Found 327.1244, Δamu 0.0002. 
1-H-Deoxytopsentin (5.33b), yellow oil (100 % yield, 46 % of tautomeric mixture); 1H NMR (600 MHz, 
DMSO-D6) δ 13.12 (s, NH-1, 1H), 12.15 (s, NH-1’’, 1H), 11.23 (s, NH-1’, 1H), 9.40 (s, H-2’’, 1H), 8.41 (d, 
J = 7.4, H-4’’, 1H), 7.91 (d, J = 8.1, H-4’, 1H), 7.83 (1H, s, H-2’), 7.69 (s, H-4, 1H), 7.54 (t, J = 7.1, 8.3, H-
7’’, 1H), 7.44 (d, J = 7.9, H-7’, 1H), 7.25 (m, H-5’’, H-6’’, 2H), 7.19 (t, J = 7.8, 8.2, H-6’, 1H), 7.13 (t, J = 
7.5, 8.3, H-5’, 1H); 13C NMR (150 MHz, DMSO-D6) δ 176.0 (q, C-8’’), 145.2 (q, C-2), 138.5 (q, C-5), 
137.0 (CH, C-2’’), 136.2 (2xq, C-7a’, C-7a’’), 126.8 (q, C-3a’’), 124.9 (q, C-3a’), 122.8 (2xCH, C-2’, C-6’’), 
121.9 (CH, C-6’), 121.8 (CH, C-5’’), 121.6 (CH, C-4’’), 119.8 (CH, C-5’),119.5 (CH, C-4’),  114.9 (CH, C-
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4’), 113.9 (q, C-3’’), 112.3 (CH, C-7’’), 112.0 (CH, C-7’), 110.8 (q, C-3’); 15N NMR (60 MHz, DMSO-D6) δ 
222.4 (NH, N-1), 198.0 (NH, N-1’’), 185.1 (NH, N-1’); HREIMS: calcd for C20H15N4O 327.1246. Found 
327.1244, Δamu 0.0002. 
 
6.4.5. Attempted synthesis of isobromotopsentin and 5.34 
6.4.5.1. Grignard synthesis of 3-(1-hydroxyethyl)-6-bromo-indole (5.121) and 3-(1-
hydroxyethyl)-5-bromo-indole (5.122) 
 
N
H
H
O
R1
R2 NH
HO
R1
R2
              R1   R2
5.121     H     Br   
5.122     Br    H
MeMgBr
CeCl3, THF
               R1   R2
5.119      H     Br   
5.120      Br    H
1'
2'
5
3
2
7
3a
6
 
 
The following method is representative for the preparation of compounds 5.121 and 5.122.  A 
suspension of anhydrous CeCl3 (426 mg, 3.35 mmol, 1.5 equiv.) in dry THF (7 mL) was stirred under 
argon at ambient temperature (2 h), cooled to 0 oC and an aliquot (2.23 mL, 6.69 mmol, 3.0 equiv.) 
of a THF solution of methylmagnesium bromide (3.0 M) added.  The suspension was stirred (0 oC, 1.5 
h) and a solution of 5.119 (500 mg, 2.23 mmol) in dry THF (6 mL) added.  Stirring was continued (0 
oC, 1 h) and the reaction mixture gradually allowed to reach room temperature (4 h) before 
quenching with sat. aqueous NH4Cl (5 mL) and extracted with Et2O (3 x 5 mL).  The combined ether 
fractions were washed with water (2 x 5 mL), sat. brine (1 x 5 mL), dried over anhyd. MgSO4, filtered 
and concentrated under reduced pressure to yield a yellow oil.  Recrystallization from MeOH 
afforded white prisms of 5.121 (533 mg, 100%): 
3-(1-Hydroxyethyl)-6-bromo-indole (5.121) white needles from DCM, (100% yield) mp 120-122 oC; IR 
(solid) νmax 3114, 2603, 1431, 1171, 875, 789 cm
-1; 1H NMR (600 MHz, CD3OD) δ 7.59 (d, J = 8.4, H-5, 
1H), 7.51 (s, H-7, 1H), 7.17 (s, H-2, 1H), 7.12 (d, J = 8.4, H-4, 1H), 5.13 (q, J = 6.7, H-1’, 1H), 1.60 (d, J = 
6.7, H3-2’, 3H); 
13C NMR (150 MHz, CD3OD) δ 139.2 (q, C-7a), 126.2 (q, C-3a), 123.1 (CH, C-2), 122.8 
(CH, C-4), 121.8 (CH, C-5), 121.5 (q, C-3), 115.8 (q, C-6), 115.1 (CH, C-7), 64.6 (CH, C-1’), 24.2 (CH3, C-
2’); EIMS m/z (rel. int.) 222 [M+] (100), 194 (12), 143 (23), 111 (12), 88 (11); HREIMS: calcd for 
C10H9ONBr 221.9918. Found 221.9910, Δamu 0.0008.  
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3-(1-Hydroxyethyl)-5-bromo-indole (5.122) white needles from DCM, (100% yield) mp 119-120 oC; IR 
(solid) νmax 3223, 2585, 2162, 1371, 994, 759 cm
-1; 1H NMR (600 MHz, CDCl3) δ 8.02 (s, NH-1, 1H), 
7.91 (s, H-4, 1H), 7.28 (d, J = 8.9, H-6, 1H), 7.23 (d, J = 8.6, H-7, 1H), 7.15 (s, H-2, 1H), 5.19 (q, J = 6.5, 
H-1’, 1H), 1.65 (d, J = 6.5, H3-2’, 3H); 
13C NMR (150 MHz, CDCl3) δ 135.2 (q, C-7a), 127.5 (q, C-3a), 
125.2 (CH, C-6), 122.4 (CH, C-4), 121.8 (CH, C-2), 121.0 (q, C-3), 113.0 (q, C-5), 112.6 (CH, C-7), 64.0 
(CH, C-1’), 23.8 (CH3, C-2’); EIMS m/z (rel. int.) [M+] 222 (100), 142 (22), 115 (160), 89 (6), 71 (10); 
HREIMS: calcd for C10H9ONBr 221.9918. Found 221.9910, Δamu 0.0008.  
 
6.4.5.2. Trial tetrapropylammonium perruthenate oxidation of the natural product 
marrubiin (5.123) 
 
OH
O
OH
HO
O
O
OH
O
TPAP, NMO
DCM
1
5
H H
11
13
15
19
20
21
18
14
H
5.123 5.129  
Tetrapropylammonium perruthenate (0.031 mmol, 0.1 equiv.) was added to a solution of 5.123 (101 
mg, 0.313 mmol), N-methylmorpholine N-oxide (95 mg, 0.814 mmol, 2.6 equiv.) and powdered 
molecular sieves (4 Å, 30 mg) in anhydrous CH2Cl2 (5 mL).  The reaction was allowed to stir for 3 h 
under an argon atmosphere at room temperature.  The molecular sieves were removed by filtering 
the solution through Celite 545 plug and washed with DCM.  The solvent was removed under 
reduced pressure and redissolved in EtOAc.  The solution was filtered through a silica plug using 
EtOAc as a mobile phase.  The isolated oil was further purified by HPLC (25% EtOAc, 75% Hexane) to 
afford 5.129 in 98% yield.    
Marrubenone (5.129), white needles needles from hexane, (98 % yield) mp 110-112  oC, lit. 110-111 
oC481; 1H NMR (400 MHz, CDCl3) δ 10.34 (s, H-19, 1H), 7.37 (s, H-15, 1H), 7.26 (s, H-16, 1H), 6.29 (s, H-
14, 1H), 3.26 (s, H-5, 1H), 2.57, (m, H-7a, 1H), 2.55 (m, H2-12, 2H), 2.28 (septet, J = 6.6, H-8, 1H), 2.17 
(dd, J = 12.8, 4.5, H-7b, 1H), 2.11 (dt, J = 13.4, 3.8, H-1a, 1H), 1.96 (m, H-11a, 1H), 1.85 (m, H-11b, 
1H), 1.72 (q, J = 7.8, H-3a, 1H), 1.57 (m, H-3b, 1H), 1.54 (m, H2-2, 2H), 1.15 (s, H3-18, 3H), 1.07 (d, J = 
6.6, H3-21, 3H), 0.92 (m, H-1b, 1H), 0.84 (s, H3-20, 3H); 
13C NMR (100 MHz, CDCl3) δ 211.9, (q, C-6), 
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208.7 (CH, C-19), 143.6 (CH, C-15), 139.0 (CH, C-16), 125.1 (q, C-13), 111.0 (CH, C-14), 76.7 (q, C-9), 
59.9 (CH, C-5), 49.1 (q, C-10), 48.0 (q, C-4), 47.5 (CH2, C-7), 39.1 (CH, C-8), 34.8 (CH2 x 2, C-11, C-1), 
31.4, (CH2, C-3), 25.7 (CH3, C-18), 18.8 (CH2, C-2), 17.7 (CH3, C-20), 16.3 (CH3, C-21) 
 
6.4.5.3. Manganese dioxide oxidation of 5.121 and 5.122 
 
N
H
HO
R1
R2 N
H
O
R1
R2
               R1   R2
5.117      H     Br   
5.118      Br    H
MnO2
DCM
               R1   R2
5.121      H     Br   
5.122      Br    H
 
 
This method is representative for the synthesis of 5.117 and 5.118.  The alcohol (5.121, 322 mg, 1.33 
mmol) was dissolved in anhydrous CH2Cl2 (50 mL), MnO2 (3.5 g, 40.5 mmol, 30 equiv.) was added 
and the mixture was stirred under argon at ambient temperatures for 24 h.  The insoluble MnO2 was 
removed viz. filtration through Celite 545 and washed with EtOAc (200 mL).  The solvent was 
removed under reduced pressure to afford the respective pure brominated 3-acetylindole, which 
required no further purification.      
3-Acetyl-6-bromo-indole (5.121), red needles from chloroform (98 % yield), mp 162-164 oC; IR  (solid) 
νmax 2272, 1621, 1516, 1415, 840, 715 cm
-1; 1H NMR (600 MHz, CD3OD) δ 8.15 (s, H-2, 1H), 8.12 (d, J = 
8.5, H-4, 1H), 7.61 (s, H-7, 1H), 7.31 (d, J = 8.5, H-5, 1H), 2.51 (s, H3-2’, 3H); 
13C NMR (150 MHz, 
CD3OD) δ 194.9 (q, C-1’), 137.8 (q, C-7a), 134.6 (CH, C-2), 124.8 (CH, C-5), 124.3 (q, C-3a), 122.8 (CH, 
C-4), 117.1 (q, C-3), 116.1 (q, C-6), 114.4 (CH, C-7), 25.7 (CH3, C-2’); EIMS m/z (rel. int.) 236 [M
+] (45), 
224 (91), 222, (100), 194 (16), 115 (18); HREIMS: calcd for C10H8NOBr 236.9789. Found 236.9808, 
Δamu 0.0019. 
 
3-Acetyl-5-bromo-indole (5.122), purple needles from chloroform (98 % yield), mp 164-165 oC; IR  
(solid) νmax 2272, 1621, 1516, 1415, 938, 712 cm
-1; 1H NMR (600 MHz, CD3OD) δ, 8.17 (s, H-2, 1H), 
8.13 (d, J = 8.4, H-7, 1H) 7.35 (m, H-4, 1H), 7.33 (m, H-6, 1H), 2.51 (s, H3-2’, 3H); 
13C NMR (150 MHz, 
CD3OD) δ 196.3 (q, C-1’), 137.1 (q, C-7a), 136.5 (CH, C-2), 128.5 (q, C-3a), 127.1 (CH, C-6), 125.4 (CH, 
C-7), 118.0 (q, C-3), 116.6 (q, C-5), 114.5 (CH, C-4), 27.1 (CH3, C-2’); EIMS m/z (rel. int.) 236 [M
+] (47), 
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224 (93), 222, (100), 194 (12), 143 (21); HREIMS: calcd for C10H8NOBr 236.9789. Found 236.9808, 
Δamu 0.0019. 
 
6.4.5.4. N-Boc protection of 5.117 and 5.118 
 
N
H
O
R1
R2
               R1   R2
5.130      H     Br   
5.131      Br    H
Boc2O, DMAP
MeCN, 0 oC, 2 h
               R1   R2
5.117      H     Br   
5.118      Br    H N
O
R1
R2
O
O
 
Brominated 3-acetylindoles (5.117 or 5.118, 200 mg, 0.84 mmol) was dissolved in dry MeCN (2.5 mL) 
and cooled on ice.  Di-tert-butyl dicarbonate (275 g, 1.26 mmol, 1.5 equiv.) was added followed by 4-
dimethylaminopyridine (10.3 mg, 84 μmol, 0.1 equiv.) and each solution allowed to stir under argon 
for two hours.  The solvent and excess reagents were removed under reduced pressure to yield 
spectropically pure white solids of 5.130 and 5.131.  
 
3-Acetyl-6-bromo-indole-1-carbamate (5.130), white needles from hexane (100 % yield), mp 196-198 
oC; IR  (solid) νmax 1729, 1665, 1362, 1151, 844 cm
-1, 763; 1H NMR (600 MHz, CD3OD) δ 8.31 (s, H-7, 
1H), 8.22 (d, J = 8.3, H-4, 1H), 8.16 (s, , H-2, 1H), 7.46 (d, J = 8.3, H-5, 1H), 2.55 (s, H3-2’, 3H), 1.70 (s, 
H3-3’’, 9H); 
13C NMR (150 MHz, CD3OD) δ 193.6 (q, C-1’), 148.7 (q, C-1’’), 136.6 (q, C-7a), 132.5 (CH, 
C-2), 127.7 (CH, C-5), 126.2 (q, C-3a), 123.9 (CH, C-4), 120.3 (q, C-3), 119.5 (q, C-6), 118.5 (CH, C-7), 
86.1 (q, C-2’’), 28.1 (CH3, C-3’’), 27.7 (CH3, C-2’) 
 
3-Acetyl-5-bromo-indole-1-carbamate (5.131), white needles from hexane (100 % yield), mp 195-197 
oC; IR (solid) νmax 3274, 1635, 1596, 1509, 1287, 847 cm
-1; 1H NMR (600 MHz, CDCl3) δ 8.46 (s, H-4, 
1H), 8.12 (s, H-2, 1H), 7.79 (d, J =8.8, H-7, 1H), 7.40 (d, J = 8.7, 7.8, H-6, 1H), 2.48 (s, H3-2’, 3H), 1.64 
(s, H3-3’’, 9H); 
13C NMR (150 MHz, CDCl3) δ 1 93.4 (q, C-1’), 148.7 (q, C-1’’), 134.3 (q, C-7a), 132.9 (CH, 
C-2), 128.9 (q, C-3a), 128.5 (CH, C-6), 125.4 (CH, C-4), 119.8 (q, C-3), 118.1 (q, C-5), 116.3 (CH, C-7), 
85.9 (q, C-2’’), 28.1 (CH3, C-3’’), 27.6 (CH3, C-2’) 
Chapter Six:  Experimental 
 
 
211 
6.4.5.5. Attempted synthesis of the brominated indole glyoxals  
 
This method is representative for the conversion of 5.130 and 5.131 to their respective glyoxals.  
SeO2 (281 mg, 2.53 mmol, 2.7 equiv) was suspended in a mixture of 1,4-dioxane (1 mL) and H2O (20 
µL) and the indole methyl ketone, 5.130 (200 mg, 0.94 mmol) was added just before microwave 
irradiation [ramp time (1 min) to a maximum power of 250 W, hold time (40 min) at a set 
temperature of 100  °C].  Following microwave irradiation the reaction solution was rapidly cooled 
to 50 oC (5 min) by means of propelled airflow and finally allowed to cool to room temperature (ca. 
20 min).  The solution was filtered through Celite 545 , in order to remove Se, and washed with 
CH2Cl2 (10 mL).  The combined organic filtrate was washed with water (2 x 10 mL) and sat. brine (1 x 
10mL), and the organic fraction was dried over anhydrous MgSO4, filtered and concentrated under 
reduced pressure to afford a yellow oil containing an inseparable mixture of N-Boc protected glyoxal 
(5.115)  and monohydrate (5.132) as well as the deprotected glyoxal (5.134)  and monohydrate 
(5.135). 
 
6.4.5.6. Attempted synthesis of N-Boc protected isobromotopsentin (5.20)  
 
N
O
Boc
2'
3a
H
O
N
O
Boc
1'
2
OH
OH
5.115 5.132
BrBr
N
H
O 2'
3a
H
O
N
H
O
1'
2
OH
OH
5.134 5.135
BrBr
+
N
R1
N
O
R2
H
N
N
Br
Br
 
 
The mixture of glyoxals (5.115 and 5.134) and glyoxal monohydrate (5.132 and 5.135) (50 mg, ca. 
0.136 mmol) were dissolved in EtOH (2 mL) and ammonium acetate (52 mg, 0.68 mmol, 5 equiv.) 
added.  The solution was stirred at room temperature until a yellow precipitate formed (6 h).  The 
5.136 R1=Boc R2=H  
5.137 R1=H  R2=Boc 
5.20 R1; R2=H 
  
Chapter Six:  Experimental 
 
 
212 
solvent was removed under reduced pressure resulting in a yellow solid.  This yellow solid was 
washed with water and filtered under vacuum, resulting in an inseparable mixture of 5.136, 5.137 
and 5.20.  
 
(Indol-3-yl)[5-(indol-3-yl)-3H-imidazol-2-yl]-1-methylethyl ester (5.136 and 5.137); HREIMS: calcd for 
C25H21N4O3Br2 582.9980. Found 582.9989, Δamu 0.0009. 
 
Isobromotopsentin (5.20); HREIMS: calcd for C20H13N4OBr2 482.9456. Found 482.9461, Δamu 0.0005. 
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